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Thesis Summary 
Tissue Transglutaminase (TG2) and FXIIIa, members of the transglutaminase (TG) family, 
catalyses a transamidating reaction and form covalent bond between or within proteins.  
In bone development, both enzymes expressions correlate with the initial of the 
mineralisation process by osteoblasts and chondrocytes.  Exogenous TG2 also promotes 
maturation of chondrocytes and mineralisation in pre-osteoblasts. 
To understand the role of endogenous TG2 in osteoblast mineralisation, the TG2 
expression was examined during the human osteoblast (HOB) mineralisation.  The 
expression of the endogenous TG2 increased during the mineralisation, yet, its expression 
was not essential for mineral deposition due to the compensation effect by other 
members in the TG family.  The extracellular transamidating activity of HOBs was found 
increased during mineralisation and a shift from FXIIIa dominant- to TG2-dominant 
crosslinking activity was suggested after differentiation.  However, the transamidating 
activity of both TG2 and FXIIIa were not critical for cell mineralisation. 
On the other hand, Exogenous TG2 was found to enhance wild type HOB and TG2 
knockdown HOB mineral deposition.  The transamidating activity of TG2 was not required 
but most likely a close conformation was essential for this enhancement.  Results also 
demonstrated that exogenous TG2 may activate the β-catenin pathway through LRP5 
receptor thus contribute in cell mineralisation.  This enhancement could be abolished by 
addition of β-catenin inhibitors. 
Finally, using of TG2 crosslinked collagen gel for bone and cornea repair was evaluated.  
Crosslinked collagen gel showed promising results in improving HOB mineralisation, 
human corneal fibroblast (hCF) proliferation and migration.  These effects might be 
resulted from the trapped TG2 within the collagen matrix and the alteration of matrix 
topography by TG2. 
Key words: FXIIIa, close conformation, LRP5, β-catenin, human corneal fibroblast 
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1. Transglutaminase 
Transglutaminases (TGs) are a group of enzymes that catalyse the post-translational 
modification of proteins at glutamine residues through an acyl-transfer reaction.  The 
enzymes are widely distributed from bacteria (Ando et al., 1989, Nonaka et al., 1989, 
Kanaji et al., 1993) to plants (Serafini-Fracassini et al., 1995, Serafini-Fracassini et al., 2002) 
and animals (Clarke et al., 1959, Chung, 1972, Aeschlimann et al., 1995, Kim et al., 1995, 
Zhang and Masui, 1997).  In the mammalian transglutaminase (EC 2.3.2.13) family, the 
availability of calcium is essential for enzymes to form a covalent bond between the γ-
carboxamide group of peptide-bound glutamine and the ε-amino group of a peptide-
bound lysine/ a primary amine.  The first documented mammalian transglutaminase was 
derived from the soluble fraction of guinea pig liver by Clarke and co-workers in 1959.  
Fifty more years later, there are 9 members reported in higher vertebrates, TG1-7, factor 
XIIIa (FXIIIa) and band 4.2, and each of them have been characterised to some degree 
(reviewed by Griffin et al., 2002, Lorand and Graham, 2003, Esposito and Caputo, 2005, 
Mehta, 2005).  The key characteristics of these mammalian TGs are summarised in Table 
1.1.  This thesis focuses on two well studied TGs, TG2 and FXIIIa, in particular their roles in 
the mineralisation process of bone formation as well as their application in biomedical 
sciences. 
1.1. Transglutaminase 2 (TG2) 
TG2, also known as tissue transglutaminase (tTG), cytosolic transglutaminase (TGc), 
erythrocyte transglutaminase and endothelial transglutaminase, is ubiquitously expressed 
in all kinds of tissue.  Its transamidating activity is regulated by calcium and GTP/GDP 
binding in which binding of calcium results in active TG2 and binding of GTP/GDP results in 
inactive TG2 (Smethurst and Griffin, 1996).  Besides its primary function as a transamidase, 
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TG2 also has GTPase/ATPase activity (Takeuchi et al., 1994), protein disulfide isomerase 
activity (Hasegawa et al., 2003) and may even function as a protein kinase (Mishra and 
Murphy, 2004). 
1.1.1. Transamidating and deaminating function 
The transamidation activity in tissue had been first revealed in 1959 by Clarke and co-
workers, and till the mid-1980s, the transamidation and deamination reaction of TG2 was 
well studied (Folk, 1983).  The biochemical mechanism underlying the enzyme action 
involves two major steps.  First, the rate-limiting step is formation of thioester bond 
between TG2 active site cysteine (C277) and the substrate.  In this step, the sulfur of the 
active site C277 performs a nucleophilic attack on the γ-carboxamide group of a glutamine 
residue, and releases an ammonia molecule as a by-product (Fig 1.1A).  At the second 
step, the acyl intermediate is attacked by the nucleophilic substrate (acyl-acceptor).  In 
this stage, if the attacking group is a primary amine, either a small biological amine or a ε-
amino group of a peptide-bound lysine residue, the reaction is called transamidation (Fig. 
1.1B, C, D). However, if a water molecule acts as a nucleophile, it is called deamination 
(Fig. 1.1E). 
Two major outcomes result from TG2 transamidation: modification of the substrate 
protein with small amines or formation of an isopeptide bond between acyl-acceptor and 
acyl-donor proteins.  When the nucleophilic substrate is a small primary amine (Fig 1C), 
the result of transamidation reaction will be addition of a small biological amine to the 
substrate protein which can subsequently change its biological properties.  On the other 
hand, the isopeptide bond can form intermolecularly between proteins (Fig. 1.1C), or 
sometimes crosslinking happens between two proteins via a N,N-bis(γ-glutamyl)polyamine  
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Table 1.1 Summary of mammalian TGs family (adapted from Griffin et al., 2002, Lorand and Graham, 2003, Esposito and Caputo, 2005, Mehta, 2005) 
Protein Alternative name Tissue expression Molecular 
Mass (kDa)/ 
Human  
Activity and 
regulation 
Localisation (and function/ disease) 
FXIIIa 
subunit 
Fibrin-stabilising factor, Laki-
Lorand factor, pro-fibrinoligase, 
plasma pro-TG 
Platelets, astrocytes, dermal 
dendritic cells, chondrocytes, 
placenta, plasma, synovial 
fluid 
83 Thrombin activated; Ca2+ 
activated, reducing agent 
required 
Cytosolic, extracellular; (blood coagulation, bone 
growth, wound healing, ECM stabilisation) 
TG1 TGk, keratinocyte TG, 
particulate TG, membrane-
bound TG, TG-B 
Keratinocytes and brain 90 Protease activated; Ca2+ 
activated, reducing agent 
required 
Membrane, cytosolic; (cell-envelope formation in 
keratinocytes differentiation) 
TG2 TGc, tissue TG, liver TG, 
endothelial TG, erythrocyte TG, 
Gh. Ghα, tTG, 
Ubiquitous 78 Yes; Ca2+ activated, 
reducing agent required 
Cytosolic, nuclear, membrane, cell surface, 
extracellular (cell death, cell signalling ,cell 
differentiation, matrix stabilisation, adhesion 
protein) 
TG3 TGE, epidermal TG, callus TG, 
hair follicle TG, bovine snout TG 
Squamous epithelium, brain 
and hair follicle 
77 Latent (protease 
activated); Ca2+ activated, 
reducing agent required 
Cytosolic; (cell-envelope formation during terminal 
differentiation of kertainocytes, hair shaft 
formation) 
TG4 TGP, prostate TG, major 
androgen-regulated prostate 
secretory protein 
Prostate 77 Yes; Ca2+ activated, 
reducing agent required 
Extracellular; (semen coagulation) 
TG5 TGX Ubiquitous except for the 
CNS and lymphatic system 
81 Yes; Ca2+ activated Cytosolic (Cornified cell formation during 
keratinocytes differentiation) 
TG6 TGY Testis and lung 70 Yes (?) Unknown; (biomarker for developing neurological 
disease in gluten sensitive patients?) 
TG7 TGZ Ubiquitous but 
predominantly in testis and 
lung 
80 Yes (?) Unknown; (unknown) 
Band 4.2 B4.2, ATP-binding erythrocyte 
membrane protein band 4.2 
Red blood cells, bone 
marrow, foetal liver and 
spleen 
72 No enzymatic activity Membrane; (structural protein, membrane skeletal 
component in erythrocyte) 
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bridge (Fig. 1.1D).  There are more than a hundred proteins which have been recognised 
as TG2 substrates and some of them are summarised in Table 1.2. 
The deaminating reaction results in the conversion of an acyl-donor glutamine residue to 
a glutamate residue (Fig.1 E).  The deaminating reaction was first believed to occur under 
certain conditions, such as limited primary amines as acyl-acceptor, thus water acted as 
an attacking group.  It was also reported that deamination was favoured to happen in 
low pH pathological environments (Fleckenstein et al., 2002).  However, recent studies 
suggested that besides being pH-dependent, the deaminating process could also be 
dependent on structure.  Crosslinking of small heat-shock proteins (sHsps) by TG2 
revealed that only one glutamine residue of protein underwent deamination while other 
glutamine residues underwent transamidation (Boros et al., 2006).  Growing evidence 
also demonstrated the propensity for deamination by TG2 is both dependent on 
structure and influenced by pathological conditions (Stamnaes et al., 2008). 
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Figure1.1 Post-translational reactions catalysed by transamidase activity of TG2. (A) Formation of a γ-glutamylthiolester intermediate as a common first step for following reactions.  
(B) The incorporation of amine (H2NR) into the glutamine residue (C) An isopeptide bond forms between a peptide bound lysine residue and a peptide bound glutamine residue 
resulting crosslinking of two proteins (D) A primary amine acts as a bridge between two proteins by crosslinking activity (E) Water molecule is used as an acyl-acceptor to deaminate 
a peptide-bound glutamine residue to a glutamate residue.  
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Table 1.2 Known substrates of the transamidase function of TG2 (adapted from Griffin et al., 2002 and Esposito and Caputo, 2005) 
ECM and cell 
surface 
Cytosol Organelle 
Proteins 
Nucleus Others 
Collagen 
Fibronectin 
Fibronogen 
Vitronectin 
Osteopontin 
Osteonectin 
Osteocalcin 
Laminin  
LTBP-1 
β-casein 
IGFBP-1 
Substance P 
Phospholipase A2 
Midkine 
Actin 
Aldolase A 
β -crystallin 
β -tubulin 
C-CAM 
GADPH 
GST 
Glucagon 
Lipocortin I 
Melittin 
Myosin 
Phosphorylase 
kinase 
RhoA 
Secretory vesicle 
IV 
Tau protein 
Thymosin β 
Histone H2B 
α-oxoglutarate 
dehydrogenase 
Acetycholine 
esterase  
CD38 
Cytochromes 
Erythrocyte 
band III 
 
Core histones 
Importin-α3 
pRB 
Calbindin 
 
Wheat gliadin 
Whey proteins 
Soy Protein 
Pea legumin 
Candida albicans 
surface proteins 
HIV envelope 
glycoproteins gp120 
and gp41 
HIV aspartyl 
proteinase 
Hepatitis C virus core 
protein 
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1.1.2 GTPase/ ATPase function 
Binding and hydrolysis of GTP by TG2 was documented as early as 1980s (Achyuthan and 
Greenberg, 1987, Lee et al., 1989).  It was reported that binding of calcium and binding of 
GTP to TG2 competitively regulated the transamidating activity of the enzyme as well as 
proteolysis of TG2 by trypsin.  The independence of GTPase activity of TG2 from its 
crosslinking activity could be further confirmed by Cys 277 mutant TG2 where mutation of 
the crosslinking active site of TG2 only affected transamidating activity but not GTPase 
activity (Lee et al., 1993) The GTPase of TG2 was proposed to be the same as Gα(h) 
protein, a functional α-subunit of a G-protein associated with α1 adrenergic receptor 
signalling,that participates in activation of phospholipase C enzyme (Im and Graham, 1990, 
Nakaoka et al., 1994, Im et al., 1997).  It was also suggested that oxytocin receptor (Baek 
et al., 1996) and TPα thromboxane A2 receptor (Vezza et al., 1999) exploited TG2 as a G-
protein. 
Unlike binding of GTP to TG2, which suppressed crosslinking activity of TG2, binding of ATP 
to TG2 only affected GTPase activity but not transamidation activity of TG2 (Lai et al., 
1998).  The authors also suggested that the binding sites for GTP and ATP were distinct 
due to binding of ATP greatly inhibiting GTP binding, whereas binding of GTP only reduced 
ATP hydrolysis by 20%.  However, the binding sites of GTP and ATP were demonstrated to 
be located within a 5.5 kDa (47 amino acid) region at the start of the core domain (Iismaa 
et al., 1997).  Later on, the publication of the crystal structure of TG2 in complex with GTP 
(Liu et al., 2002) and ATP (Han et al., 2010) indicated that ATP bound in the GTP/GDP 
binding pocket but with different hydrogen bonds and ionic interactions with TG2. 
The function of the ATPase activity of TG2 was first suggested as an intrinsic kinase by 
Mishra and Murphy (2004).  In several in vitro studies, TG2 was recognised as a kinase 
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protein for insulin-like growth factor-binding protein-3 (IGFBP-3), histones, p53 and 
retinoblastoma protein which might participate in cancer cell biology and cell apoptosis 
(Mishra and Murphy, 2004, Mishra et al., 2006, Mishra and Murphy, 2006, Mishra et al., 
2007).  Besides its intracellular function, recent research also proposed a functional role of 
extracellular TG2 in tissue mineralisation.  As demonstrated by Nakano et al. in 2007 that 
addition of ATP, instead of β-glycerophosphate, to ascorbic acid treated pre-osteoblast 
cells was sufficient enough to induce cell mineralisation.  And ATPase activity of TG2 was 
found to play a major role in this ATP-mediated mineralisation by serving as a source of 
phosphate groups.  Further study from the same group also indicated that MT1-MMP was 
the key regulator of the pro-mineralization function of TG2 in extracellular matrix (Nakano 
et al., 2010). 
1.1.3 Structure and conformation of TG2 
The TG2 structure comprises four distinct domains: an N-terminal β-sandwich domain, the 
catalytic core and two C-terminal β-barrel domains (Fig. 1.2).  Some, but not all, critical 
active and substrates binding sites were revealed after years of studies.  A catalytic triad 
similar to cysteine proteases, but for transamidating activity has been identified, which 
consists of cysteine 277 (C277), histidine 335 (H335) and aspartate 358 (D358) (Liu et al., 
2002).  Mutating cysteine to serine at residue 277 (C277A) has been used to completely 
knock out transamidating and GTP/GDP binding ability of TG2.  Another two conserved 
tryptophan residues, W241 and W332, were also identified as critical residues for TG2 
crosslinking activity.  These two residues were believed to stabilize the enzyme-thiol 
intermediate which formed at the first step of catalysis (Murthy et al., 2002).  Tryptophan 
to alanine mutation at residue 241 (W241A) knocked out transamidating activity without 
altering GTPase activity; whereas, replacing tryptophan at residue 332 with phenylalanine 
(W377F) resulted in loss of GTP/GDP binding ability.  In addition, the tyrosine residue at 
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position 516 (Y516) within the catalytic pocket was also found to be important for 
crosslinking activity.  As suggested by Pinkas and co-workers (2007), in inactive TG2, a 
hydrogen bond formed between C277 and Y516 which was believed to favour the inactive 
state of the enzyme.  Point mutation of this residue to phenylalanine (Y516F) disturbed 
the inactive state of TG2 by greatly changing the conformation of protein.  The same 
authors also suggested a change in enzyme preference for deamination over 
transamidation by mutation of T360A.  Although the details remained unclear, the 
threonine residue 360 (T360) was shown to be important for the second step of the 
catalysis by controlling the entry of the acyl-acceptors to the catalytic site. 
 
Figure 1.2 Structure of TG2 with putative substrate binding sites.  Tg2 was composed of 4 major domains 
including N-terminal β-sandwich domain (aa 1–137), the catalytic core (aa 138–470) and two C-terminal β-
barrel domains (aa 471–583 and 584–686).  The fibronectin binding site was identified by Jeong et al. (1995) 
and Hang et al. (2005).  The postulate binding sites for GTP and ATP was proposed by Iismaa et al. (1997) 
and Han et al. (2010).  The haparan sulphates binding site was identified by Wang et al. (2012).  The catalytic 
triad was identified by Liu et al. (2002).  The calcium binding site was predicted by Fox et al. (1999) and the 
PLC binding site was recognised by Hwang et al. (1995) 
The major GTP/ATP binding site was found to be located at the first 47 residues in the core 
domain (Iismaa et al., 1997).  Yet, later research done by Han et al. (2010) has suggested 
that less hydrogen bonding occurred between ATP and the binding pocket when 
comparing to the GTP complex structure.  Also, there are 2 more residues, S482 and R580, 
which were revealed to specifically participate in GTP binding (Han et al., 2010).  Point 
mutation of R580A resulted in loss of GTP/GDP binding activity and GTP-mediated 
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inhibition of transamidase activity.  This effect was suggested to be related to the 
alteration of enzyme affinity for GTP and GDP  (Begg et al., 2006). 
While several studies used point mutated TG2 to evaluate the relevance of the crosslinking 
activity of TG2 in biological function, one key property of TG2 often overlooked was its 
conformation.  Before being characterised by x-ray crystallography, the presence of 
multiple conformations of TG2 had been suggested.  First, proteolysis studies indicated 
that GTP-bound TG2 showed higher resistance to calpain and trypsin proteolysis when 
compared to TG2 in the presence of calcium (Zhang et al., 1998, Begg et al., 2006).  Also, 
the presence of different sub-populations of TG2 was also found, since different anti-TG2 
antibodies preferentially bound to a distinct population of the enzyme (Fésüs and Laki, 
1977, Monsonego et al., 1998).  In 2007, the two major conformations of TG2 were 
demonstrated using X-ray crystallography (Fig. 1.3): one was GDP-bound (Liu et al., 2002) 
compact form (inactive) and the other was an active site covalent inhibitor bound (Pinkas 
et al., 2007) open form (active).  In the GDP-bound crystal structure (compact form or 
closing form, Fig. 1.3A), the catalytic core domain was inaccessible due to the 2 β-barrels 
domains, which effectively prevent binding of substrate to enzyme.  On the other hand, 
Figure 1.3 Structures of TG2 derived by 
X-ray crystallography (adapted from 
Collighan and Griffin, 2009). (A) GDP-
bound human TG2 and (B) irreversible 
peptide inhibitor-bound human TG2.  
The structures of TG2 are presented 
with its β-sandwich domain at the top of 
the figure. 
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the irreversible inhibitor (Ac–P(DON)LPF-NH2) reacted TG2 resulted in a stable extended 
conformation (open form, Fig. 3B).  In this conformation, the transamidating active sites 
were exposed to substrates and it was assumed that a vicinal disulphide bond between 
Cys370 and Cys371 was the key to stabilise this extended form.  These findings further 
urge future studies to clarify the biological significance of each TG2 conformation. 
1.1.4 Regulation of TG2 gene expression 
The amino acid and cDNA sequences of TG2 in guinea pig liver (Ikura et al., 1988), bovine 
vascular endothelial cells (Nakanishi et al., 1991), mouse macrophages and human 
endothelial cells (Gentile et al., 1991) and chicken erythrocytes (Weraarchakul-Boonmark 
et al., 1992) indicated that TG2 is highly conserved between species.  It is a monomer 
protein consisting of 685-691 amino acids with a molecular weight around 77-85kDa.  
Comparing mouse, guinea pig and human TG2, there is approximately 80% homology 
between these amino acid sequences with 49 of the 51 residues in the active site region 
identical (Gentile et al., 1991).  The expression of human tTG gene (TGM2) was thought to 
be controlled by various activators.  As illustrated in Fig.1.4, there are 4 identified Sp1 
binding sites within TG2 and several activator regulating sites including: retinoic acid 
response elements (RRE-1 and RRE-2), glucocorticoid response element, nuclear factor кB 
response element, interleukin-6 response element and tumor growth factor-β1 response 
element.  Retinoic acid (RA) is one of the most studied activators of TG2.  These retinoid 
response elements are located around 1.7 kb upstream of the transcription start site (Fig. 
5, Nagy et al., 1996).  This activation is a tripartite response: first, ligand activates either 
retinoic acid receptors (RAR)/ retinoid X receptor (RXR) heterodimers or RXR/RXR 
homodimers. And then RRE, through three hexanucleotide half-sites (two canonical and 
one non-canonical), binds to RAR/RXR heterodimers or RXR/RXR homodimers.  Finally, the 
complex binds to the Sp1 binding site which is possibly through other co-activators. 
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Figure 1.4 Schematic illustration of the tissue transglutaminase promoter (adapted from Gundemir et al., 2012).  TGM2 expression is regulated by mainly retinoic acid, inflammation 
factors and stress-related factors.  Retinoic acid response elements (RRE-1, -1731 and RRE-2, -1720), glucocorticoid response element (GRE, -1399), nuclear factor кB response 
element (NF-кB, -1338), interleukin-6 response element (IL-6, -1190), tumor growth factor-β1 (TGF-β1, -900), activator protein-2 (AP-2, -634), hypoxia response element (HRE, -367), 
activator protein-1 (AP-1, -183), CAAT box (-96), GC box (Sp1 binding motifs, -54, -43, +59, +65), TATA box (29), nuclear factor-1 (NF-1, +4, +12), retinoid X receptor (RXR) and retinoic 
acid receptors (RAR). 
 
Figure 1.5 Putative model of tTG and of its promoter (adapted from Griffin et al., 2002).  This model demonstrates the interaction among retinoic acid response elements (RRE-1 and 
RRE-2), retinoid X receptor (RXR)/ retinoic acid receptors (RAR) and specificity protein 1 (Sp-1) binding site upon RA induction. 
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1.1.5 Involvement of TG2 in cell adhesion/ signalling 
The biological role of TG2 is highly related to the location of TG2.  The majority of cellular 
TG2 is predominantly distributed in the cytosol (Bruce and Peters, 1983) and it is also 
found on the plasma membrane (Im and Graham, 1990, Iismaa et al., 2000, Begg et al., 
2006), mitochondria (Piacentini et al., 2002, Rodolfo et al., 2004) and nucleus (Bruce and 
Peters, 1983, Singh et al., 1995, Lesort et al., 1998).  There are also accumulating results 
which show the presence of TG2 and crosslinking activity in extracellular matrix (ECM) 
(Zemskov et al., 2006). Generally, endothelial cells, fibroblasts and smooth muscle cells 
express constitutive levels of TG2; however, TG2 is often considered as a stress-related 
protein as its expression undergoes dramatic change upon stress or injury. 
It has been well studied that TG2 can promote cell-ECM adhesion, cell migration and 
organisation of extracellular matrix protein through two different pathways: syndecan-4–
TG2 complexes and Integrin–TG2 interaction (reviewed by Belkin, 2011).  TG2 was found 
to associate with a membrane protein, heparan sulfate proteoglycan (HSPG) syndecan-4, 
to promote cell-ECM adhesion in an RGD-ligand independent manner (Telci et al., 2008).  
This adhesion pathway was proposed to be critical for cell survival during tissue injury 
and/or remodelling since TG2/fibronectin (FN)/syndecan-4 complexes activated PKCα 
leading to activation of β1 integrin even when the integrins were blocked by RGD peptide.  
The formation of FN/TG2/syndecan-4 complexes could also activate another HSPG family 
protein, syndecan-2, through PKCα (Wang et al., 2010).  Besides functioning as a scaffold 
protein, this complex could also mediate fibronectin fibril formation, which was 
independent of its transamidating activity and occurred in the presence of cell adhesion 
inhibitors (RGD peptides). 
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TG2 was also found to non-covalently interact with β1, β3 and β5 integrin subunits.  Also, 
the binding sites for TG2 and integrin did not overlap on fibronectin protein.  Therefore, 
the affinities of TG2 with these two proteins on the cell surface could significantly enhance 
the interaction of cells with fibronectin and further promote cells adhesion and ECM-
triggered signalling (Akimov et al., 2000, Akimov and Belkin, 2001a, Zemskov et al., 2006).  
Studies also demonstrated that cell surface TG2 could induce integrin clustering in the 
absence of integrin-ligand interactions (Janiak et al., 2006).  These TG2/ integrins 
complexes were found to down-regulate the Src-p190RhoGAP regulatory pathway thus 
amplifying the activation levels of RhoA GTPase and its downstream signalling target, 
ROCK.  Overall, the association of TG2 with cell membrane integrins and extracellular 
matrix protein could be considered as a general amplifier of outside-in adhesion signalling. 
1.1.6 Involvement of TG2 in wound healing 
The involvement TG2 in wound healing has been well described and summarised recently 
(reviewed by Verderio et al., 2005, Telci and Griffin, 2006a).  As illustrated in Fig. 1.6, TG2 
participates in different phases of wound healing process via transamidation-dependent 
and independent mechanisms.  Secretion of TG2 into ECM was observed soon after either 
chemical or mechanical injury of fibroblasts and the released TG2 was found co-localised 
with extracellular matrix proteins (Upchurch et al., 1991).  The TG2 crosslinking activity 
was detected in all layers of skin as demonstrated by a wounded rat dermal skin model 
(Bowness et al., 1988).  Indeed, upregulation of TG2 expression and activity in 
erythrocytes and vascular endothelial cells within wound areas were suggested to support 
and amplify FXIIIa-mediated blood clot formation (Murthy et al., 1991, Barsigian et al., 
1991a, Auld et al., 2001). 
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It has been postulated that TG2-promoted cell adhesion was especially important in the 
wound healing process where TG2/FN complexes could interact with cell membrane 
syndecan receptors and enhance cell adhesion and survival when cells underwent anoikis 
(Telci et al., 2008, Wang et al., 2010, Wang et al., 2011).  In addition, increase in TG2 
mRNA expression was also related to several collagen producing phenotypes at matrix 
remodelling stages (Schnabel et al., 2004, Klingberg et al., 2012, Walter et al., 2005, Ikee et 
al., 2007). It has been also postulated that TG2-promoted cell adhesion has the ability to 
facilitate and to prevent apoptosis of cells (reviewed by Fésüs and Szondy, 2005).  These 
two opposite activities may occur distinctly depending on different cell types, the kind of 
stimuli, the intracellular localization of the enzyme and the type of activity of TG2.  
However, failure of myofibroblasts to undergo apoptosis has been related to abnormal 
scar tissue formation at the end of wound healing (Sayah et al., 1999, Aarabi et al., 2007a, 
Aarabi et al., 2007b).  Therefore, the balance between TG2 pro-apoptotic and anti-
apoptotic abilities may be critical for normal wound healing process or abnormal scar 
tissue formation. 
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Figure 1.6 Roles of TG2 in the wound healing process (adapted from Telci and Griffin, 2006a).  Proposed 
roles of TG2 in different phases of wound healing were illustrated.  It was believed that TG2 could stabilise 
extracellular matrix, promote cell survival and participate in matrix remodelling during wound closure.  pFN, 
plasma fibronectin; cFN, cellular fibronectin; PAIs, plasminogen activator inhibitors; sPLA2, secretory 
phospholipase A2 enzyme; TGF-beta1, transforming growth factor beta 1; MMP, matrix metalloproteinase; 
TIMP, tissue inhibitor of matrix metalloproteinase; RGD, peptide fragments containing Arg-Gly-Asp 
recognition sequence for integrins; HSPG, heparan sulfate proteoglycans; FAK, focal adhesion kinase.  
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1.1.7 Involvement of TG2 in pathological conditions 
Cancer 
The involvement of TG2 in cancer progression is complicated and seems to be cell type-
dependent.  Nevertheless, intracellular TG2 has been suggested to have both pro- and 
anti-apoptotic ability depended on its localisations and activity state (Milakovic et al., 
2004).  As reviewed by Milakovic and colleagues, once intracellular TG2 was activated by 
stress or trauma-induced intracellular calcium homeostasis, it could perform cross-linking 
of cellular proteins and result in apoptotic death.  However, on the other hand, studies 
have indicated that cytosolic TG2 showed an anti-apoptotic effect via activation of the NF-
κB pathway in pancreatic cancer cells and neuroblastoma cells (Mann et al., 2006, 
Condello et al., 2008).  The increase in TG2 expression has also been related to increased 
drug resistance and poor patient survival rate in specific cancers including pancreatic 
cancer (Verma and Mehta, 2007, Verma et al., 2006), breast cancer (Mangala et al., 2006, 
Mehta et al., 2004), ovarian (Satpathy et al., 2007, Hwang et al., 2008), melanoma (Fok et 
al., 2006) and lung (Park et al., 2010b).  It was also demonstrated by Gundemir and 
Johnson (2009) that translocation of TG2 into the nucleus had a protective effect against 
apoptosis.  Even though there are many conflicting results concerning TG2 expression in 
cancer cells, interestingly, many studies have indicated down regulation of TG2 expression 
in primary tumours and increased TG2 expression as a key factor for secondary tumours or 
chemoresistant cancer cells (Mehta et al., 2004, Herman et al., 2006, Verma and Mehta, 
2007, Cao et al., 2008, Mehta et al., 2010). 
Extracellular TG2, on the other hand, was proposed to be involved in tumour cell survival 
and metastasis.  It has been already demonstrated that extracellular TG2 can promote cell 
growth, survival and migration in normal cells and these mechanisms were believed also 
Page | 35 
operating in cancer cells (reviewed by Mehta et al., 2010).  It was shown in T lymphocytes 
that TG2 was important for T cell transendothelial migration (Mohan et al., 2003).  Also, 
the increased expression of cell surface TG2 in TGF-β treated retinal pigment epithelial 
(RPE) cells was linked to enhancement of cell adhesion and migration (Priglinger et al., 
2004).  In fact, inhibition of endogenous TG2 using small interfering RNA (siRNA) resulted 
in the reversal of drug resistance and the invasive phenotype, whereas overexpression of 
TG2 improved cancer cell invasion and attachment to fibronectin (reviewed by Collighan 
and Griffin, 2009).  Overall, these data implied that the precise role and function of TG2 in 
cancer cell biology may be highly dependent on the cell type, stage of cancer cells and the 
localisation of the TG2.   
Fibrosis and scarring 
TG2 has been long related to abnormal wound healing processes which involves chronic 
inflammatory response and excessive matrix deposition.  Excess ECM crosslinking by TG2 
has been established in several fibrotic disease models including pulmonary (Griffin et al., 
1979, Richards et al., 1991), renal fibrosis (Johnson et al., 1997, Johnson et al., 1999, 
Johnson et al., 2007) and liver fibrosis (Skill et al., 2001, Grenard et al., 2001).  In 
development of tissue fibrosis, chronic inflammation and constant activation of TGF-β 
signalling were observed.  TG2 was related to this chronic stress by having a role in storing 
a large pool of latent TGF-β1 binding protein-1 (LTBP-1) in the ECM via crosslinking.  
Crosslinking ECM also stabilised ECM proteins and rendered the extracellular matrix 
resistant to degradation.  As seen in a recent study, TG2 knockout mice were protected 
from the development of fibrotic lesions in obstructive nephropathy as a result of 
decreasing macrophage and myofibroblast infiltration and TGF-β related ECM over-
expression (Shweke et al., 2008b).  In addition, using a membrane permeable TG inhibitor, 
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R283 (1,3-dimethyl-2[(oxopropyl)thio]-imidazolium), and a membrane-impermeable TG 
inhibitor, R281 (N-benzyloxycarbonyl-l-phenylalanyl-6-dimethylsulphonium-5-oxo-l-
norleucine) both caused a reduction in glomerular and interstitial scarring in a rat subtotal 
nephrectomy model of chronic renal fibrosis (Johnson et al., 2007).  As briefly mentioned 
above, the abnormal hypertrophic scarring, which was characterised by prolonged action 
of myofibroblasts and excessive collagen deposition, also involved TG2 activation (Linge et 
al., 2005).  Using TG2 crosslinking activity inhibitors, therefore, as a potential treatment 
for preventing fibrosis and scar formation was evaluated by several groups and a certain 
level of success was reported.  Putrescine (Fibrostat), a general TGs inhibitor, was shown 
to reduce hypertrophic scar formation in an early stage of clinical trial (Dolynchuk et al., 
1996). 
Vascular calcification 
Vascular smooth muscle cells (VSMCs) have been shown to lose their contractile 
phenotype and switch to a synthetic phenotype in culture (VanBavel and Bakker, 2008) 
and during vascular injury and repair.  Yet, abnormal vascular remodelling may result in 
many diseases including hypertension and vascular calcification.  Atherosclerosis and aging 
are common factors for developing calcification in the arterial wall.  Although the 
mechanism of vascular calcification is a subject of ongoing work, induction of an 
osteochondrogenic phenotype in the VSMCs is generally observed in calcified vasculature.  
In vitro, there are several factors known to induce the osteochondrogenic phenotype 
which are bone morphogenetic protein-2 (BMP-2) (Wang et al., 1993, Roark and Greer, 
1994, Rickard et al., 1994), a member of the transforming growth factor-β superfamily, 
and inorganic phosphate (Pi) (Beck, 2003, Rickard et al., 1994, Beck Jr et al., 2003).  Till 
very recently, the role of TG2 in vascular stiffness was first pointed out by Johnson et al in 
2008 .  In their research, the involvement of TG2 in calcification process was demonstrated 
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that TG2 -/- VSMCs failed to develop an osteochondrogenic phenotype following high Pi 
induction.  They further showed that extrinsic wild type TG2, FXIIIa and GTP-binding site 
mutant TG2 (K173L) but not catalytic site mutant TG2 (C277S) could restore the 
calcification process in knock out cells.  The authors finally concluded that TG2 and its 
activity could negatively affect remodelling in artery wall.  Another study of apolipoprotein 
E (apoE)/ TG2 double knockout mouse model in atherosclerosis suggested that TG2 did 
not influence plaque composition or calcification (Williams et al., 2010); however, the 
researchers also indicated that one or more members of the transglutaminase family may 
have compensated for the deficiency in TG2 expression. 
Transamidating activity may be important for TG2-induced calcification, however, 
Faverman and colleagues (Faverman et al., 2008) proposed the presence of 
another TG2 transamidating independent pathway in developing calcified matrix.  
In their study, activation of β-catenin pathway was observed following interaction 
between extracellular TG2 and low density lipoprotein related-protein 5 (LRP5) 
membrane receptors in VSMCs.  There is growing evidence that TG2 may promote 
vascular calcification by activating the β-catenin signalling pathway.  A study done 
by Beazley et al. (2012) further confirmed the importance of TG2/β-catenin axis in 
vascular calcification.  Even though the later study suggested that TG2 activity was 
necessary for preventing warfarin-regulated calcification.  Overall, these results 
identified a crucial role of TG2 in vascular stiffness and targeting TG2 or its 
downstream proteins could develop a novel therapeutic for the prevention of 
vascular calcification. 
  
Page | 38 
1.2 Factor XIIIa subunit (FXIIIa) 
FXIIIa protein is one of the most studied members of the TGs and its physiological role in 
blood coagulation cascade has been firmly established.  FXIII is expressed by a wide variety 
of cell types including platelets, monocytes, their bone marrow precursors, monocyte-
derived macrophages, dendritic cells, chondrocytes, osteoblasts, and osteocytes.  The 
166kDa cellular Factor XIIIA (cFXIIIa) is a homodimer of two A-subunits; each of which 
contain 730 amino acid residues.  In plasma (plasma FXIII, pFXIII), FXIII is usually presented 
in a 320kDa tetramer (A2B2) composing of two non-covalently associated catalytic A 
subunits (A2) and two non-catalytic B subunits (B2) (Schwartz et al., 1973).  FXIII protein is 
usually in a latent form and is activated by either enzymatic cleavage of each A subunit at 
the Arg37-Gly38 peptide bond by thrombin or at very high, unphysiological Ca2+ 
concentrations (> 50mM). 
In Fig.1.7, possible activation forms of FXIIIa are summarised.  In physiological conditions, 
FXIII is activated by the concerted action of thrombin and Ca2+.  Thrombin cleaves each A 
subunit 37 amino acid residues from the N-terminus although the enzyme still remains 
inactive without the presence of Ca2+.  When Ca2+ is available at plasma concentrations, 
the B subunits then dissociate from the A subunits and the active site cysteine of the A 
subunits become accessible for the substrate or for alkylating agents.  However, a 
thrombin-independent pathway of zymogen activation was suggested under high calcium 
concentration environment that Ca2+ induces the dissociation of FXIIIb, also activates the 
FXIIIa dimer without involvement of proteolysis (Credo et al., 1978).  Similarly, the cFXIII 
can be activated via thrombin cleavage or via a non-proteolytic pathway.  In this case, a 
lower concentration (2mM with the presence of chaotropic agents) of Ca2+ is sufficient to 
bring about the active configuration of FXIIIa dimer (Polgar et al., 1990). 
Page | 39 
 
Figure 1.7 Illustration of the plasma and cellular factor XIII activation pathways (adapted from Muszbek et 
al., 2007).  White triangle indicates exposure of the active site cysteine.  Inactive proteolytically cleaved 
intermediate form is presented with a (').  Proteolitically cleaved active form is presented with a (*).  
Enzymatic form without cleavage by thrombin is presented with a (º)  
1.2.1 Structure and Substrate of FXIIIa 
The three dimensional structure of FXIIIa was first revealed by x-ray crystallography by Yee 
et al. in 1994 (Fig. 1.8).  Similar to TG2, FXIIIa consists of 4 domains including a β-sandwich 
domain (a.a. 38-184), the catalytic core (a.a. 185-515) and two C-terminal β-barrel 
domains (a.a. 516-628 and a.a. 629-731).  The three residues (Fig.1.9A): Cys314, His373 
and Asp 396 are recognised as the proteinase-like catalytic triad of FXIIIa (Pedersen et al., 
1994).  The calcium binding site (Fig 1.9B) has also been identified with the carboxylate 
group of Asp438, Glu485, and Glu490 side chains, the carbonyl O atom of Asn436, as well 
as the backbone carbonyl O atom of the Ala457 residue all involved in calcium binding (Fox 
et al., 1999). 
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Figure 1.8 Structure of human FXIIIa (DOI:10.2210/pdb1ggt/pdb).  The four main domains are (1) a β-
sandwich domain (2) the catalytic core C-terminal (3) β-barrel 1 and (4) β-barrel 2. 
 
Figure 1.9 (A) Catalytic site of FXIIIa and (B) calcium binding site of FXIIIa.  Picture is adapted from Muszbek 
et al., 2011.   
FXIIIa has a more restricted specificity for substrate compared to TG2.  In addition 
to 2 primary physiological substrates of FXIIIa, fibrin (Lorand et al., 1962) and α2- 
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plasmin inhibitor (Sakata and Aoki, 1980), another 27 proteins have been identified 
and documented in the TRANSDAB database (http://genomics.dote.hu/wiki).  
Compared to TG2 which has more than 150 listed substrates in the TRANSDAB 
database, most of the FXIIIa substrate are substrates for TG2 as well (Table 1.3). 
Table1. 3 Summary of substrates for FXIIIa (adapted from Muszbek et al., 2011. and the TRANSDAB 
database) 
Coagulation 
factors 
Fibrinolytic 
proteins 
ECM and 
Adhesion proteins 
Cytoskeletal 
proteins 
Fibrin(ogen) α 
chain 
Fibrin(ogen) γ 
chain 
Factor V 
α2- plasmin 
inhibitor 
Lipoprotein A 
Plasminogen 
Procarboxypep
tidase B/U 
Fibronectin 
Osteopontin 
Vitronectin 
Collagen 
Laminin 
Thrombospon-
din 
 
Actin 
Myosin 
Vinculin 
1.2.2 Functions of FXIIIa 
The transamidase activity of FXIIIa is important for its physiological role in the blood 
coagulation cascade.  It serves as a clot stabiliser at the final step of coagulation by 
forming γ-glutamyl-Є-lysyl-isopeptide bonds between fibrin molecules (Fig. 1.10).  The 
field of FXIIIa research has been extended in addition to its contribution to haemostasis for 
the past few decades.  The role of FXIII in the wound healing process, angiogenesis as well 
as its contribution in cartilage and bone development, inhibition of vascular permeability, 
cardioprotection and maintaining pregnancy are suggested by current studies (reviewed 
by Muszbek et al., 2011). 
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Figure 1.10 The blood coagulation cascade and proteins involved (adapted from 
http://blogs.scientificamerican.com/the-curious-wavefunction/2012/07/27/gene-duplication-frees-up-
enzymes-for-molecular-promiscuity/) 
According to clinical data, FXIII-deficient patients suffer not only from severe bleeding 
complications but also poor wound healing and abnormal scar formation (Board et al., 
1993, Anwar et al., 1999, Ivaskevicius et al., 2007).  The relation of FXIIIa deficiency and 
impaired wound healing was also demonstrated in FXIII-deficient mice (Inbal et al., 2005).  
The impaired wound healing process observed in FXIIIa deficiency models could be due to 
low proliferation of fibroblasts and failure of collagen fibre production by fibroblasts (Beck 
et al., 1961).  And the impairment of cell function could be restored using 
supplementation of FXIIIa and FXIIIa crosslinked matrix (Ueyama and Urayama, 1978).  
Besides proliferation, the migration of fibroblasts was also enhanced on FXIIIa treated 
fibrin gel (Brown et al., 1993) and fibrin clot (Grinnell et al., 1980).  A recent study 
suggested that the effect of FXIIIa on fibroblasts involved binding of FXIIIa to integrin αvβ3 
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which leads to cJun upregulation and TSP-1 downregulation (Dardik et al., 2007).  Another 
possible cell to be affected by FXIIIa deficiency is the monocyte/macrophage.  A similar 
effect was found in monocytes, that FXIIIa enhanced cell proliferation and migration and 
inhibited cell apoptosis.  This effect was found to be abolished by the addition of antibody 
against integrin αvβ3 and the activity of FXIIIa was essential for this effect on monocytes 
(Dardik et al., 2007).  However, the effect of FXIIIa deficiency on monocyte/macrophage 
migration still remains questionable since contradictory evidence are reported (Akimov 
and Belkin, 2001b) and requires further study. 
FXIIIa is also a proangiogenic factor and this function is believed to take part in the wound 
healing process.  The effect of FXIIIa in angiogenesis has been well established in several in 
vitro and in vivo models.  FXIIIa could induce a dose-dependent effect on tube formation 
of human umbilical endothelial cells (Dardik et al., 2003).  The same study also showed 
that injection of FXIIIa into cornea sub-epithelium resulted in neovascularisation of cornea.  
Also, the formation of new blood vessels into implants was greatly reduced in FXIIIa-
deficient mice (Dardik et al., 2006).  The mechanism behind the proangiogenesis mediated 
by FXIIIa was found to be crosslinking activity dependent (Dardik et al., 2003).  This effect 
also involved its binding to integrin αvβ3 which enhanced the formation of vascular 
endothelial growth factor receptor-2 (VEGFR-2)/β3 complex and further activating VEGFR-
2 signalling (Dardik et al., 2005). 
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Involvement of TG2 and FXIIIa in physiological bone development 
TGs have long been implicated in the promotion of chondrocyte and osteoblast 
differentiation and matrix mineralization.  It is generally believed that one or more 
members of the TG family are involved in these processes and these effects can be 
mediated by protein cross-linking activity of TGases, by GTPase activity of TG2 or via non-
catalytic signalling effects (reviewed in Nurminskaya and Kaartinen, 2006).  The expression 
patterns of TG2 and FXIIIa in early limb development has been demonstrated in animal 
models.  The immunohistochemistry of embryonic tibia revealed that, during bony collar 
formation, TG2 and FXIIIa were both present throughout the areas of chondrocyte 
condensation with higher levels of both proteins in the hypertrophic zone and epiphyseal 
regions of the long bone, and a slightly lower expression in the zone of chondrocyte 
proliferation.  Later in development, the TGase expression was more restricted, and 
towards the end of embryonic development, the expressions of TG2 and FXIIIa were only 
in the superficial layers of cells (Pechak et al., 1986, Nurminskaya and Linsenmayer, 1996).  
These results suggested an early activation of TG2 and FXIIIa in the mesenchymal 
condensation phase.  And in later development, the expression of these proteins was 
restricted to proliferative chondroblasts close to the epiphyses, and to the pre-
hypertrophic and differentiated hypertrophic chondrocytes.  
Study of TGs expression in the perichondrium/ periosteum area also gave a clue of TGs 
role in osteoblast differentiation (Fig. 1.11).  There was an absence of TGs expression in 
perichondrium (cartilage part) during the mesenchymal condensation phase; however, the 
expression of TGs coincided with the ossification occurring in periosteum (mineralised 
part).  It suggested that TGs were expressed in cells undergoing differentiation into 
osteoblasts.  Therefore, initiation of TGs synthesis by osteoblasts correlated with 
deposition of mineral matrix (Pechak et al., 1986, Nurminskaya et al., 2003). 
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Intriguingly, according to the expression of TGs in long bone development which was 
located at the borderline of differentiated hypertrophic chondrocytes and differentiated 
osteoblasts, Nurminskaya et al. (2003) hypothesised that chondrocyte-derived 
transglutaminase could mediate maturation of preosteoblasts in periosteal bone (refer to 
Fig 1.14 for bone structure).  In fact, they showed that co-culture of pre-osteoblasts with 
hypertrophic chondrocytes significantly increased the mineralisation area and shortened 
the time course for mineralisation while only limited mineralised matrix was found in pre-
osteoblast monoculture.  They further demonstrated that addition of exogenous guinea 
pig TG2 to pre-osteoblast culture could increase mineralisation by 3 to 5- fold over the 
untreated cultures.  Exogenous TG2 also increased gene expressions of bone sialoprotein 
(BSP) and osteocalcin (OCN), molecular markers that indicated osteoblast maturation. 
Many studies have demonstrated that transamidating activity of TG2 was important for its 
role in bone development and TG2 induced mineralisation.  Blocking TG2 with general TGs 
inhibitors, cystamine, resulted in impaired mineralisation in MC3T3-E1 (subclone 14) pre-
osteoblast culture (Al-Jallad et al., 2006).  Later on, the same group emphasised that 
transamidating activity of FXIIIa, but not TG2, was important for pre-osteoblast 
mineralisation (Al-Jallad et al., 2009).  Meanwhile, other research groups proposed 
Figure 1.11 Expression of FXIIIa (and TG2, same pattern) analyzed by immunohistochemistry 
(adapted from Nurminskaya and Kaartinen, 2006).  (A) chicken wing, (B ) chicken tibia, (C) mouse
tibia.  Pictures are taken under 10x magnification objective.  Boxed areas are shown at higher 
magnification in the lower panels.  Perichondrium/periosteum is indicated by arrow points, zone
of hypertrophy is indicated with a H and epiphysis is indicate with a E.  
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different roles that TG2 may play in mineralisation, such as via its ATPase activity (Nakano 
et al., 2007, Nakano et al., 2010) or via activating LRP/ β-catenin axis (Faverman et al., 
2008, Beazley et al., 2012). 
1.3.1 Matrix Maturation Hypothesis 
TGs are well known as matrix stabilisers and there are several bone matrix proteins, for 
example collagen I, fibronectin, OPN and BSP that have been identified as TGs substrates 
(Mosher and Schad, 1979, Kaartinen et al., 1997, Kaartinen et al., 1999, Forsprecher et al., 
2011).  TGs expression level, especially TG2, has been related to secretion and deposition 
of ECM proteins.  Also, crosslinking of ECM proteins has been demonstrated to improve 
cell adhesion, proliferation and differentiation in many studies. 
Type I collagen comprises 90% of the organic bone matrix and is one of the well studied TG 
substrates in mineralised tissues.  Up regulation of TG2 has been related to increase of 
collagen I deposition in many pathologically fibrotic conditions (Jones et al., 2005, Shweke 
et al., 2008a, Telci et al., 2009).  On the other hand, additional FXIIIa potentially lowers 
collagen synthesis in a fibroblast model (Paye et al., 1990, Paye et al., 1989).  However, the 
data remain controversial since lower collagen I expression was found in FXIII-deficient 
mice that underwent a myocardial repair process (Nahrendorf et al., 2006).  It has also 
been suggested that membrane FXIIIa is crucial for collagen deposition and its expression 
was regulated by extracellular type I collagen as part of the ECM-feedback loop (Al-Jallad 
et al., 2011, Piercy-Kotb et al., 2011).  For extracellular collagen, polymerisation could 
occur via intramolecular crosslinking (Chau et al., 2005) or between collagen and other 
non-collagenous bone matrix proteins (Mosher and Schad, 1979, Mosher, 1984, 
Aeschlimann et al., 1995, Kaartinen et al., 2005).  TGs were suggested to play a role in fibre 
organisation via their crosslinking activity.  Indeed, a well organised fibrillar collagen 
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network is the foundation of mineralisation and evidence has shown that TGs could 
promote collagen synthesis and assembly and thus promote cell differentiation (Al-Jallad 
et al., 2006). 
Fibronectin is another important ECM molecule produced by osteoblasts.  It is strongly 
suggested that fibronectin could be involved in the early stage of osteogenesis.  Weiss and 
Reddi (1981) showed the appearance of fibronectin and fibrillar networks of fibronectin 
during mesenchymal precursor cell proliferation and osteoblast maturation.  The mRNA 
and protein levels of fibronectin were found highly increased in the early stage of bone 
development with a subsequent increase in type I collagen expression (Stein et al., 1990, 
Cowles et al., 1998).  In fact, increased TG activity has been linked to an increase in 
extracellular matrix proteins under both physiological and pathological conditions.  It has 
been demonstrated that TG2 over-expression in Swiss fibroblasts led to higher fibronectin 
deposition and synthesis (Telci et al., 2009).  Furthermore, the assembly of fibronectin was 
colocalised with TG2 expression and could be reduced by inhibition of transamidase 
activity in glioblastoma cells (Yuan et al., 2006).  Fibronectin and collagen I were also found 
colocalised with crosslinking activity on the osteoblast cell surface (Al-Jallad et al., 2006).  
It has been demonstrated that crosslinking of fibronectin matrix could fundamentally 
affect collagen deposition (McDonald et al., 1982, Speranza et al., 1987, Dzamba et al., 
1993, Kadler et al., 2008, Shi et al., 2010).  Taken together, TGs could participate in 
fibronectin fibril maturation and thus contribute to collagen matrix formation and 
osteoblast mineralisation. 
In most mineralized tissues, certain non-collagenous proteins, many of which belong to 
the SIBLING (small Integrin binding ligand N-linked Glycoprotein) protein family, were 
found also structured at the macromolecular scale via crosslinking.  OPN and BSP are two 
proteins belong to SIBLING family and their presence, both monomeric and oligomeric 
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forms, in bone have been demonstrated.  OPN has been identified as a substrate of TG2 by 
Prince et al. (1991) where the polymerization of OPN occurred in connective tissues.  TGs 
mediated crosslinking of OPN to fibronectin was suggested (Beninati et al., 1994) and 
altering the conformation of OPN via crosslinking was also reported to increase its binding 
to collagen (Kaartinen et al., 1999).  Furthermore, the co-localisation of oligomerised OPN, 
TG2 and integrin αvβ3 on the cell surface suggested that high molecular weight OPN may 
function as a cell attachment molecule (Wozniak et al., 2000).  Although very little is 
known about the biological role of OPN and BSP oligomerisation, it has been shown that 
surface immobilised and oligomerised OPN and BSP by TGs improved osteoblast adhesion 
(Forsprecher et al., 2011). 
Overall, the putative role of TG2 in osteoblast mineralisation involves promoting matrix 
protein secretion, deposition and maturation via its crosslinking- mediated modification of 
ECM which further enhances cell attachment. 
1.3.2 Putative transamidating independent pathway 
Cell-ECM Adhesion and Signalling 
Currently, there are several models of TG2-containing adhesive/signalling pathways which 
have been proposed.  Among all, involvement of TG2 in RGD dependent integrin signalling 
is one of the well studied pathways.  It was first indicated by Akimov et al. (2000) that TG2 
non-covalently interacted with the β1 and β3 integrins on the cell surface and regulated 
the interaction between Fn and integrin.  In this case, TG2 was proposed as an integrin-
associated coreceptor to improve cell adhesion and spreading.  Later on, this interaction 
between extracellular TG2 and integrins was implied to play a role in Fn deposition 
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(Akimov and Belkin, 2001a, Zemskov et al., 2006), integrin clustering on cell surface (Janiak 
et al., 2006) and cell migration (Akimov and Belkin, 2001b). 
Another important TG2-containing adhesion pathway was also reported by Telci et al. 
(2008) that TG-FN binding to syndecan-4 could associate with integrin β1 signalling 
through PKCα and trigger an RGD-independent cell adhesion process.  These complexes 
were also found to trigger another downstream signal effector, syndecan-2, which 
modulated the cytoskeletal organization through the ROCK pathway to maintain the RGD-
independent adhesion of fibroblasts (Wang et al., 2010) and osteoblasts (Wang et al., 
2011).  Overall, increasing Fn interaction with cell surface integrins and syndecans by TG2 
and further maturation of the cytoskeleton structure has been shown to improve 
fibronectin deposition as well as fibronectin fibril formation, cell differentiation  and the 
promineralising effect of biomaterials (Geiger et al., 2001, García and Reyes, 2005, Chau et 
al., 2005, Forsprecher et al., 2009, Vagaska et al., 2010). 
ATPase activity 
TG2 was also proposed to act as ATPase to regulate the level of local phosphate (Pi) 
concentration within mineral tissue.  Local phosphate (Pi)/ pyrophosphate (PPi) ratio plays 
an active role in regulation of physiological and pathological mineralization (reviewed by 
Sapir-Koren and Livshits, 2011).  PPi is a common by-product of cellular metabolic 
reactions and is considered as an inhibitory molecule for hydroxyapatite (HA) formation.  
Hydrolysis of PPi into 2 Pi molecules takes place in the ECM by the tissue-nonspecific 
alkaline phosphatase (TNSALP) enzyme which is located on the osteoblast cell surface 
(Murshed et al., 2005, Hessle et al., 2002).  TNSALP promoted bone mineralization by 
increasing Pi level, meanwhile, maintaining proper low extracellular PPi concentrations 
and allowing normal bone mineralization.  However, other phosphatases, including plasma 
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membrane Ca2+ transport ATPase 1 (PMCA1) (Stains et al., 2002, Francis et al., 2002, 
Nakano et al., 2004) and ATPase activity of TG2 (Nakano et al., 2007), might also 
contribute to mineralisation by locally raising Pi levels.  Studies further suggested that 
cleavage of guinea pig TG2 by membrane type I- matrix metalloproteinase (MTI-MMP, also 
known as MMP-14) in vitro resulted in approximately a 3-fold increase in the ATPase 
activity of TG2.  The cleaved 56-kDa fragment of TG2 was also demonstrated to have ATP 
binding ability.  Nakano et al. (2010) proposed a hypothesis that MT1-MMP functioned as 
a modulator for extracellular TG2 as part of a regulatory mechanism which could activate 
the pro-mineralisation function of TG2. 
Exogenous TG2 signalling Pathway 
Studies in various cell cultures revealed that addition of exogenous TG2 promoted pre-
osteoblast differentiation (Nurminskaya et al., 2003), chondrocyte maturation to 
hypertrophy (Johnson and Terkeltaub, 2005) and calcification of vascular smooth muscle 
cells  (VSMCs) (Faverman et al., 2008).  These studies demonstrated a correlation between 
extracellular TG2 and the mineralising process in a variety of cell lines.  The following 
observations were also suggested by these researches:  
First, exogenous TG2 promoted pre-osteoblast differentiation and matrix mineralisation in 
a non-crosslinking activity dependent mechanism.  This hypothesis is supported by the 
finding that there are no changes in the pattern of protein crosslinking after treatment of  
pre-osteoblasts with chondrocyte-derived TG2 (Nurminskaya et al., 2003).  Chondrocytic 
cells transfected with mutant inactive TG still reserved the ability to develop hypertrophic 
differentiation.  Meanwhile, extracellular TG2 induced hypertrophy was not affected by 
using GTP-bound, transamidase inactive TG2 (Johnson and Terkeltaub, 2005). 
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Secondly, GTP-bound TG2 acted as a molecular switch for hypertrophic differentiation and 
calcification of the chondrocytes in which its transamidase and GTPase activities were not 
required.  As suggested by (Johnson and Terkeltaub, 2005), this could be due to the 
nucleotide-bound form of TG2 being in an ideal conformation for triggering type X 
collagen expression and calcification of chondrocytes in response to specific agonists.  The 
importance of protein conformation in TG2-induced mineralisation also provides critical 
information that the results should be evaluated carefully when crosslinking inhibitors are 
used.  Since transamidating activity inhibitors are reported to change the conformation of 
TG2 (reviewed by Pinkas et al., 2007). 
Finally, direct binding of TG2 to cell surface protein in pre-osteoblasts, hypertrophic 
chondrocyte and VSMCs without the formation of cross-links in these proteins has been 
demonstrated (reviewed by Nurminskaya and Kaartinen, 2006).  More recently, a potential 
cell surface receptor superfamily was identified to interact with TG2 directly.  TG2 was first 
found to interact with low density lipoprotein receptor related-protein (LRP) 1, one of the 
major endocytic receptors functioning in lipoprotein metabolism (Zemskov et al., 2007).  
This interaction was suggested to play a role in internalisation and degradation of cell 
surface TG2 and further regulate cell adhesion and signalling.  Later on, another member 
of this superfamily, LRP5, was also reported to interact with TG2 and was believed to be 
involved in pathological calcification of vascular smooth muscle.  A clear example has been 
demonstrated in VSMCs that binding of exogenous TG2 to cell membrane LRP5 was 
revealed using immunoprecipitation (Faverman et al., 2008).  LRP5 has been implied in the 
bone formation process for more than a decade since the discovery that loss-of-function 
mutants in LRP5 presented a severe osteoporosis phenotype (Gong et al., 2001).  
Conversely, studies of gain-of-function mutant in LRP5 showed a high bone mass 
phenotype (Boyden et al., 2002, Little et al., 2002a).  Current researches widely agreed 
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that β-catenin signalling, a major component of the canonical Wnt pathway (Fig 1.12), via 
the cell-surface molecule LRP5/LRP6 could directly regulate osteoblast maturation or 
function (reviewed by Ling et al., 2009).  Alternatively, a parallel pathway mediated by 
LRP5 was demonstrated  where increased gut-derived serotonin synthesis was found in 
LRP5-/- mice and specifically deleted LRP5 in duodenum but not osteoblasts resulted in 
low bone mass (Yadav et al., 2008).  It was proposed that the LRP5 functioned indirectly 
through its effects on serotonin synthesis in the duodenum and to regulate bone mass. 
Even though there is a great controversy on whether crosslinking activity is essential for 
the exogenous TG2 induced mineralisation (Beazley et al., 2012), the interaction between 
TG2 and cell membrane LRP5, as well as the downstream activation of β-catenin pathway 
might play a common role in calcified tissue. 
 
Figure 1.12 Scheme of Wnt signalling and its antagonists (adapted from Kawano and Kypta, 2003)(a) Binding 
of Wnt to Frizzled and coreceptors, LRP5/6, activates the canonical pathway.  It involves recruitment of Axin 
to LRP5/6 and subsequent degradation of Axin and the disruption of the link between β-catenin and 
Glycogen synthase kinase 3 beta (GSK-3β).  Intracellular β-catenin is stabilised due to free from 
phosphorylation.  (b) Presence of Wnt signalling antagonists, such as secreted Frizzled-related protein 
(sFRP), Wnt inhibitory factor-1 (WIF-1) and Cerberus (CER), block both the canonical and the noncanonical 
pathways.  Bone morphogenetic protein (BMP) and Nodal are two subsets of transforming growth factor-
beta (TGF-β) superfamily. (c) Interaction among antagonist Dickkopf-1 (Dkk-1) and LRP5/6 and the co-
receptor Kremen 1/2 (Krm, green) triggers LRP5/6 endocytosis.  The canonical pathway is inactive due to 
absence of LRP5/6–Wnt–Frizzled complex.  β-catenin is phosphorylated by GSK-3β thereby undergoes 
degradation.  However, the noncanonical pathway remains active via interaction of Wnt with Fz without 
LRP5/6..  
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1.4 Expression of TGs in cornea tissue and ocular diseases 
Abundant TGs transamidase activity was first demonstrated by Raghunath et al. (1999) 
that they found TGs activity in all ocular tissues especially in ciliary body, zonular fibers, 
and blood vessel walls.  They also suggested TG2 as the predominant crosslinking enzyme 
in ocular tissue in comparison with TG1, TG3 and FXIIIa.  A later study by Barathi et al. 
(2011) clearly demonstrated that TG1 expression (Fig.1.13) had a remarkable 
preponderance for the epithelium while TG2 expression was barely found in epithelium 
but mainly in the corneal subepithelium (CS) and stroma (S).  On the other hand, TG3 and 
TG5 were localised in the entire corneal epithelial, stromal and endothelial layers.  
Although literatures have shown the involvement of TG in ocular wound healing process 
and many numerous ocular diseases, such as pterygium (Kim et al., 1998), dry eye 
(Toshino et al., 2005), cicatricial conjunctivitis (Nakamura et al., 2001)and glaucoma 
(Priglinger et al., 2006), only a few molecular pathways have been studied.  Therefore, the 
elucidation of molecular mechanisms underlying TGs-related ocular disease is needed. 
Page | 54 
 
  
Figure 1.13 (A) Structure of eye and cornea. Picture source:  http://www.lab.anhb.uwa.edu.au-
/mb140/corepages/eye/eye.htm (B) Localization of transglutaminases (TGs) in mouse eye as 
demonstrated by immunohistochemistry (adapted from Barathi et al., 2011).  The nuclear DAPI staining is 
shown in blue and the TGs staining is shown in green.  The epithelial layer is highlighted with white line 
and corneal subepithelium and stroma are indicated with CS and S respectively.   
Page | 55 
2. Biomaterial for Tissue Repair 
Since TG2 is widely expressed in a range of tissues and it is involved in several tissue 
developmental and wound healing processes, it is reasonable to assume that a TG2-based 
biomaterial would benefit from the different properties of TG2.  Here, the potential and 
advantage of using TG2 crosslinked biomaterial for soft and hard tissue repair are 
summarised. 
2.1 Tissue engineering 
The term “tissue engineering” is thought to have been first coined in 1988 at a National 
Science Foundation (NSF) workshop by Robert Nerem.  The concept was further extended 
and formalized in a review paper in Science (Langer and Vacanti, 1993) in which the 
authors gave a modern definition: “Tissue engineering is an interdisciplinary field that 
applies the principles of engineering and the life sciences toward the development of 
biological substitutes that restore, maintain or improve tissue function.”  This concept 
introduces a great promise and potential for producing engineered replacements as 
alternative therapies for human disease and injury.  Yet, decades of research since the 
field of tissue engineering was formalized, few successful approaches have been made as 
determined by current engineered constructs approved for clinical use. 
The main progress in this area is first understanding the cell-cell interaction, then selecting 
appropriate matrices based on cell-matrix interaction and finally supplying with extra 
biochemical signalling (growth factors).  Therefore, cell sources, biomaterials and growth 
factors are three fundamental elements in tissue engineering.  In addition, the importance 
of vascularisation of engineered tissues has drawn more attention recently especially in 
reconstructing bioengineered tissue on a larger and more complicated scale (Naderi et al., 
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2011).  Following this classical approach, a certain level of achievement has been made in 
basic research and in the clinic including skin, cartilage, bone, muscle, heart valves, blood 
vessels, esophagus, connective tissue, pancreas, liver, peripheral nerves and tracheal 
constructs (reviewed in Horch, 2006). 
Bioengineered bone substitutes are considered as one of the most studied and successful 
subjects in tissue engineering.  Currently, there is high demand for bone substitutes to 
repair and replace damaged and diseased tissue due to trauma, degenerative disease and 
cancer.  Also, due to the increasing aging population, substitutes to replace, restore, or 
regenerate bone have become a major clinical need in the fields of orthopaedic, spinal, 
dental, cranial, and maxillofacial surgery.  Even though bone implements are only second 
to transfused blood products as the most implanted materials, the availability and quality 
of bone substitutes still fall short of the current requirement.  Therefore, developing 
appropriate bone constructs for clinical use is important.  On the other hand, due to 
regeneration of complex tissues or organs, such as heart, muscle, kidney, liver, and lung, 
are still a distant milestone in tissue engineering, developing comparably “simple” tissue, 
such as cornea, is a more promising short term aim (Ruberti and Zieske, 2008).  Cornea is a 
thin and avascular tissue but with a highly organised matrix layer.  Again, the quality and 
quantity of artificial cornea graft is far behind the clinic demand (Aiken-O'Neill and 
Mannis, 2002, Thompson Jr et al., 2003).  Thus, it is beside the academic challenge but also 
clinical demand in developing a suitable replacement for cornea graft. 
In this thesis, evaluating TG2 crosslinked type I collagen as a biomaterial for both bone and 
cornea reconstruction is one of the aims.  The background and detail of the bone and 
cornea regeneration will be summarised respectively in following sections. 
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2.2 Bone tissue engineering 
According to statistics, the annual medication cost for fractures is $10 billion with over 1.2 
million cases in USA and 5% of overall cases showed delayed healing or non-union after 
surgery.  In fact, there are around 4 million operations involving bone grafting or bone 
substitutes performed around the world each year (reviewed in Brydone et al., 2010).  A 
growing number of joint replacements due to aging societies also highlights the 
requirement of bioengineered bone tissue.  During 2011/2012, there were about 180,000 
cases of primary hip and knee replacement procedures entered into the National Joint 
Registry (NJR) in the UK with around 8.7% of primary joint replacements undergoing 
revision surgery (NJR, 2011).  Therefore, the clinical need for continued advances in bone 
engineering is urgent.  The following sections aim to summarise the bone biology, current 
options available for bone grafting and recent developments in cell engineering. 
2.2.1 Bone biology 
Bones are rigid tissues which provide mechanical support for anchoring muscles, 
facilitating movement and protecting organs.  The detail of the bone structure is 
illustrated in Fig. 1.14.  According to the morphology, there are two forms of bone which 
are cortical (compact) bone and trabecular (cancellous or spongy) bone.  The cortical bone 
is a condensed layer, consisting of densely packed collagen fibrils in concentric lamellae, of 
all bone tissues with low porosity (5-30%).  It accounts for the mechanical property of the 
skeleton and contributes to 80% of the total bone mass of an adult.  The trabecular bone is 
composed of a porous latticework matrix and mainly functions as a reserve of minerals in 
body (Standring and Gray, 2008). Bone tissue contains several types of bone cells and 
bone extracellular matrix.  There are four different cell types in bone: osteoblasts, bone 
lining cells, osteocytes and osteoclasts 
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• Osteoblasts/ bone lining cells/ osteocytes 
Osteoblasts arise from osteoprogenitor cells which synthesise new bone matrix composing 
mainly type I collagen.  Flattened bone lining cells are thought to be quiescent osteoblasts 
which line nonremodeling endosteal bone surfaces.  It has been suggested that bone lining 
cells may regulate bone remodelling signals and they are important in the maintenance of 
mineral homeostasis (Miller et al., 1989).  Osteocytes are star shaped cells that originate 
from osteoblasts trapped inside the matrix they secret.  Osteocytes reside inside lacunae 
and network to each other, in a similar way to the nervous system, via long cytoplasmic 
extensions in tiny canals called canaliculi.  Although osteocytes have lower synthetic 
activity, research has shown that they are actively involved in turnover of bony matrix 
through various mechanosensory mechanisms. 
Mesenchymal stem cells (MSCs) are capable of differentiating into lineages of 
mesenchymal tissue including bone, cartilage, muscle, fat and fibrous connective tissue 
(Pittenger et al., 1999) and they have been isolated from adult peripheral blood, tooth 
pulp and bone marrow.  The canonical Wnt/β-catenin pathway is considered as one of the 
master modulators in differentiation of MSCs to osteoprogenitor cells (Logan and Nusse, 
2004).  In fact, high and low bone mass phenotypes have been associated with activation 
of LRP5, a co-receptor of Wnt protein receptor (Gong et al., 2001, Boyden et al., 2002, 
Little et al., 2002a, Little et al., 2002b).  Furthermore, multipotential myogenic cells give 
rise to osteoprogenitor by dedifferentiation under the right circumstances (Doherty et al., 
1998).  In this case, blood vessel pericytes may undergo dedifferentiation and develop 
other phenotypes such as osteoblasts, chondrocytes, adipocytes, and fibroblasts. 
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Figure 1.14 The histology of bone. (A) A human femur (Resource: The Internet Encyclopedia of Science http://www.daviddarling.info/encyclopedia/ETEmain.html) (B) Structure of the 
diaphysis in long bone (C) Enlarged aspect of Haversian systems in compact bone (D) Detail of spongy bone trabculae (Resource: Rutgers University online lecture 
http://www.rci.rutgers.edu/~uzwiak/AnatPhys/APFallLect8.html) 
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Osteoblast precursors go through morphology change, from spindle-like to large cuboidal 
shape, when differentiated into mature osteoblasts.  The mature, functioning osteoblasts 
are usually surrounding by alkaline phosphatase (ALP) positive osteoprogenitor cells in the 
bone remodelling nodules.  Stein et al. (1990) proposed that there are three major stages 
of osteoblast differentiation/ mineralisation which can be summarised in Figure 1.15. 
Highly proliferating osteoblastic cells produce abundant ECM protein including fibronectin 
and type I collagen at the early stage of differentiation.  The proliferation rate declines 
when the early mineralisation marker, ALP, appears and it accompanies the secretion of 
osteopontin and osteonectin.  An increase in osteocalcin expression and mineral 
deposition, composed of calcium and phosphate, can be observed at the onset of 
mineralisation while the ALP expression starts to decline. 
 
Figure 1.15 Three principle stages of osteoblast differentiation- a) proliferation, b) matrix maturation and c) 
mineralisation 
• Osteoclasts 
It is generally believed that osteoclasts are derived from mononuclear precursor cells of 
the monocyte-macrophage lineage in bone marrow (Nijweide et al., 1986).  Two cytokines, 
Receptor activator of nuclear factor κB ligand (RANKL) and macrophage colony-stimulating 
factor (M-CSF), have been identified as key regulators in osteoclast formation.  Both 
stromal cells and osteoblasts are required in osteoclastogenesis and this process is 
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regulated by membrane anchored and soluble RANKL and M-SCF which are secreted by 
stromal cells and osteoblasts (Teitelbaum and Ross, 2003).  RANKL signals through 
Receptor activator of nuclear factor κB (RANK) on osteoclast precursor cells and mediates 
osteoclast differentiation, activation and survival during normal bone modelling and 
remodelling processes and in a variety of pathologic conditions characterized by increased 
bone turnover.  This signalling can be antagonised by osteoprotegerin (OPG) which binds 
to RANKL and prevents binding of RANKL to RANK (Boyce and Xing, 2007).  M-CSF 
promotes survival, proliferation and differentiation of osteoclast precursors and regulates 
the cytoskeleton of cells upon bone resorption. 
Osteoclasts are the main cells known to resorb bone mineral during bone remodelling.  
The interaction between osteoclast and bone matrix relies on cell membrane integrins 
recognising bone matrix peptides.  The β1 integrin is the major anchored integrin 
expressed in osteoclasts which can bind to collagen, fibronectin and laminin.  On the other 
hand, matrix degradation is facilitated by an integrin αvβ3-mediated event that results in 
polarisation of the cell and secretion of resorptive molecules such as hydrochloric acid and 
acidic proteases (Ross and Teitelbaum, 2005). 
2.2.2 Bone development and healing 
Condensation is the initial phase in the development of mesenchymal tissues in which a 
previously dispersed population of cells gathers together to differentiate into a single 
cell/tissue type such as cartilage, bone, muscle, tendon, kidney, and lung (Hall and Miyake, 
2000).  In skeleton development, two ossification mechanisms, endochondral ossification 
and intramembranous ossification, occur after the process of MSCs condensation.  Most of 
the skeleton, including all long bones, are formed via endochondral ossification while 
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intramembranous ossification occurs primarily in the development of flat bones including 
the skull, scapula and mandible. 
As illustrated in Fig. 1.16A, endochondral ossification is a process including formation of a 
cartilage scaffold by direct differentiation of the precursor cells to pre-chondrocytes and 
chondrocytes and followed by its replacement by mineralised bone matrix.  In long bone, 
the primary ossification usually begins at the centre of this model where chondrocytes 
stop proliferating, become hypertrophic, mineralise the matrix and secrete vascular 
endothelial growth factor (VEGF) to attract migration of chondroclasts and promote 
vascular invasion.  Hypertrophic chondrocytes direct adjacent perichondrial cells to 
become osteoblasts, which secrete collagen I-rich matrix resulting in the formation of a 
bone collar.  Hypertrophic chondrocytes then undergo apoptosis and the cartilage matrix 
left behind provides a scaffold for osteoblast mineralisation.  Secondary ossification 
centres are established in epiphysis where again, chondrocytes stop proliferating, become 
hypertrophic and signal the influx of blood vessels and osteoblasts.  The lengthening of 
long bone is facilitated by zones of proliferating chondrocytes (known as the growth-plate) 
in between primary and secondary ossification centres (reviewed in Kronenberg, 2003). 
The development of flat bone and bone widening of long bones occur primarily via 
intramembranous ossification.  This process involves the direct differentiation of 
mesenchymal cells into pre-osteoblasts and osteoblasts, yet is not well characterized as 
endochondral ossification.  Studies indicate the difference in the composition and 
structure of the bone matrix formed via endochondral and intramembranous ossification 
(Scott and Hightower, 1991), however, several common molecular regulators of these 
processes have been identified by recent study (Abzhanov et al., 2007). 
Page | 63  
 
 
Figure 1.16 Scheme of endochondral ossification and bone healing process (adapted from Frohlich et al., 
2008). (A) endochondral ossification process (I) a cartilage mould produced by chondrocytes (II) 
hypertrophic chondrocytes express both angiogenic (red circles) and osteogenic (black circles) growth 
factors (III) Vascular invasion and formation of a bone collar (dark blue rectangle) and cartilage is replaced 
with trabecular bone (IV) lengthening of bone. (B) Bone healing process (I) hematoma formation, (II) 
fibrocartilaginous callus formation (III) bony callus formation, and (IV) remodelling of the bony callus.   
When a bone fracture happens, the bone healing process involves four major stages: 
hematoma formation, fibrocartilaginous callus formation, bony callus formation, and 
remodelling of the bony callus (Fig 1.16B).  First, formation of a haematoma due to the 
damage of blood vessels initiates an inflammatory response.  This inflammation 
accompanies the release of signalling molecules involved in new bone formation such as 
fibroblast growth factors (FGFs), BMPs, platelet-derived growth-factor (PDGF) and VEGF.  
Intramembranous and endochondral ossification both mediate the bone healing process 
where bone formation occurs immediately at the cortex and periosteum via 
intramembranous ossification and the internal (chondrified) callus is formed as an initial 
platform for endochondral ossification.  The internal callus further ossifies via 
endochondral ossification and toward the end of ossification, the chondroclasts resorb the 
spongy bone and mechanical continuity is established via remodelling of cortical bone 
(reviewed in Dimitriou et al., 2005). 
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2.2.3 Bone matrix protein and bone mineral 
Bone is composed of 50-70% mineral, 20-40% bone matrix proteins, 5-10% water and less 
than 3% lipids.  The major bone matrix proteins are collagenous matrix proteins in which 
type I collagen is most abundant with trace amounts of type III, type IV and fibril-
associated collagen with interrupted triple helices (FACIT) collagen.  With 85-90% of the 
bone matrix proteins composed of collagen, there are another 10% noncollagenous matrix 
proteins (NCPs) and some of them are found exclusively in bone tissue and cells.  The list 
of identified bone matrix proteins and their putative biological functions are summarised 
in table 1.4. 
Type I collagen is the major collagenous protein in bone.  The collagen types I, III and V are 
known as the fibrillar collagens which are abundant and able to form fibres in the ECM.  
Collagen is composed of a triple helix, which generally consists of two identical α1 chain 
and α2 chain with slight differences in their chemical composition.  Ascorbic acid is 
required for normal collagen I synthesis because it is a cofactor for lysyl hydroxylase in the 
synthesis of hydroxyproline and hydroxylysine in collagen.  Hydroxyproline stabilises the 
collagen triple helix and its absence results in an unstable collagen structure which affects 
synthesis of collagen (Jeffrey and Martin, 1966).  FACIT collagens are a group of nonfibrillar 
collagens which are important for the organisation and stabilisation of ECM by serving as a 
molecular bridge between fibrils or fibrils and other proteins 
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Table 1.4 List and function of bone matrix proteins 
Protein (Chromosome Location)  Characteristics and Function 
Collagen-related proteins 
type I (17q21.23, 7q22.1)  
type X (6q21)  
type III (2q31)  
 
type V (9q34.2-34.3; 2q24.3-31; 
19q13.2) 
 
Most abundant bone matrix protein 
Found in hypertrophic cartilage 
Trace amounts in bone; may regulate 
collagen fibril diameter  
Trace amounts in bone; may regulate 
collagen fibril diameter 
Serum proteins in bone matrix 
albumin (4q11-13)  
a-HS glycoprotein (3q27)  
 
Decreases hydroxyapatite crystal 
growth  
Bovine analog is fetuin 
Glycoaminoglycan-containing 
proteins and leucine-rich repeat 
proteins 
aggrecan (15q26.1) 
 
versican (5q14.3) 
decorin (12q21.3) 
 
biglycan (Xq28) 
hyaluronan (multigene complex)  
 
 
 
Matrix organization, retention of 
calcium/ phosphorus  
Defines space destined to become 
bone 
Regulates collagen fibril diameter; 
binds TGF-β 
Binds collagen; binds TGF-β  
Associates with versican 
Glycoproteins 
alkaline phosphatase (1p36.1-p34) 
 
osteonectin (5q31.3-32)  
 
Hydrolyzes mineral deposition 
inhibitors 
Regulates collagen fibril diameter 
SIBLING proteins 
osteopontin (4q21) 
bone sialoprotein (4q21)  
 
Inhibits mineralization and 
remodelling 
Initiates mineralization 
MEPE (4q21.1)  Regulator of phosphate metabolism 
RGD-containing glycoproteins 
thrombospondins (15q15, 6q27, 
1q21, 5q13, 19p13.1) 
fibronectin (2q34)  
vitronectin (17q11) fibrillin 1 and 
2 (15q21.1, 5q23-31)  
 
Cell attachment 
 
Cell attachment 
Cell attachment 
Regulates elastic fibre formation 
γ-Carboxy glutamic acid–containing 
Proteins 
matrix Gla protein (12p13.1-
p12.3) 
osteocalcin (1q25-q31) 
 
protein S (3p11.2) 
 
 
Inhibits mineralization 
 
Regulates osteoclasts; inhibits 
mineralisation 
Unknown 
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Osteoblasts synthesise several noncollagenous proteins which can be divided into 
different categories including proteoglygans, glycoproteins, glycosylated proteins with 
potential cell-attachment activities, and γ-carboxylated (Gla) proteins.  Osteocalcin (OCN) 
is one of the noncollagenous Gla proteins secreted by osteoblasts.  Although recent 
studies suggested that OCN could mainly play a role in regulating energy metabolism (Lee 
and Karsenty, 2008, Crockett et al., 2011), carboxylation of OCN confers high affinity for 
minerals.  Thus, it was first assumed that osteocalcin, like other Gla proteins, is directly 
involved in the mineralisation process (Lian et al., 1989, Hauschka et al., 1989, Price, 
1989).  Yet, a high bone mass phenotype observed in osteocalcin knockout mice suggested 
that OCN inhibited bone formation (Ducy et al., 1996). 
Alkaline phosphatase (ALP) is the main glycoprotein in bone and presents in two forms, 
anchored form and released form.   Anchored ALP is bound to the osteoblast cell surface 
via a phosphoinositol linkage or within mineralised matrix and the released form is in 
serum (Raymond et al., 1993).  The role of ALP in mineralisation is not yet defined.  
However, the deficiency of ALP is related to hypophosphatasia, a hypomineralisation 
phenotype.  It is generally believed that ALP is involved in hydrolysis of extracellular 
pyrophosphate (PPi), a mineralisation-inhibiting byproduct of nucleotide pyrophosphatase 
(NPP), and maintains the balance of phosphate (Pi)/PPi (Orimo, 2010). 
The mineral content of bone is mostly hydroxyapatite (HA, Ca10(PO4)6(OH)2) with trace 
amounts of carbonate, magnesium, and acid phosphate.  Bone hydroxyapatite crystals are 
approximately 200 Å in dimension and are more soluble than geologic hydroxyapatite 
crystals, thereby allowing them to respond to mineral metabolism.  The mineralisation 
process is associated with the expression of ALP and many other noncollagenous proteins 
and is facilitated by extracellular matrix vesicles (MVs) which are secreted by osteoblasts 
and chondrocytes.  The initial HA precipitation happens within MVs which contain a 
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nucleation core.  The mineralisation starts with recruiting Ca2+ to MVs by calcium-binding 
molecules, including calcium-binding acidic phospholipids and calcium binding proteins.  
Meanwhile, levels of local intra- and perivesicular Pi are increased by the enzymatic 
activity of ALP and nucleoside triphosphate pyrophosphohydrolase that are enriched on 
the MV membrane.  The release of HA crystals from MVs into the extravesicular fluid is 
facilitated by phospholipases and proteases within MVs and further propagation of 
mineral into the matrix requires enzymatic activity of MMPs in MVs, which are capable of 
degrading mineral-inhibiting proteoglycans (reviewed in Anderson, 2003).  Interestingly, 
TG2 is found in MVs secreted by chondrocytes (Aeschlimann et al., 1993, Rosenthal et al., 
1997, Rosenthal et al., 2001), in microparticles (MPs) secreted by smooth muscle cells (van 
den Akker et al., 2012) and its transamidating activity is also found in MVs secreted by pre 
osteoblasts (Johnson et al., 2000).  Although the exactl role of TG2 in these vesicles is 
unclear, it is suggested that the release of TG2-enriched vesicles could be the 
unconventional secretion pathway of TG2 or be directly involved in the mineralisation 
process via a transamidating-dependent or independent pathway. 
2.2.4 Biomaterial for bone repair and regeneration 
Current options for bone grafting including autografts, allografts and synthesised bone 
graft substitutes.  These options are different in their strength and osteoconductive, 
osteoinductive, and osteogenic activity which are summarised in table 1.5.  In the clinic, 
autografts are considered as ideal since they incorporate the patient's own osteogenic 
cells and an osteoconductive mineral matrix.  However, the limited amount and the 
prolonged pain at the harvest site are the major disadvantages of using autografts.  For 
allografts, the decellularisation of tissue is needed to avoid host-versus-graft immune 
response.  In this case, the allograft lacks the osteogenic properties of an autograft. 
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Table 1.5 Bone graft activity by type (modified from a table by Brydone et al., 2010)  
Bone graft Osteo-
conduction 
Osteo-
induction 
Osteogenic Mechanical 
properties 
Autograft 
Cancellous 
Cortical 
 
++ 
+ 
 
 
+ 
+/- 
 
++ 
+ 
 
+ 
++ 
Allograft 
Cancellous 
Cortical 
Demineralised 
bone matrix 
 
++ 
+/- 
++ 
 
+ 
+/- 
+++ 
 
- 
- 
- 
 
+ 
- 
++ 
Bioactive 
composites / 
growth factor 
 
+ 
 
+ 
 
- 
 
+ 
Traditionally, metals such as stainless steel 316L, cobalt chromium alloy, titanium, or 
titanium alloy (Ti-6%Al-4%V) are used in orthopaedic and dental implants.  Although the 
high stiffness of the metal material is appreciated, it results in a significant change in the 
mechanics of the implicated bone and subsequent bone remodelling may decrease the 
strength of surrounding normal bone tissue.  Current strategy of bone graft design is using 
synthesized or nature structural proteins to recreate the structure and chemical 
composition of natural bone.  Common materials used in bone graft are HA, collagen, 
calcium sulphate, silicate-substituted calcium phosphate (Si-CaP) and polyethylene (PE) 
matrix modified with HA.  Addition of osteoinductive growth factors is also found to 
increase osteoinductive property of biomaterial.  Two osteoinductive growth factors of the 
TGF-beta superfamily, rhBMP-7 (OP-1 Implant® /OP-1Putty®, Stryker-Biotec, Hopkington, 
MA, USA) and rhBMP-2 (INFUSEH/InductOs®, Wyeth, UK), are currently available on the 
market.  Although comparable healing results of OP-1/BMP7 and rhBMP2 with autografts 
are reported in clinic, in the USA, the Food and Drug Administration (FDA) advisory 
committee still holds concern of side effects, such as undesired ectopic bone formation, 
which may result in critical complications particularly in cervical spine surgery.  Besides, 
the high cost (BMP-2 is £3,200 and BMP-7 is £2,450 for 100 µg) and short shelf life are two 
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major disadvantages of using these products.  Therefore, a new generation of bone graft is 
required for clinical use. 
2.2.5 TG2 crosslinked collagen gel for bone healing 
Collagen based scaffolds are widely used in a broad range of regenerative medicine 
application.  Using collagen matrix for orthopaedic regeneration offers distinct advantages 
since type I collagen composes more than 90% of the organic fraction in native bone 
tissue.  Even though collagen scaffold has shown clinical success in a range of soft tissue 
repair applications, relatively poor mechanical properties remain a limitation for their use 
in hard tissue regeneration.  In fact, only selected researches have showed some degree of 
success in using collagen scaffolds for bone regeneration (Caiazza et al., 2000, d'Aquino et 
al., 2009, Keogh et al., 2010) compared to other synthetic materials.  The mechanical 
property problem can be overcome by the addition of a second, stiffer phase such as 
hydroxylapatite (HA) or crosslinking collagen-based matrices with glutaraldehyde 
(Weadock et al., 1983), ultraviolet (UV) radiation (Wollensak and Spoerl, 2004), 
dehydrothermal processing (Yannas and Burke, 1980), carbodiimides (Damink et al., 1996) 
and enzymatically crosslinking by microbial transglutaminase (mTG) or TG2 methods (Chen 
et al., 2005, Chau et al., 2005).  All of these methods have shown a certain level of success 
in modifying the degradation rate of collagen matrix, thus, added collagen biomaterial 
advantages in wider medical applications. 
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2.3 Cornea tissue engineering 
According to WHO global statistics in June 2012, there are about 314 million patients 
suffering from impaired vision including 45 million who are bilaterally blind.  However, 
about 85% of all impaired vision and 70% of blindness could be avoidable and cured.  The 
epidemiology of blindness shows that corneal damage remains one of the leading causes 
of blindness (Resnikoff et al., 2004), causing around 2 million new cases of bilateral 
blindness worldwide in 2002.  This number, however, did not include millions of people 
suffering from impaired and low visual acuity due to corneal opacity.  Early research by 
Negrel and Thylefors in 1998 drew attention to the global prevalence of ocular trauma and 
ulceration with an estimated 55 million new cases of ocular injuries occurring each year. 
Of these, 1.6 million people were blind, 2.3 million people had bilaterally impaired vision 
and another 19 million people were unilaterally blind or had low vision after their injuries.   
Corneal abrasion, foreign bodies striking into eyes, chemical burns and corneal ulceration 
are common eye traumas seen in the clinic.  Usually, following injury, cytokines and 
growth factors secreted by the immune cells will mediate interaction between the healthy 
tissue and immune cells in order to restore corneal structure and function. Superficial 
injury usually can heal rapidly within a week.  However, severe trauma usually involves 
stroma damage and loss.  In this case, appropriate treatment is needed or the cornea may 
fail to restore its original structure and function. Consequently, patients may suffer from 
impaired vision or even blindness.   
Ocular trauma is a global problem. However, the prevention of post-wounding blindness 
can be achieved by better medical treatment.  A corneal graft may be highly effective but 
limited due to the availability of the donor, as well as the prognosis of corneal 
transplantation is comparably poor in emergency cases.  Tissue adhesives are currently 
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used in ophthalmic surgery even though most of them are used off-label.  They can 
immediately fill the wound area and replace the damaged stroma matrix which is suitable 
for emergency use. 
2.3.1 Cornea structure 
The cornea is a transparent tissue which is about 0.5 to 0.6mm thick in the centre and 0.6 
to 0.8mm at the periphery.  It is composed of five major layers (Fig. 1.17): epithelial layer, 
Bowman’s layer, stromal layer, Descemet’s membrane and endothelial layer.  Epithelial 
cells, the main cells in epithelium, form a 5-6 cell layered, stratified tissue to protect the 
corneal interior from noxious environmental agents.  The basal layer is a monolayer of 
columnar cells. Above the basal layer are another two layers of wing cells and superficial 
squamous cells with flattened nuclei.  The epithelium comprises 10% of the total depth of 
the cornea and is regenerated by multiplication in the basal layer.  Underneath the 
epithelial layer is a basement membrane where the basal epithelial cells adhere via 
desmosomes.  The components of epithelial basement membrane (EBM) are mainly type 
IV collagen, type VII collagen, laminin-1, laminin-5, perlecan, fibronectin and 
entactin/nidogen (Ljubimov et al., 1995).  
Bowman’s membrane, an acellular layer, consists of irregularly-arranged collagen fibrils.  
The function of Bowman’s membrane is obscure.  Early research implied that the strong 
mechanical strength of Bowman’s layer helps to maintain the shape of the cornea.  A more 
recent hypothesis suggested that cytokine-mediated interaction between corneal 
epithelial cells and stromal keratocytes results in the formation of Bowman’s membrane 
which may involve chemotactic and apoptotic effects on the keratocytes (Wilson and 
Hong, 2000). 
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Figure 1.17. Cornea Histology (H&E staining).  Ep = epithelium, BM = Bowman’s membrane, SP = Substantia 
Propria or Stroma, DM = Descemet’s membrane and En = endothelium.  Adapted from Wheater’s Functional 
Histology, a text and colour atlas, p. 392, Figure 21.15. 
The corneal stroma, which contributes 90% of the total corneal thickness, is composed of 
regularly-arranged collagen fibrils which are produced by keratocytes.  The transparency 
of cornea depends on the corneal stromal ultrastructure where collagen fibres (corneal 
lamellae) are obliquely oriented from one layer to another with 49% of lamellae aligned 
orthogonally (Daxer and Fratzl, 1997).  Keratocytes play a critical role in maintaining 
corneal clarity by synthesizing and organizing stromal constituents.  The average density of 
keratocytes in the central cornea is around 20,500 cells/mm3 in which most of the cells are 
populated in the anterior 10% of the stroma (Patel et al., 2001). Normally, the keratocytes 
are quiescent in healthy cornea. Once injured, keratocytes will transform into repairing 
phenotypes, fibroblasts and myofibroblasts, to restore the damaged ECM (West-Mays and 
Dwivedi, 2006). 
Descemet’s membrane lies between the stromal layer and endothelium and serves as the 
basement membrane of endothelial cells.  Heterogeneity is found vertically across the 
Descemet’s membrane such that type IV collagen alpha 1 and alpha 2 chains and 
fibronectin are expressed on the stromal face, while alpha 3(IV)-alpha 5(IV) chains, 
entactin/nidogen, laminin-1, and perlecan appear on the endothelial face (Ljubimov et al., 
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1995).  The bottom layer of cornea is endothelium, a single sheet of squamous cell 
boundary between the posterior cornea and the anterior aqueous chamber.  The main 
function of the endothelial cells is regulating the hydration of stroma by pumping the fluid 
in and out of the corneal stromal compartments. 
2.3.2 Current treatment for corneal wound 
The prevention of post-wounding blindness can be achieved by better medical treatment.  
A donor corneal graft may be highly effective but limited due to the availability of the 
donor.  Even though with the availability of tissue, donor grafts are typically variable in 
quality from donor to donor and usually with a chance of immunological rejection or 
endothelial decompensation resulting in an 18% failure in corneal transplantation 
(Thompson Jr et al., 2003).  Also, the prognosis of corneal transplantation is comparably 
poor in emergency cases.   
Another option of using amniotic membrane (AM) in ophthalmic surgery was proposed by 
de RÖ (1940) and Sorsby and Symons (1946).  In the past few decades, great success has 
been achieved in the use of AM for repairing severe corneal defects (Kim and Tseng, 
1995), and researches reported several advantages of using AM, including reduction of 
scar formation and inflammatory response in the damaged area (Solomon et al., 2001), 
enhancement of the wound healing process and re-epithelialisation (reviewed by Choi et 
al., 2009), as well as anti-microbial and anti-viral properties (Inge et al., 1991).  A broad 
range of applications for its use in ocular surgery have expanded in the past decades, 
which includes persistent corneal epithelial defects, neurotrophic corneal ulcers, corneal 
perforations, shield ulcers, infectious keratitis, bullous keratopathy, band keratopathy and 
chemical injury.  A more recent approach also demonstrated the potential of using AM as 
a carrier for ocular surface epithelial stem cell transplants, corneal endothelial cell and 
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retinal pigment epithelial substrate (reviewed by Riau et al., 2010).  Despite the great 
benefit brought by using AM, the process of retrieving AM from donor and de-
epithelialisation of AM is complicated.  There is also possibility of disease transmission 
which requires pre-screening of the potential donor.  Additionally, the quality of AM could 
be different from donor to donor and subsequent need for storage of AM product is 
expensive.  Furthermore, the clinical indications of AM grafts or patches are generally 
limited to severe cases of ocular disease/ trauma due to the invasive surgical procedure 
that is required for this treatment.  There is also a great chance of developing a variety of 
suture-related complications in this procedure (Park and Tseng, 2000). 
Alternatively, tissue adhesives are suitable for emergency use in ophthalmic surgery.  
Current products on the market can be divided into 2 classes, synthetic (e.g., 
cyanoacrylate and acrylic-based polymers), and biological (e.g., fibrin glue, biodendrimers 
and riboflavin–fibrinogen compounds) products.  The application of tissue adhesive in 
ophthalmology provides a suture-free option which decreases postoperative discomfort, 
shortens the healing time, lowers the risk of infection as well as reduces surgical time and 
scarring.  Nevertheless delayed re-epithelialisation, toxic metabolites, possible viral 
transmission and scar tissue formation are the main disadvantages of these products 
(Lagoutte et al., 1989, Chan and Boisjoly, 2004).  
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2.3.3 Biomaterial for corneal wound closure and graft 
The properties of an ideal corneal graft include: 
• Biodegradable • Transparency 
• Enhance the healing process • Safe to use 
• Elastic mechanical properties • Reasonable price 
• Persist long enough to allow the 
cornea to regenerate 
 
Biocompatible collagen glue is a prospective solution for treatment of ocular trauma.  
Ideally, the biodegradable and non-toxic collagen glue can be applied to the wound area 
and allow cells to infiltrate.  Using collagen matrix can avoid the inconsistency of product 
quality as seen in using AM membrane.  Furthermore, by crosslinking collagen with TG2, it 
is theoretically possible to improve the matrix stability and cell adhesion.  Finally, 
crosslinked collagen gel may be provided to market at a reasonable price due the 
manufacture process of crosslinked gel being easier and without the need to screen for 
transmissible diseases. 
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3.  Objectives 
The main objectives of this thesis are to examine the expression and possible mechanism 
of action of TG2 in human osteoblast (HOB) mineralisation, as well as to produce TG2 
crosslinked biomaterials with enhanced cell inductive and cell conductive properties for 
soft and hard tissue repair. 
The first approach is to analysis the TG2 expression and extracellular crosslinking activity 
during the HOB cell mineralisation process.  TG2 knock down HOB cell lines will be 
generated in order to study the relationship of TG2 expression and mineralisation.  
Furthermore, in order to evaluate the relationship between transamidating activity of 
endogenous TG2 and cell mineralisation, TG2 crosslinking inhibitors will be used to block 
TG2 activity.  On the other hand, the pro-mineralisation effect of exogenous TG2 will be 
also examined to determine whether this effect is crosslinking activity dependent or 
independent and the possible mechanism.  Following most exogenous TG2-induced 
calcification models (Johnson et al., 2008, Faverman et al., 2008), guinea pig liver 
transglutaminase (gpTG2) will be used to induce HOB mineralisation. 
Finally, the advantage of using TG2 crosslinked biomatrix in soft and hard tissue repair will 
be evaluated.  Type I collagen extracted from rat tail and commercial gpTG2 will be used 
to generate TG2 crosslinked collagen matrix which has been demonstrated in previous 
work done by Chau et al. (2005).  HOBs will be used to represent the hard tissue model 
and human corneal fibroblasts (hCFs) and human corneal epithelial cells (hCECs) will be 
used as target cells to represent the soft tissue model. 
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Chapter II 
Materials and Methods 
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1. Materials 
1.1. General Chemicals 
All water used was distilled using a Barnstead Easypure RoDi ultrapure water purification 
system purchased from Thermo Scientific, Surrey, UK.  Sterilisation of stock solutions and 
chemicals were performed either by filtration through a 0.45µm Millex® Syringe Filter 
Units purchased from Merck Millipore, Watford, UK or autoclaving at 121°C at 1 bar for 1 
hour.  Most general chemicals were purchased from Sigma-Aldrich, Poole, UK unless 
specifically stated: 
Guinea pig liver transglutaminase (gpTG2) was purchased from Zedira GmbH, Germany 
with the activity between 14.7-16 U/mg as stated in certificate of analysis.  Recombinant 
human Factor XIII (His6-rhFXIII) was purchased from Covalab UK Ltd, Cambridge, UK.  
Fibrogammin P was purchase from CSL Behring UK Ltd, West Sussex, UK.  Biotin-
cadaverine was purchased from Zedira GmbH, Germany.  FITC-cadaverine was purchase 
from Cambridge Bioscience Limited, Cambridge, UK.  VECTASHIELD HardSet mounting 
medium with DAPI was purchased from Vector Laboratories LTD., Peterborough, UK.  
Silver (I) nitrate was purchased from Fisher Scientific UK Ltd, Leicestershire, UK.  
Cetylpyridinium chloride, p-Nitrophenyl Phosphate (pNPP) liquid substrate system, 
collagenase from Clostridium histolyticum, fibronectin from human plasma and laminin 
from human fibroblasts were purchased from Sigma-Aldrich, Poole, UK.  Tankyrase PARP 
activity inhibitor, XAV939 was purchased from Stratech Scientific Ltd., Suffolk, UK.  TG2 
activity inhibitors, R283 and R294, were kindly provided from Dr. Russell Collighan. 
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1.2. Cell Culture 
Dulbecco's modified Eagle's medium (DMEM) with high Glucose (4,5 g/L), L-glutamine, 
liquid (200mM), non essential amino acid concentrate (100x) and penicillin/streptomycin 
(100x) solution were purchased from PAA Laboratories Ltd, Somerset, UK.  EpiLife® 
medium with 60 µM Calcium and human keratinocyte growth supplement (HKGS) were 
purchased from Invitrogen Ltd, Paisley, UK. 
1.3. Immunochemicals 
Anti-TG2 (TG100) mouse monoclonal antibody was purchased from Thermo Scientific, 
Surrey, UK.  Plasmatic Transglutaminase 13 (FXIII) antibody and HRP-conjugate 
streptavidin were obtained from Covalab UK Ltd, Cambridge, UK.  Anti- N-cadherin (H-4) 
mouse monoclonal antibody, anti-LRP5 (H-105) rabbit polyclonal antibody, anti-α-tubulin 
(B152) mouse monoclonal antibody, FITC conjugated donkey anti-mouse IgG antibody and 
TR-conjugated goat anti-rabbit IgG antibody were purchased from Santa Cruz 
Biotechnology, Heidelberg, Germany.  Anti-β-catenin rabbit polyclonal antibody was 
purchased from New England Biolabs Ltd, Hertfordshire, UK.  HRP-conjugated anti-mouse 
IgG or rabbit IgG antibodies were purchased from Dako Ltd., High Wycombe, 
Buckinghamshire.  Osteocalcin Human Direct ELISA Kit was purchased from Invitrogen Ltd, 
Paisley, UK.  Pierce Co-Immunoprecipitation Kit was purchased from Thermo Scientific, 
Surrey, UK 
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1.4. Western Blot Chemicals 
Tris-glycine-SDS Buffer (10X Solution) and 40% solution containing 38.67% (w/v) 
acrylamide and 1.33% (w/v) bis-acrylamide were purchased from Melford Laboratories 
Ltd., Suffolk, UK.  Precision Plus Protein™ Dual Color Standards and blot absorbent filter 
paper were purchased from Bio-Rad Laboratories Ltd., Hertfordshire, UK.  Nitrocellulose 
membranes were purchased from Gelman Biosciences, Northampton, UK.  Enhanced 
chemiluminescence ECL reagent was obtained from Amersham Pharmacia, 
Buckinghamshire, UK.  Kodak® BioMax™ XAR Film, LX-24 developer solution and FX-40 
fixer solution were purchased from Sigma-Diagnostics, Poole, UK. 
1.5. Molecular Biology Kits and Reagents 
GenElute™ HP Endotoxin-Free Plasmid Maxiprep Kit was purchased from Sigma-
Diagnostics, Poole, UK.  NovaBlue Singles™ Competent Cells was purchased from Millipore 
(U.K.) Limited, Watford, UK.  Lipofectamine™ 2000 Transfection Reagent was purchased 
from Invitrogen Ltd, Paisley, UK.  Detergent-compatible colorimetric assay kit was 
purchased from Bio-Rad Laboratories Ltd., Hertfordshire, UK 
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2. Methods 
2.1. General Tissue Culture 
2.1.1  HOB cells culture 
Primary Human osteoblast (HOB) cell line, isolated from femoral heads of patients 
subjected to surgery, was a kind gift from Professor S. Downes and Dr. S. Anderson (School 
of Biomedical sciences, University of Nottingham).  All cells were preserved in 10% 
dimethylsulfoxide (DMSO)/ 90% foetal calf serum (PAA) and stored in -80ºC freezer 
overnight before transferring into liquid nitrogen.  To recover cells from liquid nitrogen, 
vials of cells were first thawed at 37ºC and carefully re-suspended in basic culture medium 
(see recipe below).  The cell suspension was transferred into Falcon tissue culture flasks 
and cells allowed to attach for at least 6 hours.  Medium was discarded and replaced with 
fresh culture medium after cell attachment.  All the cells were incubated at a 37ºC, 5% CO2 
incubator with regular change of medium every 4 days.  
HOBs were cultured in Dulbecco's modified Eagle medium (DMEM) -high glucose 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 2mM L-glutamine, 1% 
(v/v) non-essential amino acid and 1% (v/v) penicillin-streptomycin antibiotic (complete 
medium, CM). 
2.1.1.1 Differentiation of HOBs 
HOBs, ranging from passage 20 to 24, were subjected to differentiation treatment.  Cells 
were seeded at a density of 8×104/cm2 in complete medium for 16 hours or until cell 
cutlure reached more than 90% of confluency and differentiation treatment was initiated 
by supplementing culture medium with 50 µg/ml ascorbic acid and 10 mM β-
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glycerophosphate (differentiation medium, DM).  Medium was replaced every 2 days 
during a 12-day culture for osteoblasts differentiation and mineralisation assays unless 
otherwise indicated. 
2.1.2. hCECs and hCFs cultures 
Primary human corneal epithelial cells (hCECs) and human corneal keratocytes (hCKs) 
were kindly supplied from Dr. Naing Tint (Faculty of Medicine & Health Sciences, 
University of Nottingham).  hCECs were maintained in EpiLife® medium with human 
Keratinocyte Growth Supplement (Invitrogen Ltd, UK).  hCKs were differentiated into 
human corneal fibroblasts (hCFs) and maintained in the fibroblast phenotype using DMEM 
supplemented with 10% fetal bovine  serum (FBS), 1% (v/v) non-essential amino acids and 
2mM L-glutamine.  Additions of 1% (v/v) penicillin-streptomycin antibiotic and 0.2% (v/v) 
NormocinTM were used in medium to prevent bacterial, mycoplasma, and fungal 
contamination.  Media were changed routinely every two or three days during this study.  
All cell lines were cultured in a humidified-atmosphere incubator at 37°C and with 5% (v/v) 
CO2. 
2.1.3. Passaging, thawing and storage of cell cultures 
All cells were incubated in a humidified incubator at 37ºC with 5% CO2 and were routinely 
maintained to ensure the confluency of cell culture were never allowed to reach greater 
than 85% at any one time.  Upon reaching confluency,  monolayer of cells were rinsed with 
phosphate buffered saline (PBS) once and HOBs were detached from the tissue culture 
flask using adequate amount of pre-warmed 0.5% trypsin (PAA, Pasching, Austria) in PBS  
containing 2mM ethylenediaminetetraacetic acid (EDTA) for 5 minutes at 37ºC. Following 
detachment of cells which could be observed using a microscope, HOBs were quickly 
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recovered by addition of a double amount of fresh DMEM with 7% FBS.  The HOB cell 
suspension was centrifuged at 250×g for 5 minutes and the cell pellet was re-suspended in 
appropriate amount of CM and ready for reseeding into corresponding culture vessels. 
For hCEC and hCF cell cultures, a similar passaging protocol was used, except that 0.05% 
trypsin in PBS containing 0.2mM EDTA and 0.25% trypsin in PBS containing 1mM EDTA 
were used respectively to detach the cell monolayer.  The hCEC and hCF cell suspensions 
were centrifuged at 180×g for 7 minutes and re-suspended in the growth medium. 
Cryogenic preservation was used to maintain backups or reserve of cells.  Cells subjected 
to freezing process were detached by trypsin solution and washed once PBS.  The washed 
cell pellet was carefully re-suspended in adequate amount of 10%(v/v) dimethylsulfoxide 
(DMSO)/ FBS.  The DMSO containing cell suspension was divided into several cryogenic 
vials and the vials were allow to placed in the -20 ºC freezer for 2 hours and then in the -80 
ºC freezer overnight before transferring to a liquid nitrogen freezer for long term storage.  
To recover the cells from cryogenic storage, the frozen vials were removed from liquid 
nitrogen and rapidly thawed in 37ºC water bath for 60 to 90 seconds with gentle agitation.  
Once the cell suspension was completely thawed, the content of the vial was transferred 
to a T-75 flask containing 12 ml of culture medium and cultured at 37ºC with 5% CO2.  Cells 
were recovered from cryoprotective agent by a medium change once the cells attached to 
the flask (generally within 6 to 8 hours of thawing). 
2.2. Protein expressions, identifications and interactions  
2.3.5 Protein Concentration 
Lowry protein assay (Bio-Rad RC kit, Life Sciences, Hemel Hempstead, UK) was performed 
to quantify the obtained protein concentration of cell lysate (Lowry et al., 1951).  The 
whole assay was carried out as per manufacturers’ instructions.  In brief, 5 µl of samples 
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(diluted if needed) or bovine serum albumin (BSA) standards (ranging from 0.2-1.5 mg/ml) 
were added to each well of 96-well plate. Following addition of 25 µl of reagent A and 
200µl of reagent B, the mixture were stabilised at room temperature for 10 minutes 
before reading at 750nm using a SpectraFluor® plate reader.  Protein concentrations were 
determined against a linear standard curve produced by duplicate BSA protein standards. 
2.2.2 Collection of Total Cell Lysates and Conditioned Medium 
HOBs were initially seeded in 60 mm petri-dishes (Corning) at a density of 8×104/cm2.  At 
different time points and treatments, HOB cells were detached using pre-warmed 5mM 
EDTA in PBS for 5 minutes at 37ºC and recovered in complete medium.  Cells suspensions 
were centrifuged at 250×g for 5 minutes and cell pellets were washed in PBS once before 
re-suspension again in lysis buffer (0.025M Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-40, 5% 
glycerol; pH 7.4) supplemented with 0.2mMPMSF and 0.1% Protease Inhibitor Cocktail 
(Sigma-Aldrich Company Ltd. Dorset, UK).  After 5 minutes incubation on ice with periodic 
mixing, the lysate mixtures were centrifuged at 13,000×g for 10 minutes at 4ºC to pellet 
the cell debris. 
For collecting conditioned medium, HOBs cultured in either complete medium or 
differentiation medium were switched to serum free DMEM medium 24 hours before 
specified collecting time points.  The resultant conditioned medium was collected from the 
petridish and centrifuged at 250×g for 5 minutes to get rid of cell debris.  The conditioned 
mediums were concentrated using Amicon Ultra-0.5 centrifugal filters with 10kDa cutting 
point (Millipore Limited, Watford, UK) and subjected to total protein quantification. 
A total 50 µg of sample protein or 25 µg of total protein in conditioned medium was add-
mixed with 5X Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
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mercaptoethanol, 0.01% bromophenol blue) and adequate distilled water.  Sample 
mixtures were boiled for 5 minutes and placed on ice before loading. 
2.2.3 Western Blotting  
2.2.3.1 Preparation of Sodium Dodecyl Sulphate (SDS) Polyacrylamide Gel 
Acrylamide/ bis-acrylamide gels were cast using Mini-PROTEAN Tetra Cell Casting Module 
(BIO-RAD, Hemel Hempstead, UK) which consisted of a standard 3% (w/v) polyacrylamide 
stacking gel and a separating gel (5-15% (w/v), depending on the application required).  
Separating gels were prepared in 4X Tris-SDS stock solution  containing 1.5M Tris and 0.4% 
(w/v) SDS (pH 8.8) and standard 4% (w/v) polyacrylamide stacking gels were prepared 
using 4X Tris-SDS stock solution (0.5M Tris, 0.4% (w/v) SDS, pH 6.8).  Receipts for different 
concentrations of separating gel were listed in detail as following Table 2.1: 
 Table 2.1 Recipe for preparing different concentration of separating gel 
Stock 
solutions 
Final acrylamide concentration in the separating gel (%) (ml) 
5 6 7 7.5 8 9 10 12 
40% 
acrylamide/ 
bis-acrylamide 
1.875 2.25 2.625 2.8125 3 3.375 3.75 4.5 
4x Tris-
HCl/SDS (pH 
8.8) 
3.75 3.75 3.75 3.75 3.75 3.75 3.75 3.75 
H2O 9.375 9 8.625 8.4375 8.25 7.875 7.5 6.75 
10% 
ammonium 
persulphate 
0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
TEMED 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
The mixture of desired concentration was loaded in 80 x 60x 1.5mm module and 500 ml of 
iso-propan-2-ol was added on the surface to flatten the gel.  After 30 minutes of 
polymerisation at room temperature, the iso-propanol was removed and the surface of 
the gel was rinsed with distilled water.  Another layer of 4% stacking gel (487.5 ml of the 
40% (w/v) acrylamide /bisacrylamide solution, 1.25ml of Tris/SDS pH 6.8, 3.23 ml of 
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distilled water, 25µl 10% (w/v) ammonium persulphate and 5µl of 
tetramethylethylenediamine (TEMED)) was poured on the top of separating gel.  A 10/15 
well comb was placed into the mould and allowed to solidify at room temperature for 30 
minutes. 
2.2.3.2 Gel Electrophoresis and Protein Transferring 
Prepared samples were loaded into sample wells and another 3 µl of rainbow marker was 
loaded at the first lane of each gel.  Electrophoresis was performed at first constant 90V 
for 10 minutes and then 120V for 90 minutes until sample marker dye reached the bottom 
of the gel or rainbow marker reached desired resolution.  SDS-PAGE separated proteins 
were transferred from gel to polyvinylidene fluoride transfer membrane using Mini Trans-
Blot cell system (Biorad, Hertfordshire, UK). Briefly, the gel was removed from the plate 
module and washed once with transfer buffer contained 48.8mM Tris-HCl, 39mM glycine 
and 20% (v/v) methanol.  The apparatus was set up as manufacturer’s instruction with gel 
placed near cathode side and membrane at anode side.  Protein transferring was 
performed at constant 200mA for 2 hours on ice.  The transferred protein on the 
nitrocellulose membrane was verified by staining with Ponceau Red solution to ensure 
efficient transfer. 
2.2.3.3 Detection of Protein Using Immunoprobing 
The polyvinylidene fluoride membrane was blocked with 5% (w/v) Marvel dried milk in 
Tris-buffered saline – 0.05% Tween (TBS-T, pH 7.6) for 30 minutes, at room temperature.  
Following blocking step, the membrane was incubated with primary antibodies diluted 
1:200 to 1:1000 in blocking buffer at 4ºC overnight.  Three times washing with TBS-T 
washing solution was performed before incubating with secondary antibodies.  
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Appropriate secondary antibody was diluted 1:2000 in blocking solution and further 
incubation of membrane in secondary antibody at room temperature for 2 hours.  All the 
dilution factor can be found in Table 2.2 below.  Another three- time washing was 
performed and the membrane was incubated with ECL chemiluminescence substrate 
(Amersham, Buckinghamshire, UK) according to the manufacturers’ instructions.  The 
membrane was covered with cling film and the signal was detected by Kodak X-Omat 
chemiluminescence detection film (Roche Diagnostics, East Sussex, UK) in a Kodak Biomax 
exposure cassette.  Exposure time was varied depending on the intensity of signal and the 
resulting film was developed in 20% (v/v) LX-24 developer and fixed in 20% (v/v) FX-40 
fixer. 
Table 2.2 Dilution of primary and secondary antibodies 
Antibodies Dilution 
TG2 (TG100) mouse monoclonal antibody 1:1000 
plasmatic Transglutaminase 13 (FXIII) 
antibody 
1:200 
N-cadherin (H-4) mouse monoclonal 
antibody 
1:1000 
LRP5 (H-105) rabbit polyclonal antibody 1:1000 
α-tubulin (B152) mouse monoclonal 
antibody 
1:1000 
β-catenin rabbit polyclonal antibody 1:1000 
mouse IgG HRP-conjugated antibody 1:2000 
rabbit IgG HRP-conjugated antibody 1:2000 
 
2.2.4 Immunohistochemical Staining 
HOBs were cultured on Four Well Pattern Microscope Slides (TEKDON, INC., Florida, USA) 
and differentiated in DM as mentioned before for 4 hours to 48 hours.  The samples were 
washed with PBS (pH 7.4) and fixed with 3.7% (v/v) para-formaldehyde (PFA) /PBS (pH 7.4) 
at room temperature for 20 minutes.  Three times washing with PBS were applied to 
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samples between each step in the following procedure.  To stop the crosslinking of 
samples by residual PFA, slides were incubated with 30mM Glycine/PBS at room 
temperature for 10 minutes.  Permeabilisation step was only applied to samples which 
were stained for intracellular protein expression.  In order to permeabilise cell membrane, 
5% Triton X-100 was added to sample slides and removed after 2 minutes incubation at 
room temperature.  The sample slides were then blocked with 10% goat serum in PBS at 
room for 30 minutes.  Rabbit polyclonal LRP5 (H-105, Santa Cruz biotechnology, Inc., 
Heidelberg, Germany) antibody or rabbit polyclonal β-catenin (New England Biolabs Ltd, 
Herts, UK) antibody was used, depending on the experiments, in 1:200 dilution using 0.5% 
goat serum/TBS-T.  Incubation of primary antibody was performed at 37ºC for 1 hour or 
4ºC for 16 hours.  Following incubation of goat anti-rabbit IgG-TR conjugated antibody 
(dilute in 1:200, Santa Cruz Biotechnology, Inc., Heidelberg, Germany) was performed at 
37ºC for 1 hour or 4ºC for 16 hours.  All the samples were co-stained with mouse 
monoclonal TG2 (TG100, Thermo Scientific, Surrey, UK) antibody and donkey anti-mouse 
IgG-FITC conjugated antibody (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) at 
1:200 dilution.  Finally, the samples were washed with PBS for three times and with 
distilled water for extra 2 times.  After washing, the slides were allowed to dry against the 
tissue carefully from the edge without damaging the samples.  Samples were mounted in 
VECTASHIELD® HardSet™ Mounting Medium with DAPI (Vector Laboratories LTD, 
Peterborough, UK) and pictures were acquired using Leica TCS MP5 multiphoton 
microscope. 
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2.2.5 Protein Complex Immunoprecipitation (Co-IP) 
The interaction between TG2 and LRP5 receptor was studied using immunoprecipitation 
technique.  The Pierce® Co-Immunoprecipitation kit (Thermo Scientific, Surrey, UK) was 
used in following experiments to avoid contamination by the IP antibody.  The following 
optimised protocol was used for this study. 
2.2.5.1 Lysis of Cell Monolayer Cell Cultures 
Cultured and differentiated HOBs cell lysates were sampled at 4 hours, 1 day and 2 days 
post exogenous 1µg/ml TG2 treatment.  Monolayer of cells was washed once with PBS 
(pH7.4) and lifted up using 5mM EDTA/PBS.  Cell suspension was centrifuged at 250×g for 
5 minutes to pellet the cells and adequate IP Lysis/Wash buffer provided from the kit was 
added to resuspend the cell pellet.  After 5 minutes incubation with periodic mixing on ice, 
the cell lysate was centrifuged at 13,000×g for 10 minutes to pellet the cell debris.  The 
resultant supernatant was transferred to a new microcentrifuge tube and subjected for 
quantification of protein concentration. 
2.2.5.2 Pre-clear Cell Lysate Using Control Agarose Resin 
For clearing, cell lysate contained total 1mg of protein, the sample clearing column was 
constructed with 80μL of the control agarose resin slurry.  Washing the clearing column 
with 1X coupling buffer provided from the kit, the columns were ready to be loaded with 
cell lysates from previous step.  The lysates were incubated with clearing resin at 4ºC for 1 
hour on the orbital shaker with end-to-end mixing.  The columns containing samples were 
centrifuged at 1,000×g for 1 minute to obtain the cleared cell lysates. 
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2.2.5.3 Immobilisation of Antibody 
To prepare the binding column, 25μl of the AminoLink Plus coupling resin slurry was added 
to the each column and washed it twice with 1X coupling buffer.  A total 2 μg of antibody, 
rabbit polyclonal LRP5 antibody or mouse monoclonal TG2 antibody, was adjusted to final 
volume at 200μL and added to pre-packed column.  After addition of sodium 
cyanoborohydride solution, columns with antibody/resin mixtures were incubated at room 
temperature for 90 minutes with gentle shaking.  Once finished coupling, the antibody 
bound resin was washed once with coupling buffer and further incubated with Quenching 
buffer provided from the kit for another 15 minutes at room temperature with gentle 
shaking.  2 times washing with 1X Coupling Buffer plus 6 times washing with Wash solution 
were applied to antibody-coupled resin and the columns were ready to perform Co-IP. 
2.2.5.4  Co-IP 
The prepared columns from previous step were washed with IP Lysis/Wash buffer for two 
times and a total 800µg of whole cell lysates was added to each column.  The columns 
with cell lysate were incubated with gentle rocking at 4ºC overnight allowing the desired 
protein to be caught by the resin-bound antibody.  After incubation, the protein bound 
resin was washed with IP Lysis/Wash buffer for 3 times or more if needed. 
2.2.5.5 Elution of Co-IP and Evaluating Protein Interaction by Western 
Blotting 
The columns were placed in new collection tubes and 10μl of elution buffer was added to 
each column.  The flow through was collected by centrifuging the column at 1000×g for 1 
minute, and another 40μl of elution buffer was added to each column.  With 5 minutes 
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incubation at room temperature without shaking or mixing, the total elution was collected 
by centrifuging at 1000×g for 1 minute.  5X Laemmli sample buffer was added to each 
sample to make a 1X final sample solution and the samples were subjected to Western 
blotting analysis.  TG2/LRP5 binding was confirmed by reciprocal Western blot analyses 
using mouse monoclonal TG2 antibody or rabbit polyclonal LRP5 antibody. 
2.2.6 ELISA 
2.2.6.1 Sample Collection 
HOBs were seeded in 6-cm petri dish the day before differentiation.  Once cells were 
ready, cell layer was washed with PBS (pH 7.4) once before any treatment.  HOBs were 
subjected to different treatments and were collected at specified time points.  24 hours 
prior collecting samples, the medium were switched to 1.5 ml of serum-free medium.  On 
the day of sample collection, conditioned medium was carefully collected by pipette and 
cell debris removed by centrifugation at 250×g for 5 minutes.  Samples were either used 
immediately or stored at -80ºC for future use.  The remaining cell layer was lifted up from 
tissue culture dish using 5mM EDTA/PBS solution, lysised with RIPA buffer (0.1% SDS, 1% 
NP-40, 1% sodium Deoxycholate, 5mM EDTA, 150mM NaCl in 10mM Tris buffer, pH 7.2) 
and total protein concentration was determined using Lowry assay described previously. 
2.2.6.2 Quantification of OCN in Conditioned Medium using ELISA assay 
The osteocalcin level in conditioned medium was determined using Novex® Osteocalcin 
Human Direct ELISA Kit (Invitrogen, Paisley, UK).  As per manufacture’s instructions, 
standards and controls were reconstructed with distilled water and both samples and 
microtiter plates were thawed at room temperature before assay.  25 µl of each standard, 
control or sample was added to appropriate wells and the addition of 100 µl of working 
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anti-OST-HRP conjugate to each testing well was performed before 2-hour incubation at 
room temperature.  The reaction mix was discarded after incubation and the microtiter 
plate was washed with the washing solution for 3 times, each time for 30 seconds.  
Following the washing step, 100 µl of chromogen solution was added to each well and the 
plate was incubated at room temperature in the dark until the colour development had 
finished.  The reaction was terminated by adding 100 µl of stop solution and the optical 
density of the sample was read at 450nm using a SpectraFluor® plate reader.  The 
concentration of each sample was further normalised against the total protein extracted 
from the whole cell layer. 
2.2.7 Zymography 
Collagenase and gelatinase expression was detected using zymography technique adapted 
from Herron and colleagues work (1986).  The recipes for the resolving gel and stacking gel 
are summarised in Table 2.3 below. 
7.5 % Separating gel Stacking gel  
40% acrylamide/ bis-
acrylamide 
3 ml 
40% acrylamide/ bis-
acrylamide 
0.639 ml 
1.5M Tris-HCl pH 8.8 4 ml 0.5M Tris-HCl pH 8.8 1.71 ml 
10X gelatine or 
collagen solution 
(8mg/ml) 
1.6 ml Sucrose solution (50%) 1.71 ml 
Sucrose solution (50%) 3.44 ml Water 2.78 ml 
Water 3.96 ml 
10% Ammonium 
persulfate 
80 µl 
10% Ammonium 
persulfate 
60 µl TEMED 18 µl 
TEMED 10 µl   
Table 2.3 Recipe for preparing separating gel and stacking gel for collagen or gelatine zymography 
The conditioned medium collected on day 8 from HOBs treated with CM, DM, or different 
concentration of inhibitors was mixed with 5X Laemmli buffer to make up final 1X sample 
solution and loaded to the prepared gel.  Electrophoresis was performed at constant 120 V 
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on the ice in a chilled-cabinet (4°C) to avoiding overheating.  After electrophoresis, the gels 
were washed with enzyme renaturing buffer (see Table 2.4 for recipe) for 2 times, each 
time 30 minutes.  Renatured gels were transferred to digesting buffer (see Table 2.4 for 
recipe) and incubated at 37ºC for 48 hours.  Once finished digestion, gels were washed 
with distilled water once and stained with PageBlue Protein Staining Solution (Thermo 
Scientific, Surrey, UK) for 2 hours at room temperature.  Destaining was performed using 
distilled water for at least 4 times until the gel reached desired condition. 
Digesting Buffer (500ml, pH 7.5)  
Tris base (Final Conc. 100mM) 6.055 g 
NaCl (Final Conc. 200mM) 5.845 g 
ZnCl2 (Final Conc. 2.6µM) 0.35 mg 
CaCl2 ·2H2O (Final Conc. 5mM) 0.37 g 
NaN3 (0.02%) 0.1 g 
Renaturing Buffer  
2.5% Triton X-100 in digesting buffer  
Table 2.4 Recipe for preparing digesting buffer and renaturing buffer 
2.3 Determination and Inhibition of Transglutaminase Activity 
2.3.1 Crosslinking activities of TG2 and FXIIIa  
In order to distinguish TG2 enzymatic activity from FXIIIa, a non-specific, cell permeable 
inhibitor- R283 and TG2-specific, non-permeable inhibitor- R294 were used in following 
experiments.  The inhibitory effect of the inhibitors was first examined at protein level 
before in vitro testing.  A modified protocol to evaluate the transglutaminase was used by 
adapting the procedure mentioned by Slaughter et al., (1992) 
2.3.1.1  Sample preparation 
Guinea pig liver Transglutaminase (gpTG2) purchased from Zedira, human recombined 
FXIII purchased from Covalab and Fibrogammin® P manufactured by CSL Behring UK Ltd 
were used in this 96-well plate based assay.  2U/ml of thrombin treatment to activate FXIII 
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for and pre-incubation of enzyme with inhibitors were needed before assay.  The detail of 
setting up was summarised in the Table 2.5 below: 
 2U/ml Thrombin  Inhibitor R283 Inhibitor R294 
TG2 (100ng/well) - - - 
 - + - 
 - - + 
TG2 (100ng/well) + - - 
 + + - 
 + - + 
FXIII 
(100ng/well) 
+ - - 
 + + - 
 + - + 
Fibrogammin P  + - - 
(13.6µg/well) + + - 
 + - + 
Table 2.5 Preparation of sample in summary.  All sample were diluted in 5mM DTT and 5mM CaCl2 in 10mM 
Tris buffer (pH 7.4) and adjusted the volume to 50µl per well.  Thrombin treatment was performed on ice for 
15 minutes.  After activation of enzyme, different concentrations of inhibitors (100µM, 250µM and 500µM) 
were added to pre-activated enzyme and the mixtures were incubated on ice for another 15 minutes. 
2.3.1.2 Biotin Cadaverine Incorporation into N,N'-dimethylcasein Assay 
A 96-well plate was coated with 200µl of 100mg/ml N,N’-dimethylcasein in 100mM Tris-
HCl (pH 8.5) overnight at 4°C.  Two-time washing with PBS, 0.05 % (v/v) Tween20 was 
applied to the coated plate following with another two-time washing with distilled water.  
The plate was then blocked with 250µl of 3% (w/v) BSA in 100mM Tris-HCl (pH 8.5) for 30 
minutes at room temperature.  Plate was once again washed 3 times with PBS, 0.05 % 
(v/v) Tween20 and once more with 100mM Tris-HCl (pH 8.5).  The reaction was initiated by 
addition of 50µl of pre-treated samples and 150µl of 0.1mg/ml biotin-cadaverine in 5mM 
DTT and 5mM CaCl2 in 10mM Tris buffer (pH 7.4).  The reaction was performed at 37°C for 
30 minutes and terminated with 10mM EDTA.  A series washing with PBS, 0.05 % (v/v) 
Tween20 and once more with 100mM Tris-HCl (pH 8.5) was applied to the plate.  
Incorporated biotin-cadaverine into N,N’-dimethyl was detected by incubation with 
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extravidin peroxidase conjugate in 1:2000 dilution for 1 hour at 37oC.  Development of the 
reaction was performed using SIGMAFAST OPD (o-Phenylenediamine dihydrochloride) 
tablets (P9187, each tablet set dissolved in 20ml dH2O yields a ready-to-use buffered 
solution containing OPD and urea hydrogen peroxide).  The colour development was 
terminated by addition of 50µl of 2.5M H2SO4 and the absorbance was read at 450nm 
using a plate reader. 
2.3.2 Cell Surface Crosslinking Activity Assay 
2.3.2.1  Cell Culture and Sample Preparation 
HOBs were cultured and differentiated for 2 days, 6 days and 12 days.  To measure the cell 
surface transglutaminase activity, HOBs, at different time points, were detached from the 
tissue culture flask using 5mM EDTA/PBS.  Obtained cells were centrifuged down, washed 
once with PBS and resuspended in serum free medium.  A final 1×105 HOBs were added to 
each well of 96-well plate.  A parallel set of samples was set up with addition of 2U/ml of 
thrombin to activate FXIIIa crosslinking activity.  To further distinguish the crosslinking 
activity between tissue transglutaminase and FXIIIa, a final concentration of 250µM of 
R283 or R294 was also added to cell suspension.  50ng/well of gpTG2 and 50ng/well of 
human FXIIIa were used as positive controls. 
2.3.2.2 Biotin Cadaverine Incorporation into Fibronectin Assay 
Transglutaminase activity on cell surface was determined by the incorporation of biotin 
cadaverine into fibronectin coated microtiter plate.  96-well plate was coated with 50µl of 
5µg/ml fibronectin solution in 50mM Tris-HCl pH 7.4 overnight at 4ºC.  Before use, the 
plate was washed with 50mM Tris-HCl (pH 7.4) once and preserved in serum free cell 
culture medium.  Samples prepared as described above were added to 96 well plate and 
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the assay was initiated by addition of reaction buffer which contained 0.1mM biotin-
cadaverine and 1mM DTT in serum free medium.  The reaction was performed at 37°C for 
3 hours and terminated using PBS (pH7.4) containing 2mM EDTA.  A detergent solution 
(100µl) consisting of 0.1% (w/v) deoxycholate in 2mM EDTA /PBS (pH 7.4) was then added 
to each well and the mixture incubated with gentle shaking for 10 minutes at room 
temperature.  Further washing of fibronectin layer with 50mM Tris-HCl (pH7.4) was 
performed 3 times before blocking with 3% (w/v) BSA in 50mM Tris-HCl buffer for 30 
minutes at 37ºC.  The incorporated biotin cadaverine was revealed with a 1/2,000 dilution 
of Extravidin peroxidase conjugate (Sigma-Aldrich Co. Ltd) which was incubated for 1 hour 
at 37°C.  After incubation, a series of washes with 50mM Tris-HCl, pH 7.4 were performed 
as above.  Colour development was achieved using SIGMAFAST OPD (o-
Phenylenediamine dihydrochloride) tablets and terminated by 2.5N H2SO4 and the 
resultant absorbance was read at 450nm in a SpectraFluor® plate reader. 
2.3.3 Cell Mediated Incorporation of FITC-Cadaverine into Extracellular 
Matrix  
HOBs were cultured on Four Well Pattern Microscope Slides (TEKDON, INC., Florida, USA) 
and differentiated in DM as mentioned before for 2, 6 and 12 days.  At different time 
points, CM and DM were switched to serum free DMEM containing 0.1mM FITC labelled 
Cadaverine with or without either R283 or R294.  Cells were allowed to crosslink FITC-
cadaverine into extracellular matrix at 37ºC for 24 hours.  After incubation, medium was 
removed and cells were gently washed with PBS (pH 7.4) for three times.  Ice cold 100% 
methanol (-20 ºC) was used to fix the cells for 15 minutes at -20 ºC.  In order to remove 
non-crosslinked FITC-cadaverine, fixed samples were carefully washed with 70% ethanol 
for another three times.  Finally, another 3-time washing with PBS (pH7.4) was applied to 
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sample slides before being mounted in VECTASHIELD® HardSet™ Mounting Medium with 
DAPI (Vector Laboratories LTD, Peterborough, UK).  Sample slides were viewed and 
pictures were acquired using Leica TCS MP5 multiphoton microscope. 
2.3.4 Knockdown TG2 Expression in HOBs 
2.3.4.1 Plasmid Preparation 
  Plasmid Transformation 
NovaBlue Singles™ Competent Cells (Millipore Limited, Watford, UK) were used for 
transformation of TG2 MISSION® shRNA Plasmid DNA, shRNA 239, 240, 241, 243 and 
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA (Sigma-Aldrich 
Company Ltd. Dorset, UK), to E. coli.  As described in manufacturer’s instruction, 
microcentrifuge tubes were pre-chilled on ice before aliquot of 20µl competent cells each 
tube.  1µl of shRNA plasmid DNA was added directly to competent cells with gently mix.  
Mixtures were placed on ice for 5 minutes before heat shocking at 42ºC water bath for 
exactly 30 seconds.  2-minute incubation on ice, 140μl of room temperature Luria Broth 
(LB, 1% tryptone, 0.5% yeast extract and 1% NaCl) was added to each tube.  Cell 
suspensions were allowed to grow at 37ºC incubator with shaking at speed 250rpm for 1 
hour.  50μl of cell suspension was spread on Luria Agar (LA, 1% tryptone, 0.5% yeast 
extract, 1% NaCl and 1.5% agar) containing 100mg/L of Ampicillin.  Cells were incubated at 
37ºC incubator overnight and transformed colonies were selected the next day. 
 Plasmid DNA Isolation 
GenElute HP Plasmid Maxiprep Kit (Sigma-Aldrich Company Ltd. Dorset, UK) was used to 
purify plasmid DNA from transformed E. coli.  In brief, selected single cell colonies from 
each group were cultured in 3ml LB medium containing ampicillin at 37°C for 
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approximately 8 hours while shaking at 250 rpm.  These starting cultures were further 
diluted 1:500 in 200ml of LB medium with ampicillin and incubated at 37°C for 16 hours 
with shaking at 250 rpm.  150ml of overnight cell culture suspensions were pelleted by 
centrifuging at 5000×g for 10 minutes.  Supernatant was discarded and resultant cell pellet 
was resupended in Resuspension/RNase A Solution.  Resuspended cells were lysed by 
additional of lysis buffer with gently inverting 6 to 8 times and allowed to be chill on ice for 
3 minutes.  Within 5 minutes, cell lysates were neutralised with chill neutralization 
Solution.  Resultant cell lysates were first filtered through filter column to get rid of cell 
debris and binding solution was added to filtered lysates with gently mixing.  Mixtures 
were transferred to prepared binding column and allowed to pass through the binding 
columns.  After a series washing with wash solution, the DNA bound columns were dried 
for at least 10 minutes by applying vacuum to the columns.  Once the columns were dried, 
DNA plasmids were recovered by adding 1.2 ml of Endotoxin-free water and collected by 
centrifuging down at 1000 x g for 5 minutes.  DNA concentration of samples was 
determined using NanoDrop 3300 Micro-Volume Full-Spectrum Fluorospectrometer. 
2.3.4.2 Generation of Stable Transfected HOBs cell line 
 Determination of Puromycin Working Concentration 
In order to generate stable cell lines expressing the shRNA of interest, it is necessary to 
determine adequate concentration of puromycin in order to select transfected cells.  In 
short, 1×104/well of HOBs were seeded in a 96-well plate and cultured in a 37°C, CO2 
incubator the day before carrying out the assay.  A series dilutions of puromycin, 0, 
0.125ng/ml, 25ng/ml, 50ng/ml, 125ng/ml, 250ng/ml, 500ng/ml, 1µg/ml, 2µg/ml and 
4µg/ml, were prepared in antibiotics-free DMEM and added freshly to HOBs cell culture.  
After 48 hours incubation with puromycin, the cytotoxicity of puromycin was assayed by 
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using Cell Proliferation Kit II (Roche Diagnostics Ltd., West Sussex, UK) as mentioned 
previously in section 2.5.1.  The lowest concentration that killed 100% of the cells was 
chosen as initial working concentration for stable cell line selection. 
 shRNA Transfection and Stable Cell Line Selection 
Stable transfected HOBs were generated using Lipofectamine® 2000 Reagent (Life 
Technologies Ltd, Paisley, UK).  According to manufacturer’s instruction, initial 5×105/well 
of HOBs were seeded in 6-well plate and grown in normal DMEM culture medium without 
antibiotics for 24 hours.  On the day of transfection, well layer was washed with 1× PBS 
once and replaced with 2ml fresh DMEM without antibiotics.  Desired amount of 
lipofectamine reagent was add mixed with DMEM medium without antibiotics and 
plasmid DNA, shRNA 239, 240, 241, 243 and SHC002 was diluted in antibiotics-free DMEM.  
Transfection reagent and diluted DNA were allowed to incubate at room temperature for 
5 minutes separately.  After 5 minutes incubation, lipofectamine and diluted DNA were 
mixed gently in 1:1 ratio and the mixture was further incubated for 20 minutes at room 
temperature.  Once incubation had finished, the lipofectamine/DNA complex was added 
to each well containing cells and medium immediately and HOBs were incubated at 37°C 
in a CO2 incubator for 6 hours.  Transfection was terminated by switching 
lipofectamine/DNA containing medium to fresh antibiotics-free medium after 6 hours.  
HOBs cell culture was allowed to grown at 37°C, CO2 incubator for another 48 hours before 
selection.  To start the selection, post-transfected HOBs cells were cultured in DMEM 
supplemented with 500ng/ml of puromycin until shRNA transfected HOBs were selected.  
Medium was changed every 2 days if needed.  Once stable transfected cells had been 
selected, the knockdown cell lines were cultured in DMEM supplemented with 250ng/ml 
of puromycin for all the following experiments.  The protein expressions of TG2 and FXIIIa 
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in each stable knocked down cells lines were analysis using Western blotting to confirm 
the knock down efficiency. 
2.3.5 Inactivation of gpTG2 Crosslinking Activity Using Inhibitors 
In order to prepare inactive gpTG2, crosslinking inhibitors, R283 an R294 were used to 
block the crosslinking activity.  The concentration of gpTG2 stock solution was first 
adjusted to 0.995µg/ml containing 5mM of CaCl2 and 5mM of DTT and the active TG2 
mixture was allowed to be incubated for 5 minutes on ice.  500mM R283/R294 stock 
solution was used to minimise the volume change and the calcium bound active gpTG2 
was inhibited with a final concentration of 500µM of R283/R294 on ice for another 15 
minutes.  To avoid introducing excess inhibitor to the cell culture, inhibitor-treated gpTG2 
was underwent dialysis to remove unbound inhibitor.  Mini dialysis kit with 1kDa cut out 
point was used to clean up the inactive gpTG2.  According to the instruction, samples were 
loaded into conical bottom of the tubes.  The capped tubes were inserted into floats and 
then with the membrane down, the tubes were placed into a stirred beaker containing 
50mM Tris-HCl buffer (pH 7.4) dialysis solution.  Samples were allowed to be dialysed 
against Tris buffer for 2 hours at 4ºC and then recovered from the dialysis device by 
centrifuging. 
2.4 Cell Biological Behaviours 
2.4.1 Cell Proliferation- XTT Reduction 
The cell proliferations of HOBs, HCFs and HCECs with or without different treatments were 
measured at different time points by using Cell Proliferation Kit II (Roche Diagnostics Ltd., 
West Sussex, UK).  In brief, XTT labelling reagent and electron coupling reagent were 
mixed as manual instruction and 40µl of mixture was added to each well of 96- well plate.  
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Cells and XTT mixture were allowed to be cultured at 37°C in a CO2 incubator for 4 hours.  
Once incubation had finished, 100 µl of culture supernatant from each well was 
transferred to a new microplate and the resultant orange formazan solution was 
spectrophotometrically quantified using ELISA plate reader (absorbance wavelength: 
450nm and reference wavelength: 750nm). 
2.4.2 Mineralisation of HOB Cultures 
HOBs were subjected to different treatments for a 12-day period with regular change of 
medium every 2 days.  On day 12, Mineralised bone matrix, composed of hydroxylapatite 
(Ca10(PO4)6(OH)2), could be visualised using von Kossa staining where the silver ions 
replace calcium and form precipitation complex with phosphate group (Von Kossa, 1901).  
A modified protocol was used to determine the mineralisation of HOBs at day 12 post 
differentiation.  The samples were washed, fixed in 3.7% Paraformaldehyde for 30 minutes 
and further dehydrated in 70% ethanol for 1 hour.  Dehydrated samples were quickly 
washed with distilled water once.  After additional of 2% silver nitrate, samples were 
exposed to UV light for at least 20 minutes, washed with distilled water for 5 times and 
then fixed with 5% sodium thiosulfate for 3 minutes.  Another washing with distilled 
water, samples were viewed at x40 magnification using a Nikon CK2 microscope.  At least 
12 fixed-size, non-overlapping, random fields from each sample were photographed with 
an Olympus DP10 digital camera.  The images were converted into negative images and 
the mineralised area was quantified by using Image J software. 
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2.4.3 Evaluating ALP Hydrolysis Activity During HOBs Mineralisation 
HOB cells cultured directly on tissue culture plate or seeded on collagen matrices were 
allowed to attach to the surface for at least 24 hours before switching to differentiation 
medium (DM).  DM was changed every 2 days, and 24 hours prior sample collection, the 
medium was changed to serum-free DM.  The cultured medium collected at different time 
points were used to determine the release of ALP in the medium and the remained cell 
layer was reserved for testing anchored ALP activity. 
ALP activity was quantified by hydrolysis of p-nitrophenyl phosphate (pNPP, Sigma–
Aldrich) reaction mixture as described in Chapter III.  For analysis of released ALP activity, 
50µl of cell culture medium collected from each group was directly admixed with pNPP 
substrate.  For analysis of anchored form ALP, the cell layer was first washed with PBS, 
replaced with 50µl of fresh medium and directly interacted with pNPP substrate solution.  
The change in absorbance at 405nm was monitored over 20 minutes at 37°C.  The ALP 
activity was expressed as ΔA/min or mU (1 U reflects 1 µmole of product 
formed/minute)/cm2 culture area. 
2.4.4 Determination of Cell Number in 3D Collagen Gel Using 
Multiphoton Microscope 
hCFs were seeded on collagen matrices at the density 3,000 cells/well in a 96-well plate 
format.  The culture medium was changed once at 48 hour and after total 72-hour 
incubation, the cell containing collagen gels were washed with PBS (pH 7.4) twice and 
fixed with 3.7% PFA/PBS (pH 7.4) for 15 minutes.  After fixation, the samples were 
carefully lift from the 96- well plate, placed on the glass slide and a drop of VECTASHIELD® 
HardSet™ Mounting Medium with DAPI (Vector Laboratories LTD, Peterborough, UK) was 
added directly to the samples. 
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Samples were viewed and the images were acquired using Leica TCS MP5 multiphoton 
microscope.  The two photon excitation wavelength used was 785nm and the emission 
bandwidth was set between 395nm to 498 nm.  At least 3 areas were chosen in each 
sample which was repeated in triplicate and an 880µm size depth was scanned at a z-step 
size of 4µm.  3D projection and cross-sectional images of each series of scanning were 
generated using the LAS AF software.  The projected images were further analysed in 
ImageJ for the average cell density on each matrix. 
2.4.5 Migration of hCFs on 3D Collagen Gel 
Cell migration was determined using Boyden assay system.  A transwell protocol adapted 
from Marshall (2011) used modified and used in this study.  As illustrated in Fig.2.1, the 
polycarbonate membrane transwell inserts with 8µm pore size in 24-well plate format 
were coated with NC or TG2 gel at approximately 1.5mm in thickness.  Gels were allowed 
to settle overnight at 37 ºC and the hCFs were seeded at 156 cells/mm2 initially.  In the 
upper chamber, the serum free DMEM culture medium was used and, in order to generate 
chemo-attraction, 10% FBS/DMEM was added into lower chamber.  hCFs were allowed to 
migrate in transwell system for 48 hours.  After incubation, the serum free medium and 
the matrices were carefully lifted from transwell without disturbing the membrane.  The 
cells remained on the upper chamber side of membrane were removed using cotton swab 
and the cells attached to the lower chamber side of membrane were visualised using 
modified Romanowsky staining (Horobin and Walter, 1987).  A commercialised product, 
Diff-Quik® Stain Set (Siemens Healthcare Diagnostics, Surrey, UK), was used and in short, 
the membrane was dipped into fixative solution (Fast green in methanol) for 30 seconds, 
then transferred to Stain solution I (Eosin G in phosphate buffer) for 30 seconds and finally 
stained with Stain solution II (Thiazine dye in phosphate buffer) for 30 seconds.  The 
membranes were allowed to drain and washed with distilled water once in between 
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staining.  The stained membranes were cut out from the insert and placed to glass slide 
with the cells side facing up.  The slides were viewed using a Nikon CK2 microscope.  At 
least 7 fixed-size, non-overlapping, random fields from each sample were photographed 
with an Olympus DP10 digital camera and the cell count was performed using Image J 
software. 
 
Figure 2.1 Illustration of transwell migration assay.  6.5mm Transwell® with 8.0µm Pore Polycarbonate 
Membrane Insert (Corning) was inserted into 24-well plate.  An extra layer of collagen or crosslinked 
collagen was added on the top of membrane and hCFs were seeded on the gel.  The chemo-attraction 
generated by the 10% FBS/DMEM would encourage the migration of fibroblasts from upper chamber to 
lower chamber.  By the end of culture, the cell number on the membrane facing the lower chamber was 
analysed. 
2.4.6 CellPlayer™ 96-Well Cell Invasion assay 
2.4.6.1 Preparation of collagen coated plate and cell culture 
The day before the wound scratching assay, the 96-well plate was first coated with type I 
collagen.  Rat tail collagen I stock solution was diluted into proper concentration using 
0.017M acetic acid with stirring at 4ºC to make sure the collagen solution was dissolved 
completely.  Total 45µg/cm2 of collagen I was then added to a 96 well plate and the plate 
was incubated at 37ºC cell incubator for 1 hour.  After incubation, the collagen solution 
was discarded and the plate was washed with PBS (pH7.4) twice and equilibrated in 1X 
complete culture medium before use.  hCFs were trypsinised from the tissue culture flask 
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and seeded onto collagen coated 96i well plate at the density 8,000 cells/well.  Cells were 
cultured in 10% FBS/DMEM and allowed to form an even monolayer overnight in cell 
incubator. 
2.4.6.2 Scratch wound assay and collagen neutralisation 
Collagen gel and TG2 treated collagen gel were prepared as described before and the 
mixtures were centrifuge for 20 seconds at the top speed using a standard tabletop 
centrifuge to remove bubbles.  The neutralised collagen solutions were kept on ice to 
avoid polymerisation before use.  Once the collagen mixtures were ready, the 96- well 
plate with 90-100% confluence of hCFs was washed once with PBS (pH7.4) and the wound 
scratch was performed on cell layer using the 96-well WoundMaker™ (Essen BioScience, 
Ltd., Hertfordshire, UK).  The wounded cell layer was washed with single strength culture 
medium twice and recovered in culture medium for 5 minutes before the addition of 
collagen gel.  After recovery, the culture medium was carefully pipetted out from each 
well and 50µg/well of native collagen gel or TG2 crosslinked collagen gel was added on the 
top of wound cell layer to avoid bubble formation.  Polymerisation of collagen gel took at 
least 2 hour at 37 ºC.  Once the gel formed, complete medium was added to each well and 
the plate was placed into IncuCyte™ (Essen BioScience, Ltd., Hertfordshire, UK). 
2.4.6.3 Data collection and analysis 
In the IncuCyte™ software, the programme was set to scan 1 image per well, every hour 
for 24 hours.  The invasion of cells was determined by relative wound density (RWD) which 
was acquired using following equation: 
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w (t) = Density of wound region at time (t) 
c (t) = Density of cell region at time (t) 
The Relative Wound Density v1.0 algorithm was used to report the data and the average 
of %RWD from 4 different wells was plotted over the time points to generate a diagram.  
The real time-lapse movies from each well were also generated using the IncuCyte™ 
software. 
 
Figure 2.2 Illustration of cell invasion assay.  The plate was coated with a thin layer of collagen I protein 
before seeding cells.  Once the cell layer had reached 90-100% confluent, a wound scratch was generated 
using Essen®96-well WoundMaker™.  A layer of native collagen or crosslinked collagen gel was directly 
added to the wounded cell layer and culture medium was added after polymerisation of matrices.  Cells 
were allowed to incubate and monitored using Essen® IncuCyte™ for at least 24 hours.  Figure was adapted 
from CellPlayer™ cell invasion application note from Essen BioScience, Ltd. 
2.5 TG2 Crosslinked Collagen Matrices 
2.5.1 Type I Collagen Extraction 
Type I collagen was extracted from rat tail tendons following the same procedure used in 
published paper (Chau et al., 2005).  Briefly, tendons were isolated from freshly obtained 
rat tail, sterilised using 70% (v/v) ethanol for at least 2 hours and allowed to air-dry for 30 
minutes.  The dried tendons were dissolved in 0.017M acetic acid with stirring at 4ºC for 
48 hours.  Resulted collagen supernatant was centrifuged at 13,000×g for 1 hour at 4ºC to 
remove debris.  The dissolved type I collagen supernatant was collected and neutralised to 
pH 7.0 using 1M NaOH.  Neutralised collagen solution was allowed to be stabilised at 4ºC 
overnight with stirring.  After 16 hours incubation, solution was again centrifuged at 
Page | 107  
 
3,000×g for 20 minutes at 4ºC and resuspended in 0.017M acetic acid.  Finally 
concentration of collagen solution was determined using Lowry method described in 
Chapter II: section 2.  The type I collagen solution was stored and used within 1 month. 
2.5.2 Generating and Modifying TG2 Crosslinked Collagen Gel 
To fabricate three dimensional collagen scaffolds, collagen solution was mixed with 10X 
serum free DMEM at ratio 9:1 to make final concentration at 5mg/ml and further 
neutralised using 1M NaOH to minimise the change of the final volume.  All the 
modification of crosslinked collagen gel happened after neutralisation step.  For 
crosslinked collagen gel and BMP7 incorporated collagen gel, final concentration of 
10µg/ml TG2 (unless specific) and/or 2µg/ml of human recombinant BMP7 (Gibco®, 
Paisley, UK) were added in collagen mixture containing 5mM Dithiothreitol (DTT) and 
5mM CaCl2, pH 7.4 upon neutralising and before polymerising of collagen gel.  All collagen 
mixtures were allowed to polymerise at 37ºC overnight in cell culture incubator and 
washed with PBS twice before using.  
2.5.3 Determining Trapped TG2 in Crosslinked Matrices 
Collagen matrices were prepared for detecting the self incorporation of TG2 into collagen 
gel.  Four different groups were set up in this experiment including 5mg/ml of native 
collagen gel (NC), TG2 (10 µg/ml) crosslinked collagen gel, R283 pre-inhibited TG2 (10 
µg/ml) crosslinked gel and R294 pre-inhibited TG2 (10 µg/ml) crosslinked gel.  Inhibitors 
pre-treated TG2 was prepared.  Matrices were allowed to polymerise at 37 ºC for 16 hours.  
On the day of collection, solidified collagen gels were washed with 1X PBS (pH 7.4) three 
times and directly admixed with 5X Laemmli buffer and boiled in water at 100 ºC for 10 
minutes until the samples were all dissolved.  Electrophoresis on 7.5% SDS-PAGE gel was 
performed and further transferred to PVDF membrane.  Membrane was blocked in 5% 
dried milk in TBS-T and following mouse monoclonal TG2 (TG100, Thermo Scientific) 
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antibody was used at 1:1,000 dilution overnight at 4ºC.  With incubation of secondary anti-
mouse HRP conjugated antibody for 2 hours, the signal was visualised with Amersham ECL 
Western blotting detection reagents (GE Life Sciences). 
2.5.4 Analysis of Crosslinked Gel Surface Topography Using Scanning 
electron microscopy (SEM) 
After polymerisation, both native collagen gel (NC) and crosslinked gel (TG2) were first 
washed with single strength culture medium without serum and fixed with fixative 
solution which contains 2.5% glutaraldehyde and 1% potassium ferrocyanide in normal 
strength culture medium for 2 hours at 37°C.  Additional wash with serum free medium 
was performed and samples were freeze dried at a cycle of 50 hours till the matrices were 
completely dry.  The samples then were sputter-coated with carbon and ready for SEM 
observation.  Fibre diameters were measured at the middle of the longest perceptible part 
of the fibre.  Acquired pixels were converted to standard units (µm) of length 
measurements using SEM image scale bars.  At least 15 fibres were measured in each filed 
and 3 fields were analysed from each sample using Image J software. 
2.6 Statistical Analysis 
The Kolmogorov–Smirnov test was performed to determine the probability distributions in 
all individual data sets.  For experiments that had one independent variable across 3 or 
more experimental groups, an one-way ANOVA was used for statistical analysis.  For 
experiments that had one independent variable between two matched experimental 
groups, a paired t-test was performed for statistical analysis.  For experiments that had 
one independent variable between two sets of experimental groups, data sets were 
subjected to an unpaired t-test.  For experiments that had two independent variables 
across 3 or more experimental groups, a two-way ANOVA (Turkeys multiple comparisons 
test) was used for statistical analysis.  
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Chapter III 
Tissue Transglutaminase in 
Human Osteoblast 
Mineralisation 
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1. Introduction 
Bone is a highly dynamic tissue which undergoes continuous remodelling processes in 
response to changes in the mechanical and physiological environment throughout the 
lifetime (reviewed by SC Marks, 2002).  The process of bone remodelling involves two 
reciprocal activities, resorption of bone matrix by osteoclasts and new bone formation by 
osteoblasts.  Osteoblasts arise from mesenchymal origins and orchestrate bone formation 
under the systemic regulation of hormones, cytokines and the extracellular 
microenvironment (Raggatt and Partridge, 2010).  
TGs have been implicated in bone development, matrix maturation, calcification and 
mineralisation in the past decades.  Both TG2 and FXIIIa expression were found in cartilage 
by hypertrophic chondrocytes (Aeschlimann et al., 1993, Aeschlimann et al., 1996, 
Nurminskaya et al., 1998, Johnson and Terkeltaub, 2005) and in MC3T3 pre-osteoblasts 
(Al-Jallad et al., 2006) while TG2 showed even wider expression across primary human 
osteoblasts (HOBs), human osteosarcoma cells HOS and MG-63 (Heath et al., 2001) and rat 
osteosarcoma cells (Kotsakis and Griffin, 2007).  Positive association between increasing 
TG2 expression and promotion of cell differentiation (Nurminskaya et al., 2003, Johnson 
and Terkeltaub, 2005) has been described in in vitro models.  However, the mechanism 
behind TG-mediated mineral deposition has not been well established.  Although most 
TGs functions are attributed to their enzymatic activity, TG2, as a multifunction protein, 
may exert its pro-mineralising activity in a transamidase activity-independent way under 
certain instances (reviewed in Lorand and Graham, 2003, Nurminskaya and Kaartinen, 
2006). 
The expression of TGs in physiological bone development indicated the appearance of TGs 
was related to chondrocyte hypertrophy and osteoblast mineralisation (Nurminskaya and 
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Kaartinen, 2006).  The importance of transglutaminase activity in mineralisation has also 
been demonstrated by Al-Jallad et al. (2006) who showed that the mineralisation of 
mouse pre-osteoblasts was blocked by using transamidase activity inhibitors in vitro, even 
though TG2/FXIIIa double knockouts mice have no abnormality observed in bone 
formation (Williams et al., 2010).  It is reasonable to hypothesise that TG-mediated 
differentiation could be transamidase activity-dependent since several bone matrix 
proteins are known to be TGs substrates, for example collagen I, fibronectin, and 
osteopontin (Mosher and Schad, 1979, Kaartinen et al., 1997, Kaartinen et al., 1999).  
Studies have indicated that these ECM protein assemblies, in the presence of TG2 could 
potentially participate in matrix stabilisation and especially cell adhesion processes 
(Verderio et al., 1998, Chau et al., 2005, Telci et al., 2008, Forsprecher et al., 2009, Wang 
et al., 2011).  Recent work suggests that mineralisation induced by TG crosslinking activity 
may involve a complex interplay between extracellular matrix proteins and local 
adjustment of calcium concentration in mineral tissue (reviewed in Nurminskaya and 
Kaartinen, 2006). 
Another question is whether TG2 and/or FXIIIa crosslinking activities are critical for 
mineralisation.  Al-Jallad et al. (2006) have shown the importance of TG activity in 
mineralisation by using TG activity inhibitors to abolish mineralisation in a mouse pre-
osteoblast model.  Regardless of the expression of TG2 on osteoblasts, it was suggested by 
Al-Jallad and colleagues (2011) that FXIIIa was the dominant transglutaminase which 
contributed to cell surface transamidase activity and matrix deposition.  However, neither 
TG2 knockout mice nor FXIIIa knockout mice were reported to have skeletal or dental 
abnormalities.  This suggests that the enzymatic activity of each individual TG is not 
essential in bone formation or it is very likely that TG2 and FXIIIa can compensate each 
other in the genetic knockout mice (reviewed by Nurminskaya and Kaartinen, 2006).  The 
Page | 112  
 
compensation effect of TGs has been demonstrated in TG2 knock-out (TG2-/-) mice where 
the expression of FXIIIa in femurs of TG2-/- mice was increased (Tarantino et al., 2009).  
Furthermore, by studying the mRNA transcription levels of different TGs in different 
tissues from TG2-/- mice, Deasey et al. (2013) showed up-regulation of TG1 and induction 
of TG3 expression within the joint/ ossifying cartilage of TG2-/- mice.  TG1 and TG3 
compensation for the loss of TG2 expression may also explain the normal skeleton 
development in TG2/FXIIIa double knock-out mice (Williams et al., 2010). 
The aim of this chapter was to evaluate the TG expression and cell surface crosslinking 
activity during mineralisation by using different approaches.  First, the expression pattern 
of TG2 and FXIIIa in whole cell lysates were evaluated using Western blotting analysis.  
Secondly, the cell surface TG2 and FXIIIa activities were determined using in situ FITC- 
cadaverine or in vitro biotin- cadaverine incorporation assay with or without presence of 
TG activity inhibitors.  Finally, TG2 knockdown expression HOB cell lines were generated to 
study how TG2 activity is involved in osteoblast mineralisation. 
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2. Results 
2.1 Mineralisation of HOBs 
HOBs were cultured in complete medium (CM; 10% fetal bovine serum in Dulbecco's 
Modified Eagle Medium) or differentiation medium (DM; CM supplied with 50 µg/ml 
ascorbic acid and 10 mM β-glycerophosphate) for 12 days and the mineralisation was 
determined using von Kossa staining.  As shown in Fig. 3.1, HOBs cultured in CM displayed 
no visible mineral deposition on day 12 while cells cultured in DM showed positive von 
Kossa staining.  It suggested that 12-day differentiation treatment was an appropriate time 
frame to evaluate osteoblast mineralisation in vitro and this model would be used in all 
following experiment. 
 
Figure 3.1 Mineralisation of HOBs visualised by von Kossa staining.  HOBs cultured with complete medium 
(CM) or differentiation medium (DM) were subjected to von Kossa staining on day 12.  The mineral 
depositions were stained in black as indicated by arrows.  The scale bars represent 300 µm. 
2.2 TG2 and FXIII protein expression in HOBs during mineralisation 
By monitoring the TG2 expression in whole cell lysates during the mineralisation process, 
it was found that TG2 levels steadily increased during the whole 12-day culture period (Fig. 
3.2A).  Although the expression of TG2 in the differentiation medium-treated group was 
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lower but not significant at the early stage (day 2), it was approximately 1 fold higher than 
in complete medium at day 12 (Fig 3.2B). 
 
Figure 3.2 Expression of TG2 in whole cell lysate as demonstrated using Western blotting.  Whole cell lysates 
were collected at time point 2 days, 6 days and 12 days post differentiation treatment and Western blotting 
was performed to analysis TG2 protein expression.  A representative western blot result from three 
individual experiments is shown in (A)  α-tubulin was used as loading control and normalised data were 
showed in chart (B).  The results represent mean values +/- SEM. from three individual experiments (n=3).  
Statistical analysis was carried out using the two-way ANOVA test (Turkeys multiple comparisons test) and 
the p-values corresponding to p<0.01 was presented with a *٭and p<0.0001 was presented with a ****. 
Low amounts of ~76kDa and ~51kDa FXIIIa fragments were observed in whole cell lysates 
during the entire culture period but a short fragment (<25kDa) was most abundant at all 
time points (Fig. 3.3A).  On the other hand, in conditioned medium, ~90kDa and ~51kDa 
fragments could be detected in HOBs cultured in both CM and DM at all time points and 
~76kDa fragments could be detected in conditioned medium from day 6 in DM treated 
Page | 115  
 
HOBs (Fig. 3.3B).  Also, a low but visible amount of ~80kDa fragment could be observed in 
DM group on day 12.  However, only the <25kDa fragments were majorly found in the 
biotinylated cell membrane fractions in both groups during mineralisation (Fig 3.3C). 
According to literature, full length FXIIIa (80 kDa) is activated by thrombin which cleaves 
the Arg37-Gly38 peptide bond and releases a 76kDa, transamidase-active subunit, FXIIIa 
(Chung et al., 1974).  Research also has suggested that this cleavage of FXIII mediated by 
thrombin could produce an enzymatic 51 kDa fragment and inactive 19 kDa fragment 
(Greenberg et al., 1988) by further proteolysis of FXIIIa.  In addition to thrombin, platelet 
acid protease (Lynch and Pfueller, 1988) and calpain (Ando et al., 1987) have been shown 
to activate FXIII by cleavage of the Arg37–Gly38 peptide in a similar manner to thrombin.  
Thus, the ~76kDa and ~51kDa FXIIIa fragments found in this experiment could represent 
enzyme-cleaved and active FXIIIa fragments.  Currently, no study reported ~90kDa and 
<25kDa FXIIIa fragments and their possible biological functions.  The anti-FXIIIa antibody 
used in this study was in antiserum form, therefore the ~90kDa and <25kDa FXIIIa 
fragments could be unspecific binding or represent unknown protein bound FXIIIa or 
cleaved FXIIIa fragments.  Although Al-Jallad et al. (2011) suggested a large FXIIIa pool 
could be found in membrane fractions of differentiated mice pre-osteoblast, no full length 
or active FXIIIa fragments were observed in biotinylated membrane protein fractions.  This 
could be due to different cells types and/or different membrane protein extraction 
methods used here and in Al-Jallad’s study.  Therefore, the results in Fig.3.3 showed that 
possible transglutaminase-active FXIIIa fragments and full length FXIIIa could be found 
mainly in cells culture medium but not whole cell lysate and membrane fractions during 
osteoblast mineralisation. 
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Figure 3.3 Detecting FXIII protein in whole cell lysate and conditioned medium using Western blotting.  
Western blotting was performed on whole cell lysate (A), conditioned medium (B) and cell membrane 
protein (C) collected on Day 2, Day 6 and Day 12 post treatment.  α-tubulin was used as loading control in 
whole cell lysate samples. 
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2.3 Inhibitory effect of TG inhibitors and cell toxicity 
In order to distinguish TG2 crosslinking activity from FXIIIa, a TG2 specific inhibitor, R294, 
and non-specific inhibitor (block both TG2 and FXIIIa), R283 were used in the following 
assay.  Samples were all treated with or without FXIIIa to activate the FXIII latent form.  
According to the results, R283 was a highly effective inhibitor of TG2 and FXIIIa, at all the 
concentrations used here (Fig. 3.4A). However, R283 was not able to block the crosslinking 
activity of Fibrogammin P as efficiently as purified FXIIIa protein.  This is possibly because 
Fibrogammin P is a human plasma-derived product and contains several excipients 
including human albumin and glucose.  This could potentially lower the inhibitory effect.  
On the other hand, R294 was a TG2-specific inhibitor at lower concentration (<250 µM) 
without significant inhibitory effect on FXIIIa (Fig. 3.4B). 
The cell toxicities of transglutaminase inhibitors were also determined before the using of 
inhibitors for a 24- hour culture period.  As showed in Fig. 3.5, although when R294 used in 
high dose (500 µM) showed significantly lower XTT reduction rate when compared to the 
DM group and the R283 (500 µM) at 48 hours, no significant cell toxicity was found at the 
end of the 96-hour culture period.  Therefore, this suggested that both inhibitors showed 
no significant cell toxicity to the HOBs and could be used during the differentiation 
process. 
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Figure 3.4 Inhibitory assay of inhibitors R283 and R294.  Inhibitory effect of (A) R283 and (B) R294 to TG2 
(100ng/well) and FXIIIa (100ng/well) determined using biotin cadaverine incorporation into N,N’-
dimethylcasein assay.  The samples were pre-treated with or without thrombin (TH) as described in Table 
2.4 before activity assay.  The background absorbance was subtracted from the absorbance value of 
samples.  The results represent mean values +/- S.D where n=3. 
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Figure 3.5 Proliferation of HOBs culture treated with crosslinking activity inhibitors.  HOBs were seeded at 
initial number of 24,000/well in a 96-well plate and treated with CM, DM, 250 µM R283 in DM, 500 µM R283 
in DM), 250 µM R294 in DM and 500 µM R294 in DM.  The proliferation was determined by XTT assay at 0 
hour, 48 hours and 96 hours after treatment.  The medium was changed every 48 hours.  The relative 
proliferation rate was acquired by normalising the absorbance of experimental groups with the CM group.  
Data represents mean value +/- SEM from 4 individual experiments (n=4).  Statistical analysis using the two-
way ANOVA test (Turkey’s multiple comparison test) and results showed that besides at 48 hours, no 
significant difference was found between groups at other time points. 
2.4 Cell surface/ECM transglutaminase mediated incorporation of FITC-
cadaverine into matrix  
In order to see if extracellular TG2 activity increased along with its expression in whole cell 
lysates during mineralisation process, the crosslinking activity of TGs in differentiated 
HOBs was determined.  An in situ method was used to demonstrate cell surface/ECM TG 
crosslinking activity in HOBs cell culture using FITC- cadaverine.  After 2 days (Fig. 3.6), 6 
days (Fig. 3.7) or 12 days (Fig. 3.8) differentiation treatment, HOB cell cultures were 
incubated with FITC-cadaverine with or without R283/R294 for 24 hours in serum free 
differentiation medium.  TG mediated incorporation of FITC-cadaverine into ECM was 
visualised using a confocal microscope. Incorporation of FITC signal could be detected in 
both samples treated in complete medium or differentiation medium during the 
Page | 120  
 
mineralisation period.  Slightly higher but not quantified signal could be found in DM 
group on day 2 (Fig.3.6) and day 6 (Fig 3.7) when compared to cells cultured in CM.  It 
could suggest that differentiated osteoblasts had higher crosslinking activity in 
extracellular environment (membrane and/or matrix).  Data was not subjected to 
quantification due to unspecific FITC-cadaverine precipitation on the sample slides which 
could not be completely removed during the washing step. 
On the other hand, partial, but not complete, inhibition of substrate incorporation could 
be observed while blocking both TG2 and FXIIIa activity with inhibitor R283 and blocking 
only TG2 activity with R294.  Although none of the inhibitors could abolish the crosslinking 
activity to baseline as in pure protein assay (Fig. 3.4), it might be because of some 
extracellular TG was potentially masked from inhibitors, for example the enzyme on the 
cell surface binding to tissue culture/matrix directly could be prevented from binding to 
inhibitors.  Therefore, it suggested that there would be a minimum crosslinking activity 
presenting in inhibitor-treated in vitro system which should be taken into consideration 
when evaluating data in the future.  However, judging from the different inhibition level 
between R283 and R294, greater inhibitions were found on day 2 cell culture treated with 
R283 suggesting a greater FXIIIa crosslinking effect was detected.  It could imply that the 
crosslinking activity might shift from FXIIIa dominated at earlier stage toward TG2 
dominated at later stage of mineralisation. 
Page | 121  
 
 
Figure 3.6 Cell surface/ECM crosslinking activity visualised using FITC cadaverine.  After 2-day culture in 
either CM or DM, cells were cultured in 0.1 mM FITC-cadaverine containing serum free complete medium 
and serum free differentiation medium with or without 250 µM R283 or 250 µM R294 for another 24 hours.  
The images were acquired by using Leica TCS MP5 multiphoton microscope where the incorporated FITC 
cadaverine is shown in green and DAPI staining is shown in blue.  The scale bar represents 10 µm. 
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Figure 3.7 Cell surface/ECM crosslinking activity visualised using FITC cadaverine.  After 6-day culture in 
either CM or DM, cells were cultured in 0.1 mM FITC-Cadaverine containing serum free complete medium 
and serum free differentiation medium with or without 250 µM R283 or 250 µM R294 for another 24 hours.  
The images were acquired by using Leica TCS MP5 multiphoton microscope where the incorporated FITC-
cadaverine is shown in green and DAPI staining is shown in blue.  The scale bar represents 10 µm. 
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Figure 3.8 Cell surface/ECM crosslinking activity visualised using FITC cadaverine.  After 12-day culture in 
either CM or DM, cells were cultured in 0.1 mM FITC-Cadaverine containing serum free complete medium 
and differentiation medium with or without 250 µM R283 or 250 µM R294 for another 24 hours.  The images 
were acquired by using Leica TCS MP5 multiphoton microscope where the incorporated FITC cadaverine is 
shown in green and DAPI staining is shown in blue.  The scale bar represents 10 µm. 
2.5 Crosslinking activity of the cell surface TG2 and FXIIIa  
In order to quantify the crosslinking activity on the cell surface of differentiated cells, 
another method was used in the following experiment.  HOBs cultured in DM for 2 days, 6 
days and 12 days were first detached from culture plate, washed and suspended in serum 
free medium and then subjected to cell surface crosslinking activity assay using the biotin 
cadaverine incorporation method.  This assay was different from the previous in situ 
Page | 124  
 
system as the cells were detached from the tissue culture plate before assay, therefore, 
only membrane presenting but not extracellular (cell surface and matrix) TGs activity was 
assayed.  In order to activate the latent FXIII pool on cell surface, samples were pre-
activated with thrombin.  Thrombin activation of FXIII was first confirmed using human 
recombinant FXIII protein.  As shown in Fig. 3.9A, there was a 5-fold increase in 
crosslinking activity of FXIII by pre-treatment of thrombin (p<0.01) and a slight increase in 
TG2 activity was also observed after thrombin treatment.  This indicated that treating cells 
with thrombin could amplify the crosslinking effect of latent FXIIIa in osteoblasts.  In HOB 
cell samples, no significant difference in cell surface crosslinking activity was found 
between HOBs cultured in CM and DM during the 12-day culture.  It suggested that the 
cell surface crosslinking activity was not increased after cell differentiation and the 
increase in extracellular FITC-cadaverine incorporation (Fig 3.6, 3.7, 3.8) may resulted from 
trapped TG2 in the matrix. 
Thrombin treatment did not significantly alter cell surface TG activity of HOBs cultured in 
CM.  On the other hand, the cell surface TG activity of differentiated cells could be further 
activated by thrombin treatment at day 2 but not at day 6 and 12.  It suggested a presence 
of FXIII on cell surface at early stage of differentiation.  This effect could be further 
amplified after treating with thrombin such that differentiated HOBs showed higher 
crosslinking activity when treated with TG2 specific inhibitor (R294) than when treated 
with non-specific crosslinking inhibitor (R283) at day 2 (Fig. 3.9B).  This is consistent with in 
situ FITC-cadaverine incorporation assay that a significantly larger pool of latent FXIIIa 
appeared when osteoblasts were treated in differentiation medium at an early stage of 
mineralisation.  However, the cell surface crosslinking activity assay was only repeated in 
twice, further experiments would be necessary to conform this finding. 
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Figure 3.9 Cell surface crosslinking activity determined by biotin cadaverine incorporation assay as described in the Materials and Methods.  (A) TG2 and FXIIIa treated with or without 
thrombin were used as control to validate the assay each time.  The data represents mean values +/- S.D. from a representative experiment.  HOBs cultured in either CM or DM were 
harvested on day2 (B), day 6 (C) and day 12 (D) then seeded on fibronectin pre-coated plate with/without crosslinking inhibitors R283 or R294.  The crosslinking activity was verified by 
spectrophotometrically measuring incorporated biotinylated cadaverine.  The Y axis stands for equivalent amounts of TG2 (ng) in 1*10
5
 HOBs.  Data represents mean values +/- S.D. from 
a representative experiment with triplicate setting.  Statistical analysis was carried out using the one-way ANOVA test (turkey’s post test) and the p-values corresponding to P< 0.05 is 
represented with a * and p<0.01 is represented with a †.  Yet, this experiment was repeated twice (n=2) and further experiments would be needed for complete statistical evaluation. 
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2.6 Generation of TG2 knockdown HOBs cell lines 
In order to understand the relationship between TG2 expression and mineralisation, TG2 
expression knockdown HOBs were generated for study.  PLKO.1 vector backbone inserted 
with non-mammalian target shRNA was used as a control and commercially available TG2 
shRNA plasmids,TG2 MISSION® shRNA Plasmid DNA (shRNA 239, 240, 241 and 243, Sigma-
Aldrich, Poole, UK), were used to generate stable TG2 knockdown cell lines.  PLKO.1 
vectors contain puromycin resistance gene for mammalian selection and 500 ng/ml of 
puromycin was chosen as selective concentration for transfected HOBs according to cell 
toxicity assay (Fig. 3.10). 
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Figure 3.10 Determining cell toxicity of puromycin using XTT assay.  HOBs were cultured in 0, 0.125ng/ml, 
25ng/ml, 50ng/ml, 125ng/ml, 250ng/ml, 500ng/ml, 1µg/ml, 2µg/ml or 4µg/ml of puromycin /DMEM for 48 
hours and XTT assay was performed.  Data represents mean value +/- SEM, from 3 experiments (n=3). 
HOBs transfected with shRNA 239 (HOB-239), shRNA 240 (HOB-240), shRNA 241 (HOB-
241), shRNA 243 (HOB-243) and shRNA Control Plasmid (HOB-SHC) were selected out by 
treating with 500ng/ml puromycin.  The expression of TG2 and FXIII were detected using 
Western blotting as shown in Fig. 3.11.  The TG2 expression was knocked down in HOB-
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239, HOB-241 and HOB-243 but not in HOB-240.  However, a greater reduction of TG2 
expression was found in HOB-SHC cells compared to wild type HOBs.  Giving the fact that 
although TG2 expression decreased in HOB-SHC cell culture, HOB-239 and HOB-241 still 
presented approximately 60% and 90% of reduction in TG2 expression when compared to 
HOB-SHC. 
Furthermore, the overall FXIII expressions, full length and 76 kDa were found up-regulated 
in all the transfected cells compared to wild type HOBs (Fig. 3.11 C).  It suggested that up-
regulation of FXIIIa compensated the loss of TG2 in this model.  This is consistent with 
studies done by Tarantino et al. (2009) and Deasey et al. (2013) that loss of TG2 was 
compensated by increased FXIIIa in TG-/- mice.  However, the quantification of TG2 and 
corresponding FXIIIa expression in knockdown HOBs was only done once, further 
experiments would be needed to validate this finding was statistically significant. 
 
Figure 3.11 Expression of TG2 and FXIII in TG2 knockdown HOB cell lysates as demonstrated using Western 
blotting.  (A) Whole cell lysates were collected from wild type HOBs (WT), shRNA 239 transfected HOBs 
(HOB-239), shRNA 240 transfected HOBs (HOB-240), shRNA 241 transfected HOBs (HOB-241), shRNA 243 
transfected HOBs (HOB-243) and shRNA control plasmid transfected HOBs (HOB-SHC) cell culture and 
Western blotting was performed to analyse TG2 and FXIIIa protein expression as described in the Materials 
and methods.  α-tubulin was used as a loading control and normalised expression of TG2 and both 80kDa 
and 76kDa FXIII fragments were shown in chart (B) and chart (C) respectively. 
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2.7 Mineralisation of TG2 knockdown HOBs 
 
Figure 3.12 Mineralisation of HOBs visualised by von Kossa staining as described in the Materials and 
Methods.  Wild type HOBs (A, E), vector transfected control cell line: HOBs-SHC (D, H) and TG2 knockdown 
HOBs: HOBs-239 (B, F) and HOBs-241 (C, G) cultured on tissue culture plate were treated with DM (A, B, C, D) 
or 1µg/ml of gpTG2 in DM (E, F, G, H).  After 12 days, samples were fixed and von Kossa staining was 
performed.  Samples were viewed at ×40 magnification using a Nikon CK2 (10× objective) and photographed 
with an Olympus DP10 digital camera (4× optical zoom).  The mineral deposition is stained in black.  The 
scale bars represent 100µm. 
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The mineralisation of TG2 knock down cells was determined in order to further assay the 
mineralisation ability of TG2 knockdown cells and test if adding back exogenous gpTG2 
could recover the effect of reduced TG2 expression.  The TG2 expression knockdown cell 
lines, HOBs-239 and HOBs -241, cultured with or without exogenous TG2 were subjected 
to mineralisation assay on day 12.  According to the von Kossa staining (Fig. 3.12), 
mineralisation occurred in all cell lines grown in differentiation medium.  It suggested that 
knockdown of endogenous TG2 did not affect cell mineralisation.  Even though no 
significant association was found between endogenous TG2 levels and mineralisation (Fig. 
3.13A), exogenous TG2, surprisingly, improved cell mineralisation in a significant manner.  
The exogenous TG2-induced mineralisation could be observed in both wild type and TG2  
knockdown cells with an approximately 2 to 3 fold increase compared to non-treated one 
(Fig. 3.13B). 
 
Figure 3.13 Relative mineralisation of HOBs culture.  The mineralised area was visualised by using von Kossa 
staining and the percentage area of positive staining was quantified by image J.  The diagram represents the 
mean values ±SEM of mineralised area where n=3.  In diagram (A), the statistic analysis was carried out 
using the one way ANOVA (Dunnett’s multiple comparison test).  No significant difference was suggested 
between wild type HOBs and TG2 knockdown HOBs.  In diagram (B), the statistical analysis was carried out 
using the paired t test.  Exogenous TG2 enhanced mineralisation in both wild type and TG2 knockdown 
HOBs.  The p-values <0.05 are presented with a * and the p-values <0.01 are presented with a **. 
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3. Discussion 
The aim of this study was to understand the transglutaminase expression, both TG2 and 
FXIIIa, during mineralisation and evaluate the relationship between crosslinking activities 
and expression of enzymes in osteoblast differentiation using several approaches including 
functional inhibitors and gene silencing techniques. 
The expression of full length TG2 analysed by Western blotting was found to steadily 
increase during mineralisation.  This finding was in contrast with previous works which 
suggested that the TG2 protein expression (Al-Jallad et al., 2006) and mRNA level (Piercy-
Kotb et al., 2011) remained constant after differentiating.  On the other hand, it was also 
demonstrated that FXIIIa was detected in HOBs culture during mineralisation and the 
transglutaminase active fragments of FXIIIa distributed mainly in conditioned medium but 
not in whole cell lysates and membrane protein factions.  However, according to cell 
surface crosslinking activity, a clear shift from TG2 dominated crosslinking activity to FXIIIa 
dominated crosslinking activity was observed on osteoblast cell surface 2 days after 
treating with differentiation medium.  This finding supported the model proposed by Al-
Jallad et al. (2011) that expression of FXIIIa on cell membrane occurred only after inducing 
differentiation and this membrane FXIIIa was suggested to be involved in collagen I 
secretory machinery. 
Another trend observed in in situ crosslinking activity was that differentiating osteoblasts 
had mainly TG2 oriented activity in later stages of mineralisation.  According to cell surface 
TG activity assay, there was no significant difference in cell surface crosslinking activity of 
differentiated cells and non-differentiated cells during mineralisation, therefore, the 
increase in FITC-cadaverine incorporation observed in differentiated cell culture may have 
resulted from TG2 trapped in the ECM.  Many studies have showed that the interaction 
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between collagen I and fibronectin in the extracellular matrix is important for a more 
stable matrix formation (McDonald et al., 1982, Dzamba et al., 1993, Shi et al., 2010).  This 
could imply that TGs activity plays a critical role in stabilising the extracellular matrix.  
Although type I collagen could act as a FXIIIa substrate in vitro (Mosher, 1984), no further 
study suggested that crosslinking of collagen I by FXIIIa was found in cell culture systems 
(Barry and Mosher, 1989).  Hence, it would be reasonable to assume that TG2 dominated 
crosslinking activity at later stages of mineralisation could directly contribute to matrix 
stabilisation considering TG2 has a wider range of substrates compared to FXIIIa (Mosher 
and Schad, 1979, Mosher, 1984, Aeschlimann et al., 1995, Kaartinen et al., 2005). 
In this chapter, the correlation between the expression of TG2 and osteoblast 
mineralisation was also examined using TG2 knockdown cells.  Mineralisation assay of TG2 
knockdown cell lines showed that, even with lower endogenous TG2 expression, 
knockdown of TG2 in osteoblasts had no effect on mineralisation.  Since the TG2 
expression was not completely knocked down in the HOBs in this system, the possibility 
that minimum TG2 expression and/or crosslinking activity was sufficient for osteoblast 
mineralisation cannot be ruled out.  Furthermore, the notion that expression of one TG 
isoform could be compensated by other members of the TG family was supported by an 
up-regulation of FXIIIa expression that was observed in TG2 knockdown osteoblasts.  This 
was also consistent with the data that TG2 or FXIIIa or TG2/FXIIIa knockout mice displayed 
no skeletal or dental abnormalities, possibly due to the compensation between TG2, FXIIIa 
and other TGs expression (Nurminskaya and Kaartinen, 2006).  Therefore, the knockdown 
models had their own limitation to study the role of TGs in mineralisation and the 
development of TG2/FXIIIa double knockout model in the future may not be sufficient 
enough to understand how TGs participate in bone development and formation. 
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An unexpected result, however, was that HOBs cultured with exogenous TG2 could 
enhance mineral deposition in both wild type and TG2 knockdown osteoblasts.  Along with 
increasing TG activity observed in situ, these data implied that extracellular TG2 could 
contribute to cell mineralisation.  Several pathways have been proposed for how TG2 
mediates osteoblast mineralisation via transamidating dependent and independent 
mechanisms.  First, TG2 is recognised as a matrix stabiliser and TG2 crosslinked matrix is 
known to increase cell adhesion and HOB proliferation (Chau et al., 2005).  Therefore, a 
matrix stabilised by TG2 could enhance HOB mineralisation by accelerating HOB 
maturation from the proliferation stage to the mineral deposition stage.  Also, 
extracellular TG2 is proposed to contribute to mineralisation through transamidase activity 
independent pathways, mostly likely through ATPase activity (Nakano et al., 2007, Nakano 
et al., 2010) or activation of β-catenin pathway (Faverman et al., 2008). 
Thus, taking these results and the current study into account, a proposed model of TGs in 
cell mineralisation is summarised in Fig. 3.14.  An early increase in membrane FXIIIa after 
treating with DM could be involved in the type I collagen secretion pathway (Al-Jallad et 
al., 2009).  Meanwhile, the matrix organisation and stabilisation process involving both 
FXIIIa and TG2 activity in which the accumulating TG2 in ECM and increasing active FXIIIa 
in medium during mineralisation could modify fibronectin and collagen I fibres.  In 
particular, the localised TG2 in the ECM, compared to FXIIIa in medium, plays a major role 
in crosslinking ECM proteins in later stages of the mineralisation process as demonstrated 
by the in situ FITC incorporation assay.  TG2 may also interact with integrins and syndecans 
which further activate adhesion and proliferation signalling with or without binding of 
ligand to integrins (Wang et al., 2010).  Extracellular TG2 has also been found to interact 
with LRP5 receptors, which consequently activate β-catenin signalling and the canonical 
Wnt pathway (Faverman et al., 2008).  Finally, TG2 is also proposed to behave as an 
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ATPase after MMP cleavage and contribute to mineralisation by regulating extracellular Pi 
concentration (Nakano et al., 2007, Nakano et al., 2010).  In the following chapters, the 
role of extracellular TG2 in mineralisation will be discussed in more detail. 
 
Figure 3.14 A putative scheme of current studies in extracellular TG2 and osteoblasts mineralisation.  (I) 
Presenting of membrane FXIIIa crosslinking activity is stimulated by differentiation medium and it is related 
to collagen I (COL I) secretion.  (II) Membrane and matrix TG2 activity mediates crosslinking of ECM proteins.  
(III) Extracellular TG2 enhances cell adhesion and proliferation via integrin and syndecans.  (IV) Binding of 
TG2 to LRP5 on cell surface triggers osteogenesis gene transcription.  (V) Cleavage of TG2 by MMPs increases 
ATPase activity of TG2 and further regulates the Pi concentration. 
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Chapter IV 
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Activity Independent 
Pathway 
  
Page | 135 
1. Introduction 
Immunohistochemistry of mammalian mineralized bone tissue showed that TG2 was 
highly expressed not only in osteoblasts located in the perichondrium/periosteum area 
during bone development but also in borderline chondrocytes which are located at the 
advancing edges of the growth plate (Nurminskaya and Kaartinen, 2006).  In fact, 
increasing data has shown that exogenous TG2 could promote pre-osteoblast 
differentiation (Nurminskaya et al., 2003), chondrocyte maturation to hypertrophy 
(Johnson and Terkeltaub, 2005) and calcification of vascular smooth muscle cells  (VSMCs) 
(Faverman et al., 2008). 
TG2 is a multifunctional enzyme whose function is regulated by levels of Ca2+/ nucleotides 
(Lai et al., 1998, Liu et al., 2002) and MMP proteolysis (Belkin et al., 2001, Belkin et al., 
2004) in its microenvironment.  Although the importance of transamidase activity of TGs 
was demonstrated by Al-Jallad et al. (2006), further studies suggested that it was a FXIIIa 
dependent pathway rather than a TG2 mediated effect (Al-Jallad et al., 2009, Al-Jallad et 
al., 2011).  Given the fact that TG2 enzymatic activity may not play a dominant role in 
mineralisation and its activity is transient in non-reducing microenvironments, it is 
reasonable to assume that TG2 also regulates bone mineralisation in a non-transamidating 
dependent manner.  In this chapter, two hypotheses were examined: that TG2/ATPase 
regulates mineralisation and that TG2 stimulates the LRP5/ Wnt/ β-catenin pathway. 
ATPase activity of TG2 
Local phosphate (Pi)/ pyrophosphate (PPi) ratio is suggested to play an active role in 
regulation of physiological and pathological mineralization.  Several enzymes are 
recognised to regulate Pi and PPi concentration extracellularly including tissue non-specific 
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alkaline phosphatase (TNSALP) and plasma membrane Ca2+ ATPase1 (PMCA1).  The 
concept of TG2 involved in regulating Pi levels via its ATPase activity was first raised by 
Nakano et al. (2007).  It was suggested that ATP could induce mineral deposition in a 
similar way to conventional β-GP treatment by serving as an alternative source of 
phosphate groups.  This ATP-induced mineralisation was not affected by TNSALP inhibitor 
but was affected by PMCA inhibitor and TG2 crosslinking inhibitor.  Yet the release of Pi 
from ATP was not suppressed by PMCA inhibitor but was by TG2 inhibitor as 
demonstrated in the same study.  Therefore, Nakano et al. proposed that PMCA1 could 
contribute to mineralisation by pumping calcium to ossified sites and TG2 could act as an 
ATPase in the ECM.  This hypothesis was further expanded by the same group in which 
they showed that MTI-MMP may act as a modulator to activate the pro-mineralization 
function of TG2 (Nakano et al., 2010). 
LRP5/ Wnt/ β-catenin pathway 
Canonical Wnt signalling (Fig 3.1) is suggested as a major pathway to control osteoblast 
differentiation and bone formation in differentiated osteoblasts.  The Wnt/β-catenin 
signalling pathway controlled by LRP5 in bone mass regulation has been widely 
investigated.  Loss-of-function and gain-of-function mutants of LRP5 showed osteoporosis 
and high bone mass phenotypes, respectively, in human diseases (Gong et al., 2001, 
Boyden et al., 2002, Little et al., 2002b).  As seen in Fig. 4.1, under resting conditions, a 
degradation complex forms which comprises two scaffold proteins: Axin and adenomatous 
polyposis coli (APC) and two degradation complex kinases: glycogen synthase kinase 3 
(GSK3) and casein kinase 1α (CK1α).  This complex mediates the phosphorylation of β-
catenin and results in ubiquitination of β-catenin by β-transducin repeat-containing 
protein (β-TrCP).  The ubiquitinated β-catenin is subsequently degraded by the 26S 
proteosome.  Upon Wnt binding to Frizzled and co-receptors LRP5/6, the Dishevelled (Dvl 
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or Dsh) protein is recruited to the plasma membrane and it further aggregates axin to the 
LRP5/6 cytoplasmic tail.  Sequestration of axin by LRP receptors leads to inhibition of β-
catenin degradation complex and thus increases the accumulation of β-catenin and its 
translocation to the nucleus.  Once β-catenin is translocated to the nucleus, it competes 
with Groucho family protein, a transcriptional repressor, from binding to lymphoid 
enhancing factor (LEF) and T-cell factor (TCF) and acts as a transcriptional co-activator to 
modulate downstream gene expression (reviewed by Angers and Moon, 2009). 
Wnt canonical signalling is tightly regulated by Wnt proteins and/or Wnt signalling 
partners.  Several endogenous and synthetic inhibitors targeting different components in 
the Wnt canonical pathway are well studied, including Dickkopf (Dkk), secreted Frizzled-
related protein (sFRP), Wnt inhibitory factor (WIF), XAV939 compound, IWR compound 
and pyrvinium.  XAV939 is a synthetic small molecule which can inhibit tankyrase (TNKS).  
The inhibition of TNKS activity results in prolonging the half life of axin and stabilisation of 
the axin/ APC/ GSK3α/β complex which consequently increases β-catenin degradation. 
The interaction of TG2 and LRP5 was first reported by Faverman and co-workers (2008).  
They demonstrated binding of exogenous TG2 to cell membrane LRP5 and subsequent 
activation of β-catenin signalling including translocation of β-catenin to the nucleus.  
Another cell membrane receptor, N-Cadherin, was also related to osteoblast 
mineralisation and β-catenin signalling.  It was suggested that N-cadherin sequestered β-
catenin at the cytoplasmic membrane by direct protein interaction thus inhibiting WNT 
signalling.  Also, it was recently found that N-cadherin could negatively regulate β-catenin 
signalling via interaction with the LRP5 receptor (Marie, 2009). 
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Figure 4.1 The current model of the Wnt canonical pathway implies that binding of Wnt to LRP5 and Frizzled 
leads to recruitment of axin to LRP5, inhibition of GSK-3β, decrease in phosphorylation of β-catenin and 
subsequent translocation of β-catenin into the nucleus where it activates TCF/LEF transcription factors and target 
genes.  In the absence of Wnt-signal, β-catenin is targeted for degradation mediates by formation of the 
APC/Axin/GSK-3β-complex.  Phosphorylation of β-catenin by CK1 and GSK-3β leads to its ubiquitination and 
following proteasomal degradation.  β-TrCP- β-transducin repeat-containing protein, CK1- Casein kinase 1, Dvl (or 
Dsh) - Dishevelled-1, FRAT- Frequently rearranged in advanced T-cell lymphomas, LEF- Lymphoid enhancing 
factor, TCF- T-cell factor and ub- ubiquitin. 
Therefore, the aim of this chapter was to examine current hypotheses of how extracellular 
TG2 contributes to mineralisation.  To address this goal, first, the involvement of TG2 
crosslinking activity in HOB mineralisation was determined.  Secondly, the possibility of 
enzyme-mediated TG2 cleavage in osteoblast cell culture and its relationship with 
mineralisation were examined and collagenase and gelatinase profiles of differentiated 
HOBs was also analysed.  Finally, the expression and interaction of TG2 and LRP5 were 
examined and the activation of downstream pathway was further evaluated using 
immunohistochemical and β-catenin inhibitor, XAV939.  
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2. Results 
2.1 Mineral deposition of HOBs treated with crosslinking inhibitors  
The expression of endogenous TG2 as well as extracellular crosslinking activity increased 
during the mineralisation were demonstrated in previous chapter, however, TG2 
knockdown HOBs showed no effect on mineralisation and it was plausible that up 
regulation of FXIIIa expression compensated for the loss of TG2.  In order to understand 
whether the crosslinking activity of endogenous TG2 was essential for mineralisation, a 
TG2 specific inhibitor (R294) and a TG2/FXIIIa inhibitor (R283) were used to block the 
endogenous crosslinking activity during mineralisation.  Since both inhibitors showed no 
cell toxicity at working concentrations, HOBs were cultured with R283 or R294 
supplemented DM for 12 days and the mineralised area of HOBs was evaluated at the end 
point.  It appeared in Figure 4.2 that no mineral deposition was detected by von Kossa 
staining in negative control while there was positive staining in DM group.  Surprisingly, 
cells treated with inhibitors still presented positive von Kossa staining after 12 days 
culture.  Further analysis of the mineralised area from each group (Fig. 4.3) suggested that 
mineralisation was not inhibited when treated with non-specific inhibitor (R283) and TG2-
specific inhibitor R294.  This result indicated that crosslinking activity of transglutaminase, 
both FXIIIa and TG2, may not play a dominant role in HOBs mineralisation.  Nevertheless, 
the possibility that residual activity present in the cell/ECM was sufficient for 
mineralisation could not be ruled out. 
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Figure 4.2 Mineralisation of HOBs visualised by von Kossa staining.  HOBs cultured on tissue culture plate were treated with CM, DM, 250 µM R283/DM, 500 µM R283/DM, 250 µM 
R294/DM or 500 µM R294/DM.  After 12 days culture, samples were fixed and stained with silver nitrate to assay the mineralisation of HOBs on day 12.  Samples were viewed at x40 
magnification using a Nikon CK2 and photographed with an Olympus DP10 digital camera.  The mineral deposition was stained in black as indicated by arrow.  The scale bars 
represent 150µm. 
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Figure 4.3 Mineralisation of HOBs culture measured by Von Kossa staining.  The percentage area of positive 
staining was quantified by using image J.  The diagram represents the mean values ±SEM of mineralised area 
from one experiment with 3 replicates.  This experiment has been repeated twice where further 
experiments are needed to confirm this finding is statistically significant. 
2.2 Existence of small TG2 fragments in ECM in HOBs cultured with inhibitors at 
the later stage of mineralisation  
The mineralisation of HOBs was not inhibited by blocking of endogenous TGs activity, in 
contrast, the mineralised area could be potentially higher in R294 inhibitor treated group 
and it requires further experiments to conform this increase was statistically significant.  
Base on this observation, in the following experiments, the possibility of endogenous TG2 
contributing to cell mineralisation via its ATPase activity was examined. 
As suggested by Nakano et al. (2007), ATP could be a resource of phosphate groups for cell 
mineralisation and TG2 might contribute in regulating the release of phosphates via its 
ATPase activity.  Several MMPs, especially membrane type-I MMP (MT1-MMP, MP14), 
were found to modulate the function of extracellular TG2 as part of a regulatory 
mechanism where the pro-mineralization function of TG2 is activated (Nakano et al., 2010).  
In this study, the TG2 expression in whole cell lysate and extracellular matrix was 
determined using Western blotting.  According to the results (Fig. 4.4), smaller TG2 
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fragments were observed in day 9 and day 13 cell/ECM lysate when cells were 
differentiated.  Interestingly, the TG2 fragments appeared earlier and in higher amounts 
when inhibitors, both R283 and R294, were added to cell culture.  There were three major 
fragments found between 50 to 75 kDa, which were only detected in differentiated cells 
and a higher molecular weight TG2 fragment (~90 kDa) was detected in all groups on day 9 
and mainly in CM groups on day 13.  It suggested that the possibility of enzyme mediated 
cleavage of TG2 was found in differentiated cells and when cells were treated with 
inhibitors.  There was no direct evidence to demonstrate that these TG2 fragments had 
ATPase activity.  However, accompanying the mineralisation results found in Fig. 4.2 that 
cells treated with transamidase inhibitors had higher mineral deposition, it is highly 
plausible that these TG2 fragments found in whole cell/ECM lysate could account for the 
increase in mineralised area found in inhibitor treated cells. 
To further confirm if these fragments were present in the conditioned medium (Fig. 4.5) 
and cell membrane protein (Fig. 4.6) fractions were collected and analysed using Western 
blotting.  As shown in Fig 3.5, faint but detectable small TG2 fragments were found in all 
DM treated groups from day 5 (Fig.4.5A, indicated by arrow head).  On day 9, TG2 
fragments, but not full length TG2, could be observed in all groups (Fig. 4.5B, indicated by 
arrow head) and ~75kDa TG2 could be detected in conditioned medium on day 13 in all 
groups (Fig. 4.5C, indicated by arrow).  On the other hand, full length TG2 was observed in 
differentiated osteoblast membrane at all time points (Fig.4.6, indicated by arrows) and 
the TG2 fragments could be detected as early as day 5 in inhibitor treated groups (Fig 
4.6A, indicated by arrow head) and in all groups on day 13 (Fig 4.6C, indicated by arrow 
head). 
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Figure 4.4 TG2 expression in whole cell/ECM lysate during mineralisation.  HOBs were cultured with CM (1), 
DM (2), 250 µM R283/DM (3), 500 µM R283/DM (4), 250 µM R294/DM (5) or 500 µM R294/DM (6). Samples 
were collected 5 days (A), 9 days (B) or 13 days (C) post-treatment and Western blot analyses were 
performed.  α-tubulin was used as loading control. 
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Figure 4.5 Secreted TG2 in conditioned medium during mineralisation.  HOBs were cultured with CM (1), DM 
(2), 250 µM R283/DM (3), 500 µM R283/DM (4), 250 µM R294/DM (5) or 500 µM R294/DM (6).  Culture 
medium was replaced by serum free culture medium 24 hours before specific collecting time points which 
were 5 days (A), 9 days (B) or 13 days (C) post-treatment and Western blot analyses were performed. The 
arrows indicate full length TG2 and the arrow heads indicate small TG2 fragments. 
 
Figure 4.6 Membrane presented TG2 during mineralisation.  HOBs were treated with CM (1), DM (2), 250 µM 
R283/DM (3), 500 µM R283/DM (4), 250 µM R294/DM (5) or 500 µM R294/DM (6).  Cell membrane protein 
fractions were collected on 5 days (A), 9 days (B) or 13 days (C) post-treatment using biotin labelled method 
and Western blot analyses were performed.  The arrows indicate full length TG2 and the arrow heads 
indicate small TG2 fragments.   
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2.3 Collagenase and gelatinase expression at the later stage of mineralisation 
As suggested by Nakano et al. (2010), MT1-MMP is one of the major enzymes to regulate 
the ATPase activity of TG2.  Therefore, to gain a general view on the collagenase and 
gelatinase profile of HOBs after differentiation, day 10 conditioned medium was subjected 
to collagen and gelatin zymography.  Fig 4.7A showed active collagenase fragments 
(approx. 42kDa) could be found in CM groups and inhibitor groups but not in the DM 
group.  According to the literature, these fragments could represent stable active MMP-1 
fragments cleaved by trypsin (Wilhelm et al., 1984, Grant et al., 1987).  On the other hand, 
the gelatin zymography (Fig 4.7 B) demonstrated the existence of active gelatinase 
fragments, again in CM groups and inhibitor groups but not DM groups.  The major 
gelatinase fragment was approximately 82 kDa with another minor 130 kDa fragment.  It is 
widely known that MMP-9 is secreted as a glycosylated 92 kDa precursor (Wilhelm et al., 
1989) and proteolytic cleavage of the zymogen by MMP-3 yields an active 82 kDa MMP-9 
enzyme (Ogata et al., 1992).  It has also been shown that MMP-9 exists as a monomer, 
homodimer, or as a complex with lipocalin/tissue inhibitor of metalloproteinase-1 (TIMP-1) 
in neutrophils (Kolkenbrock et al., 1996).  All these forms showed different levels of 
enzymatic activity after activation with thrombin (Kolkenbrock et al., 1996).  Here, the 
~82kDa and ~130kDa fragments observed could be active MMP-9 monomer and MMP-9 
(82kDa)/lipocalin (23kDa) /TIMP-1 (23kDa) complex respectively. 
TG2 mediated down regulation of gelatinase, for example MMP-9, has been reported in 
several cell lines after retinoic acid treatment, including monocytes, myoblasts and breast 
cancer cell lines.  This effect could be preserved in the presence of TG2 crosslinking 
inhibitors (Ahn et al., 2008).  Increasing TG2 expression in differentiated cells at later 
stages of mineralisation was previously shown in Chapter II.  Taking the collagenase and 
gelatinase profile and TG2 expression together, here a TG2 mediated change of enzyme 
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profile in differentiated osteoblasts was demonstrated.  However, there were no bands 
corresponding to either MMP-2 or MT1-MMP detected in day 10 conditioned medium 
which could be due to MT1-MMP/MMP-2 complex tending to tether on plasma 
membrane microenvironment (Toth et al., 2003). 
 
Figure 4.7 MMPs secreted by HOBs treated with inhibitors.  Collagen (A) and gelatin (B) zymography of HOBs 
cell culture supernatants following 10 days culture in CM, DM, 250 µM R283/DM, 500 µM R283/DM, 250 µM 
R294/DM or 500 µM R294/DM.  The enzymatic activity was visualised as clear bands on the gel which could 
be observed between 34kDa and 48kDa on collagen gel (A) and approximately 82kDa on gelatine gel (B).  
The digested areas are indicated by arrow heads. 
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2.4 Effect of ATPase inhibitors on mineralisation 
Here the importance of ATPase activity on mineralisation was demonstrated by treating 
HOBs with a general ATPase inhibitor, ATP-γ-s.  As shown in Fig 4.8, the mineralising 
process was significantly inhibited by ATP-γ-s at concentrations of 10 µM and 400 µM.  
Released ALP activity was also monitored during the whole mineralisation process.  In 
order to collect the conditioned medium from each group, the HOBs were maintained in 
inhibitor-containing serum free medium 24 hours before collection.  It was found that 
released ALP in conditioned medium was significantly lower after day 6 in HOBs treated 
with 200 µM and 400µM ATP-γ-s compared to control group.  And this effect was found to 
be concentration dependent from day 8 (Fig.4.9).  These results indicated that ATPase 
played an important role in mineralisation and possibly through both inhibiting ATPase 
and down regulating ALP activity of HOBs.  However, the possibility that ATP-γ-s in the 
conditioned medium was inhibiting ALP activity could not be ruled out.  In fact, Ciancaglini 
et al.(2010) have suggested that that ATP-γ-s showed non-specific effects on several 
targets including P2Y1 receptor. The ATP-γ-s treatment greatly inhibited ALP activity at 
high concentrations. Nevertheless, when used at 10 µM, the maximum inhibiting effect 
was less than 5% comparing to DM treated cells at the later stage of mineralisation.  In this 
case, 10 µM ATP-γ-s still demonstrated great inhibitory effect on mineral deposition which 
suggested that inhibiting ATPase activity was sufficient enough to block the mineralisation 
process.  Overall, this preliminary data showed the ATPase activity of HOBs could be 
essential in mineralisation process, yet, more experiments would be necessary to conform 
this finding is statistically significant.  
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Figure 4.8 Mineralisation of HOBs cultured with ATP-γ-s for 12 days.  HOBs were cultured in differentiation 
medium with different concentration of ATP-γ-s for 12 days.  Mineral deposition in extracellular matrix was 
stained in black using von Kossa staining and the mineralised area was quantified using Image J software.  
The chart represents the mean values ±SEM of mineralised area from one experiment with 3 replicates.  This 
experiment was repeated twice and further experiments would be needed to confirm that the observed 
inhibitory effect of ATP--γ-s was statistically significant.  The scale bars represent 150µm. 
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Figure 4.9 Released ALP activity in conditioned medium collected from HOBs culture with ATP-γ-s during 
mineralisation.  Data represents mean values +/- S.D. from a representative experiment with 3 replicates.  
The experiment was repeated 2 times (n=2) and further experiments would be necessary to confirm the 
finding was statistically significant. 
2.5 Exogenous TG2-induced mineralisation in human osteoblasts cell culture in 
vitro 
Endogenous TG2 activity may not play a dominant role in osteoblast mineralisation, yet, 
the exogenous TG2 enhanced mineralisation of wild type and TG2 expression knockdown 
cells in vitro was demonstrated in the previous chapter and also a published study 
(Nurminskaya et al., 2003).  It suggested that TG2 in the extracellular environment may 
trigger an outside-in signal for cell mineralisation.  Here, the exogenous TG2 dependent 
effect on HOB mineralisation was demonstrated in Figure 4.10.  Cells cultured with 1µg/ml 
of exogenous TG2 were found to be highly mineralised at day 12 when compared with 
differentiation medium treated group.  An approximately 9 and 3 times increase in mineral 
area was observed in 1µg/ml of TG2 and 0.5µg/ml of TG2 treated group, respectively. 
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Figure 4.10 Mineral deposition of HOBs cultured with exogenous active TG2 in different concentrations for 12 days.  HOBs were cultured in differentiation medium with 1, 0.5 or 
0.25µg/ml of gpTG2 (TG 1, TG 0.5 and TG 0.25) for 12 days.  Mineralisation of matrix was visualised using von Kossa staining where the mineral deposition was stained in black.  The 
actual mineralisation area was quantified by using image J and the results were further normalised with the DM groups from each individual experiment.  The average mineralisation 
area of the DM group from 3 experiments is 2.28± 0.37%.  The diagram represents mean values +/- SEM of fold change from 3 individual experiments (n=3).  Statistical analysis was 
carried out using the one way ANOVA (Turkey’s multiple comparison test) and the p-values corresponding to p<0.05 is represented with a 
†.
  Significant differences were observed in 
the negative control (CM) group compared with positive control (DM) group, 1µg/ml TG2 group compared with CM group and 1µg/ml TG2 group compared with positive control 
group (DM), .  The scale bars represent 200 µm. 
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To further understand the exogenous TG2 induced mineralisation, one of the biomarkers, 
osteocalcin (OCN), was monitored after treatment of cells with exogenous TG2.  As shown 
in Figure 4.11, the TG2 group showed no significant difference in OCN secretion when 
compared with the DM group on day 2.  On the other hand, exogenous TG2 significantly 
decreased the level of OCN in conditioned medium at day 6 post treatment when 
compared to the DM group.  OCN is a non-collagenous bone matrix specifically secreted by 
differentiated osteoblasts.  Although there is no evidence to show that OCN is a TG2 
substrate, it has been suggested that OCN could bind to osteopontin (OPN) and 
consequently prevent crosslinking of OPN by TG2 (Kaartinen et al., 1997).  Here, the 
decreasing OCN in conditioned medium could result from more binding of OCN to other 
extracellular matrix proteins, which might be directly or indirectly mediated by crosslinking 
activity of exogenous TG2. 
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Figure 4.11 Released osteocalcin (OCN) in conditioned medium.  The releasing of OCN in the conditioned 
medium of HOBs cultured in complete medium (CM), differentiation medium (DM) or 1µg/ml of TG2 in DM 
(TG2) was quantified using ELISA technique.  .  Samples were collected at 2 days and 6 days after treatment.  
The acquired OCN concentrations from ELISA kit were further normalised with the total protein (mg) 
measured from each sample.  Data represents mean values ± S.D. from one experiment with 2 replicates.  
The ELISA has been done twice, yet, further experiment would be necessary to conform the decrease 
observed was statistically significant. 
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Alternatively, the decrease in OCN secretion could be directly linked to the increase in 
mineralisation of TG2 treated HOBs cells since OCN has been demonstrated as a negative 
regulator of mineralisation, which could be linked to specific inhibition of crystal 
maturation (Ducy et al., 1996, Boskey et al., 1998).  Therefore, it was also possible that 
exogenous TG2 could down regulate OCN expression in osteoblasts thus increasing cell 
mineralisation. 
In order to distinguish whether this TG2-induced mineralisation was transamidase activity 
dependent or independent, inactive TG2 was generated by using crosslinking inhibitor 
R283 or R294.  Addition of R283 treated TG2 (TG2/R283) to HOB cell culture induced a 
significant increase in mineralisation when compared to the DM group. However, the fold 
change in mineral area was not as high as in the TG2 group (Fig. 4.12).  On the other hand, 
a higher, but not significant, difference in mineral deposition was observed in the 
TG2/R294 group when compared to the DM group.  This result implied that the 
transamidase activity of TG2 was involved in TG2 induced mineralisation.  However, the 
influence of conformational changes in TG2 when inhibitor is bound must be taken into 
account.  It is clear that multiple conformations of TG2 exist (Liu et al., 2002, Pinkas et al., 
2007), but very little is known about the biological relevance of each conformation.  
Conformational change could potentially mask binding sites within TG2 thus regulating the 
function of TG2 (reviewed by Park et al., 2010a).  Therefore, it was reasonable to suggest 
that the results obtained here could represent the importance of transamidase activity but 
also the conformation of the protein in exogenous TG2-induced mineralisation. 
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Figure 4.12 Mineralisation of HOBs cultured with inactive TG2 for 12 days.  HOBs were cultured in differentiation 
medium with 1µg/ml of gpTG2 (TG2), R283 pre-treated TG2 (TG2/R283) or R294 pre-treated TG2 (TG2/R294) for 
12 days.  Mineral deposition in extracellular matrix was stained in black using von Kossa staining and the 
mineralised area was quantified using Image J software.  Data represents mean values +/- SEM from one 
experiment with 4 replicates.  This experiment was repeated in twice, yet, further repeats would be needed to 
conform the enhancement observed was statistically significant.  The scale bars represent 150µm. 
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2.6 N-Cadherin, β-catenin and LRP5 expression in early differentiation of HOBs 
Since the effect of exogenous TG2 induced mineralisation has been established here and 
in the literature, the possibility that extracellular TG2 serves as an outside-in signal 
through LRP5 receptors was examined.  The expression of related proteins, including LRP5, 
β-catenin, TG2 and N-cadherin, in HOBs during mineralisation was determined using 
Western blotting.  A 2 to 3 fold decrease in β-catenin and LRP5 expression from the 
baseline (CM) was observed as early as 4 hours after differentiation (Fig. 4.13).  The 
expression of both β-catenin and LRP5 were lower in differentiated cells at 4 hours post 
treatment but increased gradually, reaching the highest levels around 48 hours post 
differentiation and declining after this.  On the other hand, the expression of N-cadherin 
transiently increased in differentiated cells at 4 hours and gradually decreased from 24 
hours after differentiation (Fig. 4.14).  Interestingly, N-cadherin expression in HOBs 
showed a reciprocal relationship to the expression of β-catenin, LRP5 and TG2. 
A transient upregulation in N-cadherin expression was consistent with current studies in 
pre-osteoblast or osteosarcoma at early stages of growth factor or anabolic molecular 
treatment (Haÿ et al., 2000, Debiais et al., 2001, Delannoy et al., 2001).  A gradual 
decrease in N-cadherin expression during osteoblast mineralisation was also supported by 
recent findings that the mRNA level of N-cadherin decreased during differentiation in 
chondrocytes (Nurminsky et al., 2011).  Furthermore, the relationship found between N-
cadherin and β-catenin was also suggested in other research (Hay et al., 2009).  There is no 
clear evidence that TG2 may regulate N-cadherin expression or vice versa; however, 
elevation in LRP5/β-catenin signalling was observed on day 2, which suggested that an 
early activation of LRP5/ β-catenin could be important for osteoblast differentiation. 
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Figure 4.13  (A) Expression of β-catenin and LRP5 in whole cell lysate as demonstrated using Western 
blotting.  Whole cell lysates were collected at time point 4 hours, 1 day, 2 days, 6 days and 12 days post 
differentiation treatment and Western blotting was performed to analysis β-catenin and LRP5 protein 
expression.  α-tubulin was used as loading control and normalised data of β-catenin (B) and LRP5 (C) were 
showed in chart. 
 
Figure 4.14 (A) Expression of N-Cadherin and TG2 in whole cell lysate as demonstrated using Western 
blotting.  After treating HOBs with DM for 4 hours, 1 day, 2 days, 6 days and 12 days, whole cell lysates were 
collected and Western blotting was performed to analysis N-cadherin and TG2 protein expressions.  α-
tubulin was used as loading control and normalised data are shown in chart (B) and (C). 
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2.7 Binding of TG2 to LRP5 receptor 
A possible relationship between TG2 and the LRP5/ β-catenin pathway was proposed by 
Faverman et al. (2008) and the hypothesis of binding of TG2 to LRP5 receptor was tested.  
As demonstrated by Western blot, the β-catenin pathway related proteins showed a 
transient increase in early cell differentiation.  Therefore, the following experiments 
focused on determining the presence of early LRP5/ β-catenin signalling in differentiated 
osteoblasts.  The colocalisation of TG2 and LRP5 proteins was examined by double 
immunohistochemical staining with TG2 and LRP5 antibodies (Fig. 4.15).  Colocalisation of 
these two proteins was found in all groups 24 hours post treatment which suggested a 
possible interaction between TG2 and LRP5 receptor.  However, this data may not 
represent direct physical contact of TG2 to LRP5.  Therefore immunoprecipitation was 
used to confirm the binding of TG2 to LRP5. 
As shown by Faverman and colleagues study (2008), TG2 could bind to LRP5 receptors and 
trigger the β-catenin pathway in vascular smooth muscle cells (VSMCs).  Here, the 
interaction between exogenous TG2 and LRP5 was demonstrated using Co-IP.  Fig. 4.16 
shows that binding of TG2 to LRP5 receptor could be observed as early as 4 hours post 
differentiation with exogenous TG2 treatment but not in HOBs cultured in CM.  Whilst the 
interactions of these two proteins was observed in all groups 24 hours post treatment, the 
signal decreased at 48 hours with only a weak interaction shown in CM group. 
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Figure 4.15 Localisation of LRP5 and TG2 proteins on cell surface of HOBs.  HOBs were seeded on 4 well microscope slide overnight in complete medium.  Following 24 hours 
incubation in complete medium (CM), differentiation medium (DM) or DM supplemented with 1µg/ml of gpTG2 (TG2/DM), cells were fixed with 3.7% paraformaldehyde without 
permeabilisation.  The sample slides were double stained with anti-LRP5 (red) and anti-TG2 antibodies (green).  Colocalisation of LRP5 and TG2 is indicated with a white arrow.  The 
scale bar represents 10µm. 
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Figure 4.16 Binding of TG2 to LRP5 receptor on human osteoblasts.  HOBs were cultured in complete 
medium (CM), differentiation medium (DM) or 1µg/ml of gpTG2 in DM (TG2) for 4 hours, 24 hours or 48 
hours.  The Co-immunoprecipitaion was performed with anti-LRP5 antibody (H-105) and the binding of 
TG2/LRP5 was confirmed using Western blot analysis with anti-TG2 antibody. 
Although Co-IP using Anti-LRP5 antibody (H-105) and counter detecting TG2 (TG100 
antibody) protein showed that there was direct binding of these two proteins, no LRP5 
signal was detected when immunoprecipitation was performed using Anti-TG2 antibody 
(data not shown).  In this study TG100 antibody, which recognises a.a. 447-538 of TG2, 
failed to precipitate the LRP5/TG2 complex, possibly because the binding site for TG100 
antibody on TG2 is masked when TG2 is bound to LRP5.  In Faverman’s work (2008), Anti-
TG2 antiserum recognized full length gpTG2 (multiple epitope sites) and was used to pull 
down the LRP5/TG2 complex.  Also, In Zemskov’s paper (2007), mouse anti-TG2 mAb 4G3 
which has epitope site 1-165 was used to determine LRP1/TG2 colocalisation in vitro.  It 
was suggested that LRP1 might have a similar binding site to LRP5 (Belkin, 2011).  Even 
though there are no current data demonstrating the precise binding site(s) for TG2 on the 
LRP5 molecule, this result could indicate that a.a. 447-538 of TG2 was involved in binding 
to LRP5 receptor or masked because of conformation. 
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2.8 Activation of β-catenin pathway by exogenous TG2 
In order to examine whether the β-catenin pathway could be activated via exogenous TG2 
binding to LRP5 receptor, HOBs were treated with differentiation medium with or without 
exogenous TG2 and the β-catenin was stained and visualised using immunohistochemical 
staining.  At 4 hours post treatment, cells grown in complete medium and differentiation 
medium showed low and mainly cytoplasmic membrane localised signal.  Interestingly, 
cells treated with gpTG2 showed more intense β-catenin staining which had a mainly 
cytosolic and nuclear localisation (Fig. 4.17).  48 hours after treatment, all groups showed 
β-catenin positive signal which was mainly cytoplasmic membrane located (Fig. 4.18).  
There was no significant colocalisation found between TG2 and β-catenin proteins. In 
contrast, polarisation of these two proteins was found where TG2 mainly distributed away 
from β-catenin protein 
 Figure 4.17 Translocation of β-catenin after exogenous TG2 treatment for 4 hours.  HOBs were seeded on 4 well microscope slide overnight in complete medium.
incubation in complete medium (CM), differentiation medium (DM) or DM supplement
permeabilised with 5% Triton X-100.  The sample slides were double stained with anti
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ed with 1µg/ml of gpTG2 (TG2/DM), cells were fixed with 3.7% paraformaldehyde and 
-β-catenin (red) and anti-TG2 antibodies (green).  The scale bar represents
 
  Following 4 hours 
 10µm. 
 Figure 4.18 Translocation of β-catenin after exogenous TG2 treatment for 48 hours.  HOBs were seeded on 4 well microscope slide overnight in complete medium
incubation in complete medium (CM), differentiation medium (DM) or DM suppleme
permeabilised with 5% Triton X-100.  The sample slides were double stained with anti
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nted with 1µg/ml of gpTG2 (TG2/DM), cells were fixed with 3.7% paraformaldehyde and 
-β-catenin (red) and anti-TG2 antibodies (green).  The scale bar represents
 
.  Following 48 hours 
 10µm. 
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2.9 Inhibition of the β-catenin pathway abolishes exogenous TG2 induced 
mineralisation  
Since early stimulation of the β-catenin pathway could be one of the mechanisms behind 
TG2-induced mineralisation, here a β-catenin pathway inhibitor, XAV 939, was tested to 
determine the importance of the β-catenin pathway in TG2 induced HOB mineralisation.  
XAV 939 stimulates β-catenin degradation and axin stabilisation, thus antagonising the 
Wnt/β-catenin pathway.  Cells treated with 0.1µM XAV939/DM for 12 days showed no 
significant difference in mineralised area compared to cells cultured in DM (Fig. 4.19). This 
suggested that HOBs could deposit mineral matrix in a Wnt/β-catenin independent 
manner.  However, when treated with exogenous TG2, HOBs treated with β-catenin 
inhibitor showed a reduced mineralised area comparable to cells treated with DM only.  
This indicated that TG2-induced mineralisation was Wnt/β-catenin dependent, and 
blocking β-catenin by forcing protein degradation could abolish this effect.  However, this 
experiment has only be done twice, further experiments would be necessary to validate 
the importance of β-catenin pathway in TG2 induced HOB mineralisation. 
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Figure 4.19 Mineralisation of HOBs cultured with β-catenin pathway inhibitor for 12 days.  HOBs were 
cultured in differentiation medium with or without 1µg/ml of gpTG2 (TG2) plus inhibitor XAV939 for 12 
days.  Mineral deposition in extracellular matrix was determined using von Kossa staining and the 
mineralised area was quantified using Image J software.  The quantified data represent mean values +/- SEM 
from a representative experiment with triplicate setting.  This experiment was repeated two times and 
further experiments would be necessary to verify the inhibitory effect of XAV939 was statistically significant.  
The scale bars represent 150µm. 
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3. Discussion 
The object of this chapter was to investigate the possible role of endogenous and 
exogenous TG2 in human osteoblast differentiation and mineralisation.  It was shown in 
the previous chapter that the expression of endogenous TG2 either did not affect the cell 
mineralisation process or it could be compensated by upregulation of FXIIIa.  In this 
chapter, it was demonstrated that endogenous TG2 activity was not essential for 
osteoblast mineralisation, since blocking TG2 activity could not abolish cell mineralisation.  
Also, TG2/FXIIIa activity inhibitor R283 could not block the mineralisation process, 
suggesting that both TG2 and FXIIIa activity were not needed in this process or that only 
minimum crosslinking activity was required for mineralisation. 
ATPase activity of TG2 
TG2 was suggested to act as an ATPase in the extracellular matrix, especially the cleaved 
TG2 by MT1-MMP, and serve as a source of Pi thus contributing to osteoblast 
mineralisation (Nakano et al., 2007, Nakano et al., 2010).  This study tested the hypothesis 
that ATPase activity of TG2 plays an important role in the mineralising process by 
examining TG2 fragments in whole cell/ECM extracts, collagen and gelatin zymography 
and effect of ATPase inhibitors in mineral matrix deposition.  Here, an increase in TG2 
fragments from day 8 post treatment with differentiation medium and TG2 inhibitors was 
demonstrated.  In this study, major endogenous TG2 fragments in HOBs culture were 
found in whole cells/ECM lysis and the protein sizes were between 60 kDa to 70kDa.  TG2 
inhibitor treated cells showed more TG2 fragments, possibly because inhibitors kept TG2 
in an open conformation which favoured MMP degradation.  The putative cleavage sites of 
MT1-MMP on TG2 were at Pro-375, Agr-458 and His-461 while MMP2 was found directly 
associated with the core enzymatic domain II of TG2 (Belkin et al., 2001, Belkin et al., 
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2004).  As illustrated in Fig. 4.20, R283-bound TG2 is in a semi-open form and R294-bound 
TG2 is in a fully open form.  It is reasonable to assume that R294-bound TG2 is more 
vulnerable to MMP-mediated degradation due to the cleavage site being exposed in the 
open conformation.  In fact, it has been shown that TG2 is more sensitive to enzyme-
mediated degradation when in its calcium bound open form compared to its GTP bound 
closed form (Zhang et al., 1998, Begg et al., 2006).  As future work, the susceptibility of 
TG2 and inhibitor-bound TG2 to MMP digestion could be demonstrated using purified TG2. 
 
Figure 4.20 Predicted conformation of TG2 with or without inhibitors.  The structure of TG2 has been 
revealed by X-ray crystallography.  The active TG2 was suggested to be stable extended form (Pinkas et al., 
2007) and GTP/GDP bound TG2 was observed in a compact form (Liu et al., 2002).  Inhibitor R294 was 
predicted to hold TG2 in open form while R283bound TG2 was in putative semi-open form. 
It is uncertain if these TG2 fragments retained any biological function, yet, the presence of 
these small TG2 fragments accompanied an increase in mineralisation area when treating 
cells with inhibitors.  No evidence suggested that these TG2 fragments could bind to LRP5 
receptor, since the Co-IP showed only full length TG2 interacting with LRP5.  According to 
Nakano et al.(2010), released TG2 in mouse osteoblasts culture medium was cleaved by 
MT1-MMP into ∼69, ∼55, ∼40, ∼30kDa and other minor fragments. Only the ∼55 kDa 
fragment had ATP binding ability as illustrated by its affinity for ATP-agarose.  It has been 
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also suggested that proteolytic cleavage of TG2 by MT1-MMP in vitro resulted in increased 
ATPase activity of TG2.  As reported by Belkin and his colleagues, membrane type I MMP 
(MT-MMP-1, MMP-14) and MMP-2, in tandem, regulate TG2 functionality in cell-surface 
adhesion/signalling by proteolysis of TG2 at certain cleavage sites (Belkin et al., 2001, 
Belkin et al., 2004).  This study suggests that enzyme mediated degradation of TG2 is also 
important in the osteoblast mineralisation process and that the proteolysis of TG2 might 
contribute to mineralisation via its ATPase activity.  In order to clarify if MMP-mediated 
TG2 fragmentation is accountable for the increase in ATPase activity and bone 
mineralisation, MMP inhibitors can be used in the future to verify the hypothesis. 
Collagen and gelatin zymography were performed in this study and the results suggested 
the possible presence of MMP-1 and MMP-9 in day 10 conditioned medium.  Furthermore, 
unexpected down regulation of collagenase and gelatinase was observed in differentiated 
HOBs after 10 days of culture.  Ahn et al. (2008) have demonstrated TG2-induced down 
regulation of MMP-9 in retinoic acid treated cardiac myoblasts and this effect could be 
prevented in the presence of TG2 inhibitors.  This is consistent with the result found in this 
study that collagenase and gelatinase were down regulated after stimulation with ascorbic 
acid and β-GP and addition of TG2 inhibitors could regain the expression of the 
collagenase and gelatinase.  It is hard to judge if the increase in TG2 fragments in the ECM 
could be directly linked to up regulation of collagenase and/or gelatinase expression in 
inhibitor treated osteoblasts.  So far, there has been no study suggesting TG2 as a 
substrate for MMP-1 and MMP-9.  Yet, the TG2 fragments could be found in whole cell/ 
ECM in differentiated cells but neither MMP-1 nor MMP-9 was found in conditioned 
medium of HOBs cultured in DM.  This, again, indicated that proteolysis of TG2 was mainly 
conducted by other MMPs, most likely MT1-MMP and MMP-2.  The question then was in 
which compartment the cleavage of TG2 occurred.  It was reported that activation of 
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MMP-2 was dependent on the trimolecular complex components (MT1-MMP /TIMP-2 
/MMP-2) on the cell membrane (Kazes et al., 2000).  Therefore, the lack of MMP2 in 
conditioned medium could result from binding of MMP-2 protein to cell surface MTI-
MMP1 via TIMP-2.  It is suggested that cleavage of TG2 mainly happens in the cell 
membrane associated microenvironment, for example on the cell surface and in the 
extracellular matrix.  TG2 fragments could be clearly detected on cell membrane in the 
later stage of mineralisation.  Although it remains to be confirmed, these TG2 fragments 
potentially had ATPase activity which could mediate the level of Pi in local 
microenvironment and further contribute to cell mineralisation. 
In order to study if the ATPase activity was important for cell mineralisation, a general 
ATPase inhibitor, ATP-γ-s was used to block the enzymatic activity.  The importance of 
ATPase was demonstrated here that the mineralisation was blocked when 10 µM ATP-γ-s 
was used which only caused a minimum alteration of ALP activity.  According to the 
literature, both ALP and ATPase activity are presented in matrix vesicles (MVs) where 
mineralisation happens.  It has been suggested that 85% to 90% of ATP hydrolysis is 
mediated by ALP, the remained 10% to 15% of ATP hydrolysis was not affected by ALP 
inhibitor on MVs (Majeska and Wuthier, 1975).  The presence of another ATPase other 
than ALP on MVs was also demonstrated in ATP-dependent calcium deposition (Hsu and 
Clarke Anderson, 1995).  Interestingly, TGs activity was found increased in MVs of ALP 
knockout mice which might suggest that TG2 functions as an ATPase in MVs in 
extracellular matrix.  Unfortunately, there was concern that the negative effect observed 
in cells cultured with ATP-γ-s may involve a broad range of ATPase related factors 
including PMCA1, a calcium transport protein on the cell membrane.  Although it is widely 
believed that cell membranes are imperemeable to anions, some researchers suggest cells 
can uptake extracellular ATP (reviewed by Chaudry, 1982).  In this case, uptake of ATP-γ-s 
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into cytoplasm might inhibit the PMCA1 thus inhibit the output of calcium ion to the 
calcified site.  Therefore, in the future, an indirect approach by using specific MMP 
inhibitors to abolish TG2 fragments and reverse inhibitors-induced mineralisation in 
osteoblasts culture would be a more practical way to study biological function of TG2 
fragments. 
LRP5/ Wnt/ β-catenin pathway 
On the other hand, exogenous TG2 induced calcification has been demonstrated in 
vascular smooth muscle cells (Faverman et al., 2008) where TG2 was shown to up regulate 
osteoblastic markers in VSMCs.  Here in this study, a similar effect of exogenous TG2 could 
be found in human osteoblasts where the mineral deposition of HOBs was stimulated by 
extracellular TG2.  It has been suggested that the activity of TG2 was important for TG2 
induced β-catenin activation where genetically or pharmacologically reduced TG2 activity 
fail to activate β-catenin in response to warfarin (Beazley et al., 2012).  This is consistent 
with the finding that the inductive effects of R283 inactivated TG2 and R294 inactivated 
TG2 were lower than wild type TG2.  These evidences indicated that TG2 activity was 
involved in TG2 induced mineralisation. 
Nevertheless, It is worth pointing out that the inhibitors have been reported to change the 
conformation of TG2 (reviewed by Pinkas et al., 2007) and that there is growing evidence 
for TG2 mediated differentiation dependent on TG2 confirmation but not transamidating 
activity were suggested.  Earlier study by (Johnson and Terkeltaub, 2005) proposed that 
transamidating activity was not required for TG2 induced matrix calcification as illustrated 
by the failure of active site point mutant TG2 (C277G, H335A and D358A) to block 
chondrocyte differentiation and calcification.  Moreover, the GTP binding site mutant TG2 
(K173L), which is expected to hold TG2 in the open conformation, failed to induce matrix 
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calcification in chondrocytes.  The importance of the closed conformation of TG2 was 
further emphasised as Mg-GTP treated wild type TG2, which theoretically blocked both 
GTPase and transamidating activity and kept TG2 in the closed conformation, still retained 
the capacity to promote matrix mineralisation.  Therefore, it was assumed that compact 
form of TG2 was an ideal conformation for inducing cell mineralisation.  As shown in Fig. 
4.20, the crosslinking inhibitor R283 could theoretically hold TG2 in a semi-open 
conformation while R294 tended to keep TG2 in the extended conformation (personal 
communication with Dr. R Collighan, 2012).  Accompanied by the mineralisation results 
that TG2/R283 has approximately 60% of the inductive effect compared to wild type TG2 
and no inductive effect was observed by addition of TG2/R294, this finding was in 
agreement with previous study indicating the major role of TG2 conformation in TG2 
induced mineralisation. 
Figure 4.21 Antibodies binding sites in the TG2 enzyme.  TG2 contains 4 domains including β-sandwich, core 
domain, β-barrel 1 and 2.  Mouse anti-TG2 mAb 4G3 has epitope site 1-165 (Zemskov et al., 2007) and 
TG100 antibody binding site occurs at a.a. 447-538.  Anti-TG2 antiserum (Faverman et al., 2008), on the 
other hand, has putatively multiple binding site. 
Closed conformation TG2 might also explain the failure of immunoprecipitation of 
TG2/LRP5 complex using TG100 (anti TG2 antibody).  As mentioned before, the TG100 
antibody was designed to recognise a.a. 447 to 538 of TG2.  As shown in Fig. 4.21, the 
corresponding epitope site of TG100 is situated at the region which undergoes major 
conformational change.  This again supports the hypothesis that the closed conformation 
is required for TG2-induced mineralisation.  It would be interesting to use W241A mutant 
TG2 to study the role of TG2 conformation and activity in TG2-induced calcification.  
W241A mutant lacks crosslinking function without affecting its GTP binding ability, 
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therefore, it would be a good model to look into the biological functions of different TG2 
conformations. 
The importance of conformation in TG2 induced mineralisation could give a clue that a 
certain level of interaction between TG2 and other proteins may take place on the cell 
membrane and/or in the extracellular matrix.  Research has found extracellular TG2 might 
alter the LRP5/ β-catenin pathway, a master regulatory pathway of bone formation, and 
contribute to tissue calcification.  Therefore, the related protein expression in LRP5/β-
catenin pathway was examined in the HOB mineralisation model.  The protein expression 
of β-catenin, LRP5 and N-cadherin in differentiated HOBs revealed a counter pattern 
between N-cadherin and β-catenin/ LRP5/ TG2 expressions.  It is widely believed that N-
cadherin is involved in early cell aggregation by enhancing cell-cell adhesion and 
promoting cell differentiation through activating intracellular signals (Ferrari et al., 2000).  
However, recent data implied that N-cadherin may participate in another mechanism to 
negatively regulate osteoblast differentiation and bone formation (Fig. 4.22).  The 
inhibitory effect of N-cadherin could involve interaction with Wnt signalling in which direct 
binding of β-catenin to cadherin potentially sequestrates β-catenin at the membrane, 
reduces cytosolic β-catenin pool and inhibits Wnt signalling (Conacci-Sorrell et al., 2002, 
Wheelock and Johnson, 2003, Nelson and Nusse, 2004).  Studies also revealed a novel link 
between N-cadherin and LRP5 which is independent of β-catenin binding.  Interaction of 
N-cadherin with the intracellular domain of LRP5/ axin resulted in increased β-catenin 
ubiquitination, decreased β-catenin cytosol levels and subsequent down regulation of 
nuclear translocation in response to Wnt signalling (Hay et al., 2009, Marie, 2009). 
Therefore, the transient increase in N-cadherin of DM treated osteoblasts compared to 
CM treated cells (4 hours post treatment) could promote a rapid increase in cell 
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aggregation which was generally observed in differentiating cells.  Consistent with this 
finding, the down regulation in both β-catenin and LRP5 at 4 hours post treatment could 
indicate the negative effect of N-cadherin mediated inhibition of Wnt/β-catenin signalling 
via LRP5.  Down regulation of N-cadherin during cell mineralisation, on the other hand, 
could promote the maturation process of osteoblasts. 
 
Figure 4.22 Putative mechanism of N-cadherin- mediated osteoblast function (adapted from Marie, 2009).  
(A) N-cadherin interactions between cells promote adhesion and downstream signals. (B) Direct binding of 
β-catenin to N-cadherin results in β-catenin sequestration at the membrane and down regulation in Wnt 
signalling.  (C) The interaction between N-cadherin and the LRP5/6 results in increasing β-catenin 
degradation and inhibition of Wnt/β-catenin signalling.  (UP: unknown protein; Ub: ubiquitin) 
Many studies have indicated that cell/tissue differentiation requires coordinated 
regulation of cadherin mediated cell adhesion and the WNT/β-catenin pathway 
(Westendorf et al., 2004, Nelson and Nusse, 2004, Marie, 2009). Here in this chapter, 
extracellular TG2 was demonstrated as a possible regulator for this process.  Direct binding 
of TG2 to LRP5 has been demonstrated here in osteoblasts and in VSMCs by (Faverman et 
al., 2008).  Interaction was found in DM treated and exogenous TG2 treated cells as early 
as 4 hours post treatment and up to 24 hours post treatment as indicated by Co-IP.  The β-
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catenin activation was also observed in osteoblasts treated with exogenous TG2 for 4 
hours by immunohistochemical staining.  These evidences support an early activation of 
the β-catenin pathway through binding of TG2 to LRP5 receptor, especially in a high 
extracellular TG2 environment.  The activation of the β-catenin pathway downstream of 
TG2/LRP5 binding could be further illustrated where β-catenin inhibitor blocked the TG2 
induced mineralisation but not the cell mineralisation in physiological condition. 
A regulatory effect on extracellular TG2 triggered β-catenin activation was also suggested 
in this study.  According to Western blot, the expression of LRP5 and β-catenin in 
differentiated cells was highest on day 2, however, no significant TG2 and LRP5 interaction 
was shown by co-IP assay.  A possible explanation for this observation was the presence of 
a negative signalling modulator, most likely LRP-1 in this case.  LRP-1 is known as a 
transmembrane modulator of WNT signalling (Zilberberg et al., 2004) and a cell surface 
TG2 expression regulator (Zemskov et al., 2007).  The absence of TG2/LRP5 complex may 
result from LPR1 competing for binding to TG2 on the cell surface and removal of TG2 to 
lysosomes for degradation. 
Although there is only limited understanding about the TG2 triggered β-catenin pathway, 
exposure to high levels of extracellular TG2 may counteract the negative effect of N-
cadherin in β-catenin pathway, thus enhancing osteoblast mineralisation.  In this case, 
activation of TG2/LRP5 pathway alters the balance of cytosol and nucleus β-catenin levels 
thus promoting cells to undergo differentiation and mineralisation process.  Even though 
the exogenous TG2 induced mineralisation was suppressed by the β-catenin pathway 
inhibitor- XAV939, the possibility of non-specific effect of XAV939 could not be ruled out.  
To further confirm that TG2-induced enhancement in mineralised area requires activation 
of the β-catenin pathway, setting up a positive control (e.g. Wnt3a treated cell culture) will 
be necessary in the future work. 
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Overall, the data in this chapter suggest different possibilities of how extracellular TG2 is 
involved in mineralisation process.  Interestingly, extracellular TG2 has been implicated in 
the wound healing process in the past decade by promoting repair, matrix stabilization 
and cell viability in physio-pathological condition (reviewed by Verderio et al., 2005, Telci 
and Griffin, 2006b).  Externalisation of TG2, via an atypical secretion pathway or simply 
from necrotic cells, during cell stress or tissue damage is commonly observed.  Therefore, 
the TG2 induced osteoblast mineralisation and VSMC calcification could represent a 
wound healing process mediated by TG2 under pathological conditions.  Moreover, in 
endochondral ossification, both TG2 and FXIII were detected in chondrocytes at the edge 
of the growth plate and osteoblasts in the perichondrium/periosteum area but were 
negatively expressed in the area far away from the leading edge of the bony collar as 
demonstrated in chicken embryonic models (Nurminskaya and Kaartinen, 2006).  It has 
been also indicated that culturing pre-osteoblasts with hypertrophic chondrocytes could 
increase the expression of several osteoblastic markers in osteoblasts and promote cell 
mineralisation (Nurminskaya et al., 2003).  Taking the accumulating evidences of 
exogenous TG2 to promote differentiation with the localisation pattern of endogenous 
TG2 in the embryonic long bones, it suggests TG2 secreted by chondrocytes and/or 
osteoblasts could act as an initial signal for osteoblast differentiation and mineralisation in 
bone development. 
In conclusion, under physiological conditions, MMPs could act as a switch to convert the 
function of accumulated TG2 in extracellular matrix or on the cell membrane from 
transamidase oriented to ATPase oriented, especially in later stages of differentiation and 
the start of mineralisation.  The ATPase activity of TG2 may not play a dominant role in cell 
mineralisation as it could be compensated by other enzymes such as plasma membrane 
Ca2+ transport ATPase 1 (PMCA1).  However, in endochondral ossification and under 
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pathological condition, a dramatic increase in extracellular TG2 levels may trigger an 
outside-in signal through binding of LRP5 receptor thus activating the β-catenin pathway 
which then stimulates osteoblast differentiation and mineralisation.  This effect was very 
likely crosslinking activity independent but the closed conformation of TG2 was required. 
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Chapter V 
Evaluating 
Transglutaminase 
Crosslinked Collagen Gel 
Systems for Hard and Soft 
Tissue Repair 
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1. Introduction 
Collagen based scaffolds are widely used in a broad range of regenerative medicine 
applications.  Even though collagen scaffolds have shown clinical success in a range of soft 
tissue repair applications, relatively poor mechanical properties remains as a limitation for 
their use in hard tissue regeneration.  In fact, only selected researches have showed some 
degree of success in using collagen scaffold for bone regeneration (Caiazza et al., 2000, 
d'Aquino et al., 2009, Keogh et al., 2010) comparing to other synthetic materials.  An ideal 
biomaterial for bone tissue repair should support osteogenic cells to migrate, proliferate 
and differentiate, promote new bone formation, and provides mechanical competence 
during the bone regeneration.  In order to address this goal, current strategy focuses on 
recognising the complex interplay of signals from the extracellular microenvironment to 
mediate osteogenic cell fates such as adhesion and differentiation and fabricating 
functional implants for bone repair. 
Using collagen matrix for orthopaedic regeneration offers distinct advantages since type I 
collagen composes more than 90% of the organic fraction in native bone tissue.  The 
mechanical property problem can be overcome by the addition of a second, stiffer phase 
such as hydroxylapatite (HA) or crosslinked collagen based matrix through glutaraldehyde 
(Weadock et al., 1983), ultraviolet (UV) radiation (Wollensak and Spoerl, 2004), 
dehydrothermal processing (Yannas and Burke, 1980), carbodiimides (Damink et al., 1996) 
and enzymatically crosslinking by microbial transglutaminase (mTG) or TG2 methods (Chau 
et al., 2005, Chen et al., 2005).  All these methods have showed a certain level of success 
in modifying the degradation rate of collagen matrix, giving collagen biomaterials 
advantages in wider medical applications. 
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In the first part of this thesis, TG2 was recognised as a potent pro-osteogenesis factor.  As 
an efficient transamidating agent, TG2 was first reported to play an important role in 
matrix stabilisation and the cell adhesion process.  Later on, it was demonstrated here in 
this thesis and in other studies (Faverman et al., 2008, Beazley et al., 2012) that TG2 in the 
extracellular matrix could trigger the β-catenin pathway via binding to low density 
lipoprotein receptor (LRP) 5 and further contribute to ossification.  It also had potential to 
serve as a source of phosphate via its ATPase activity and this effect was tightly regulated 
by MMPs activity during mineralisation.  Theoretically, crosslinking collagen I gel with TG2 
should not only improve its physical and biological stability but also introduce 
osteoconductive and osteoinductive properties.  The advantage of using TG2 treated 
collagen gel as bone graft was first demonstrated by Chau et al. (2005) who showed that 
TG2 crosslinked collagen matrix enhanced cell attachment, spreading, proliferation and 
expression of differentiation markers in human osteoblasts.  In addition, crosslinked gel 
also showed better resistance against cell-mediated endogenous protease degradation. 
Using collagen-based biomaterial also offers advantages for cornea regeneration since 
type I collagen composes more than 90% of the cornea.  Properties of ideal biomatrix for 
corneal wound healing include biodegradability, biocompatibility, transparency, sufficient 
mechanical competence during the cornea regeneration, short wound healing time, easy 
application, postoperative comfort and cost effectiveness.  Using fibrin glue as an original 
inspiration, here, TG2 crosslinked collagen I gel is proposed as an alternative option for 
ocular surgery.  First of all, endogenous collagen I and TG2 are ubiquitously distributed in 
the cornea tissue and especially TG2 shows a predominant presence in the corneal 
subepithelium and stromal layer (Barathi et al., 2011).  Secondly, TG2 was found to have a 
broader range of substrates than FXIIIa.  Panengad et al. demonstrated abundant TG2 
substrates distributed throughout all layers of cornea tissue and a good co-localisation of 
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TG2 with collagen and fibronectin (Panengad et al., 2011).  Finally, it was reported that the 
adhesive strength and bonding strength of TG2 based adhesive was higher than Tissucol, a 
commercialised fibrin gel (Jurgensen et al., 1997).  The potential of TG2 based glue for 
ocular applications has not yet been fully evaluated.  A recent study by Chau et al. (2012) 
suggested that TG2 treated amniotic membrane (AM) as a novel treatment for ocular 
surface disease due to its enhanced mechanical strength and stiffness without affecting its 
transparency.  However, so far no data have been published regarding the 
biocompatibility of TG2 based matrix in cornea tissue. 
Here in this chapter, a TG2 modified collagen matrix was analysed for its potential as a 
graft material for hard and soft tissues.  Surface composition and topography were two 
factors considered in evaluating the properties of TG2 crosslinked collagen gel.  The 
biological properties of crosslinked gel were also assayed including biocompatibility and 
several cell behaviours.  The cells used in this chapter were human osteoblasts (HOBs), 
human corneal epithelial cells (hCECs) and human corneal fibroblasts (hCFs) in order to 
represent the hard and soft tissue model. 
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2. Results 
2.1 Self-incorporation of TG2 into type I collagen gel 
As reported previously (Shanmugasundaram et al., 2012) ,auto-crosslinking of TG2 into 
collagen matrix occurred during collagen polymerisation. Here the amount of residual TG2 
in crosslinked gel was determined using gel electrophoresis and Western blotting.  A 
modified protocol from Shanmugasundaram’s publication was used in this study.  Briefly, 
following overnight incubation with enzyme, treated and non-treated collagen gels were 
vigorously washed with PBS several times to remove unbound TG2 before boiling with 5X 
reducing Laemmli sample buffer.  Western blotting showed low but detectable TG2 
monomer at 78kDa in TG2 crosslinked collagen gel (Fig. 5.1).  Interestingly, high molecular 
weight bands were found in insoluble fragments which were at the very top of the gel 
(>245kDa).  These high molecular weight bands were assumed to be highly polymerised 
TG2 complex or a crosslinked complex of TG2 and type I collagen.  When TG2 activity was 
inhibited with R283 and R294, the 78kDa TG2 monomer was found to be significantly 
increased; meanwhile, the highly polymerised TG2 complex band was less intense but still 
observed.  Reduction in the high molecular weight band implied that crosslinking activity 
of TG2 enhanced the formation of TG2 polymer or TG2/collagen I complex.  As for the 
faint >245kDa band found in Inhibitor-treated TG2 groups may result from residual 
transamidating activity within the TG2/inhibitor or result from the preparation stage 
where the gpTG2 was pre-activated with calcium and DTT for 5 minutes on ice before 
treatment with inhibitors.  On the other hand, this study also showed that even without its 
enzymatic activity, TG2 was still trapped in the collagen gel and could not be removed by 
washing.  These results suggested that trapped TG2 was not negligible and could serve as a 
source of exogenous TG2 for cells.  Consequently, TG2 could incorporate itself into 
collagen gel via both a crosslinking activity dependent and independent way. 
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Figure 5.1 Tethering of TG2 into type I collagen gel.  Type I collagen gels mixing with active or inhibitors pre-
treated (inactive) TG2 were sampled and the bound TG2 determined by Western blotting as described in 
Materials and Methods.  Lane 1: native collagen gel, lane 2: TG2 crosslinked collagen gel, lane 3: R283- 
inactivated TG2 crosslinked gel and lane 4: R294-inactivated TG2 crosslinked collagen gel. 
2.2 Crosslinking by TG2 alters collagen fibre structure 
Using electron microscopy, the collagen bundles in native collagen and crosslinked 
collagen gels showed similar organisation which was highly compact and roughly arranged 
in isotropic direction (Fig. 5.2).  According to image analysis, the average diameter of 
crosslinked collagen bundles was significantly higher than native collagen fibres which 
were approximately 2.6 µm and 1.1 µm, respectively (Fig. 5.3).  Studies have suggested 
that the diameters of collagen fibres vary depending on the polymerization temperature 
and pH (Christiansen et al., 2000, Raub et al., 2007).  This study demonstrated that, 
besides the factors mentioned above, treating matrix with TG2 might also alter the 
formation of collagen fibres and further affect cell behaviour. 
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Figure 5.2 SEM images of TG2 crosslinked type I collagen gel.  Native collagen gel (left) and TG2 crosslinked gel (right) were then fixed, freeze-dried for 50 hours and sputter coated 
with gold before taking pictures using SEM.  The actual scale bar was stated in each picture. 
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Figure 5.3 Change in diameter of fibres after treatment with TG2.  At least 180 fibres were measured in each 
group from 3 individual experiments using Image J software.  Data represents mean values +/- S.D.  
Statistical analysis was carried out using the one-way ANOVA test and the p-values corresponding to p<0.01 
are represented with a †. 
2.3 TG2 crosslinked collagen gel promoted HOBs differentiation and 
mineralisation 
It was demonstrated here and elsewhere that exogenous TG2 could enhance calcification 
of osteoblasts and other cell lines in vitro.  Evidence has shown that extracellular TG2 may 
trigger an outside-in signal via LRP5 and LRP6, further activate the β-catenin pathway and 
consequently promote cell mineralisation.  Combining the advantage that crosslinked 
collagen could improve osteoblast attachment and proliferation notably (Chau et al., 
2005), here the differentiation and mineralisation characteristics of crosslinked collagen 
gel were evaluated. 
One of the differentiation markers, ALP, was monitored for its released and anchored 
forms during the mineralisation process.  Native collagen gel add-mixed with 1µg/ml of 
recombinant human bone morphogenetic protein 7 (BMP7), a known osteoinductive 
reagent, was used as positive control.  5mg/ml native collagen gel (NC) was used as a 
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control and 10µg/ml TG2 crosslinked collagen gel (TG2) and TG2 crosslinked BMP7 gel 
(TG2+BMP7) were evaluated.  As shown in Fig. 5.4A, there was no significant change in 
released ALP between the groups.  A very similar trend was found in membrane/ECM 
bound ALP expression that no significant change was observed between groups in early 
mineralisation.  A small but not significant increase in anchored ALP activity appeared in 
crosslinked groups (TG2 and TG2+BMP7) on day 10 (Fig.5.4B).  This experiment was only 
done twice, however, further experiments would be needed to conclude this finding. 
 
Figure 5.4 Released (A) and anchored (B) ALP activity evaluated by using pNPP substrate system.  The 
change of absorbance per minutes per centimetre square of culture area was converted into milli-unit of 
enzyme.  The data represent mean values +/- SD from a representative experiment with triplicate setting.  
This experiment was repeated two times and further experiments would be necessary to perform the 
statistic analysis. 
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Mineral deposition was visualised by von Kossa staining 12 days post-treatment to 
evaluate the level of mineralisation of osteoblasts.  A more intense positive staining was 
found in TG2 group comparing to NC group and on day 12 (Fig.5.5).  However, admixing 
BMP7 to collagen gel did not improve cell mineralisation neither did admixing BMP7 to 
crosslinked collagen gel (TG2+BMP7).  According to the supplier, the ED50 of BMP7 used in 
this study was 0.02–0.04 µg/mL (determined by the concentration response induction of 
alkaline phosphatase production by murine ATDC5 cells).  It was possible that the release 
of BMP7 from the collagen or crosslinked collagen gel was restricted and was not enough 
for stimulating osteoblast mineralisation. 
Another concern was that crosslinking activity of TG2 may result in unwanted effects on 
BMP7 activity or vice versa.  In the following experiment, the concentration of BMP7 was 
raised to 2µg/ml and inactive TG2 (TG2+R283) was also used to determine the effect of 
TG2 crosslinking activity.  As shown in Fig 5.6 and Fig 5.7, the mineralised area in the BMP7 
group was increased and was significantly higher than the NC group.  Meanwhile, the TG2 
group demonstrated its osteoinductive characteristic and showed greater mineralised area 
than NC group and BMP7 group.  However, the TG2 + BMP7 group had no synergic effect 
on cell mineralisation and had a lower but not significant effect on cell mineralisation 
when compared to the BMP7 group.  It was also found that neither inactive TG2 
(TG2+R283) showed enhancement on cell mineralisation when compared to the BMP7 
group, nor addition of BMP7 increased the mineralisation effect of the TG2 containing 
biomaterial. 
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Figure 5.5 Relative mineralisation area of HOBs after seeding on native type I collagen gel (NC), native type I 
collagen gel admixed with 1µg/ml of BMP7 (BMP7), 10µg/ml of TG2 crosslinked type I collagen gel (TG2) and 
TG2 crosslinked BMP7 collagen gel (TG2+BMP7) incubated for 12 days.  (A) Mineral deposition was 
visualised by Von Kossa staining in black and (B) the mineralised area was quantified using ImageJ as 
described in materials and methods.  The data represent mean ± SEM value from one representative 
experiment with triplicate setting.  This experiment has been repeated twice where further experiments are 
needed to confirm this finding is statistically significant. 
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Figure 5.6 Mineralisation of HOBs after seeding on native type I collagen gel (NC), native type I collagen gel admixed with 2µg/ml of BMP7 (BMP7), 10µg/ml of TG2 crosslinked type I 
collagen gel (TG2), TG2 crosslinked BMP7 collagen gel (TG2+BMP7), R283 inactivated TG2 in collagen gel  (TG2+R283) and inactive TG2 admixed BMP7 in collagen gel (TG2+R283+BMP7) 
for 12 days.  Mineral deposition was visualised by Von Kossa staining in black as described in Materials and Methods.  The scale bars represent 150µm. 
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Figure 5.7 Quantification of mineralisation area (black dots) in HOBs cultures by analysing images from each 
group.  All results were normalised with the value of the BMP7 group from each experiment and the average 
of the BMP7 group is 3.9±3.23% from 3 experiments.  The data represent mean value ± SEM, where n=3.  
Statistical analysis was carried out using the one-way ANOVA test (Turkey’s multiple comparison test).  The 
P-values corresponding to p<0.05 is represented with a * and p<0.01 is represented with a **. 
2.4 Proliferation of HCECs and HCFs on collagen matrices determined by XTT 
assay  
The proliferation rate of HCECs grown on different concentrations of collagen gel (Fig. 5.8) 
was first determined using commercial XTT kit (Cell Proliferation Kit II, Roche Diagnostics 
Ltd., West Sussex, UK).  The result suggested that XTT reduction was lower when cells 
were grown on collagen gel compared to fibronectin (Fn) coated tissue culture plate 
(TCP/Fn).  There was no significant difference between cells cultured on different 
concentrations of collagen gel as indicated by XTT assay.  Therefore, in the following 
experiments, 5mg/ml collagen gels were used to obtain the highest mechanical strength. 
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Figure 5.8 Proliferation of HCECs on different concentrations of native collagen gel.  Cell proliferation was 
evaluated using the XTT assay over a 3 day period and the results were normalised with the TCP group.  Data 
represents mean values +/- SEM from 3 different experiments.  Statistical analysis was carried out using the 
two-way ANOVA test and no significant difference was found between groups at the same time points 
besides when compared to the TCP group.  The p value corresponding to p<0.0001 is presented with a † 
To further determine the biocompatibility of TG2 crosslinked gel, different concentrations 
of TG2, from 10µg/ml to 250µg/ml, were used and the XTT reduction rates on these gels 
were analysed.  As showed in Fig. 5.9, the XTT reduction of hCECs was once again higher in 
the positive control group (Fn/TCP).  Although there was a significant difference between 
10 µg/ml TG2 treated collagen gel and 250 µg/ml TG2 treated collagen gel at 48 hours, 
none of the TG2 gels showed a comparable proliferative effect to the positive control 
(Fn/TCP).  This suggested that both native collagen gel and TG2-collagen gel might had 
poor cell compatibility with hCECs. 
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Figure 5.9 Proliferation of HCECs on collagen gel treated with different concentration of TG2.  XTT assay was 
performed every 24 hours post seeding, up to 72 hours and the results were normalised with the TCP/FN 
group.  The results represent the mean values ±SEM from 3 individual experiments.  Statistical analysis was 
carried out using the two-way ANOVA test (Turkey’s multiple comparison test) and each group were 
compared to each other at the same time point.  The p-values corresponding to p<0.01 is presented with a 
** and p<0.0001 is presented with a †. 
In order to improve its biocompatibility, several modifications were made to the surface of 
crosslinked gel.  Laminin was chosen as one of the major proteins in the corneal epithelial 
basement membrane (Ljubimov et al., 1995) and it has been shown to promote spreading 
and attachment of corneal epithelial cells in primary culture (Qin et al., 1997).  Fibronectin 
was also used since it is an adhesion molecule which has been demonstrated to improve 
cell adhesion in a wide range of cell types.  Early research using rabbit corneal tissue and 
corneal epithelial cells suggested that fibronectin (Fujikawa et al., 1981, Nishida et al., 
1983) and its fragments (Mooradian et al., 1993) could enhance epithelial cell adhesion, 
attachment and mobility.  After polymerisation of TG2 collagen gel overnight, an extra 
layer of laminin (Lm) or Fn was coated on the surface.  However, a positive effect on 
proliferation was only detected on Lm (Fig. 5.10A) or Fn (Fig. 5.10B) modified TCP.  Again, 
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hCECs cultured on Lm and Fn modified TG2 collagen showed no significant difference on 
XTT reduction when compared at the same time point. 
On the other hand, the XTT reduction rate of was also monitored over a 168 hours period.  
As suggested by XTT assay (Fig. 5.11) the crosslinked gel showed an early increase in 
reduction rate at 24 hours when compared to native collagen gel.  But there was no 
significant difference in XTT reduction rate between TG2 group and NC group at 72 and 
168 hours.  Overall, the XTT assay offered a general view of cell metabolic activity but not 
necessarily the actual cell number or proliferation rate.  The results might be affected by a 
change of metabolic rate when cells are attached to different surfaces.  Furthermore, cells 
which had migrated into the gel might not be detected by XTT assay.  Therefore, other 
factors shall be considered when evaluating XTT results. 
 
Figure 5.10. Cell proliferation of hCECs on Lm or Fn modified TG2-collagen gel.  Cells proliferation when 
cultured on Lm modified (A) or Fn modified (B) crosslinked gel was analysed every 24 hours as described in 
Materials and Methods.  Data were normalised to the average value of the positive control groups and is 
presented as mean values +/- SEM from 3 individual experiments (n=3).  Statistical analysis was carried out 
using the two-way ANOVA test (turkey’s multiple comparison test) and no significant differences were 
found between treated groups at some time points besides when compared to the positive control groups 
which are Lm/TCP and Fn/TCP respectively.  The p value corresponding to p<0.0001 is presented with a † 
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Figure 5.11 Proliferation of hCFs cultured on crosslinked collagen gel.  3,000 hCFs/well were seeded on NC, 
TG2 gel or TCP/Fn surface (positive control).  XTT assay was performed at 24 hours, 72 hours and 168 hours 
post seeding to determine cell proliferation.  The results represent the mean values ±SEM from 3 individual 
experiments (n=3).  Statistical analysis was carried out using the two-way ANOVA test (turkey’s multiple 
comparison test) and each group were compared to each other at the same time point.  The p-values 
corresponding to p<0.05 is presented with a * and p<0.0001 is presented with a †. 
2.5 Cell proliferation and migration of hCFs assayed by multiphoton images 
With the assumption that XTT assay could not truly reflect the actual cell number/ 
proliferation rate, the cell number was determined with another methodology.  The 
multiphoton microscope generated projection images from an 880µm depth z-scanning.  
Using multiphoton scanning could avoid the hCFs, which migrated into the collagen gel, 
being masked from previous XTT assay.  Fig. 5.12 showed there were more hCFs grown on 
TG2 gel (Fig 5.12C) than NC gel after 72 hour culture (Fig. 5.12A).  Further cell counting (Fig 
5.13) suggested that the average cell density on NC was approximately 290 cells/mm2 
while the average cell density on TG2 gel was around 330 cells/mm2.  However, this 
increased was not statistically significant.  Another interesting finding was revealed by the 
projection image from cross-sectional angle which showed more hCFs distributed into the 
TG2 collagen gel (Fig.5.12D) while the hCFs on NC (Fig 5.12B) gel were mainly retained on 
 the matrix surface.  It suggested that TG2 
collagen fibres and increase
Figure 5.12 hCFs cultured collagen gel images from multiphoton 
NC gel or crosslinked gel for 72 hours.  Samples were fixed with 
nucleuses were stained with DAPI.  
scanning were combined using the LAS AF software.  
on NC gel (A,B) were comparably 
(C,D).  The scale bar on top left of each picture represents 100
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microscope.  hCFs were 
3.7% PFA/PBS (pH 7.4) 
3D projection (A,C) and cross-sectional images (B,D) of each series of 
The DAPI staining is shown in blue colour.  
fewer in number and surface located than cells grown on TG2 treated gel 
µm.  
 migration along its 
 
cultured on either 
and the cell 
Cells grown 
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Figure 5.13 The average cell density on collagen gel after 72-hour culture.  The initial cell density seeded on 
each matrix was 91 cells/mm
2
.  The average cell density of both groups after 72-hour culture period were 
quantified in ImageJ and analysed by unpaired T test.  The results represent the mean values ±SEM where 
from 3 individual experiments (n=3).  Statistical analysis was carried out using the Mann-Whitney test and 
no significant difference was found between NC and TG2 groups. 
2.6 Invasion of hCFs measured by the scratch assay 
To set up a model which could represent the cornea wound, hCFs were seeded onto type I 
collagen pre-coated tissue culture plate at 100% confluence and the confluent cell 
monolayer was subjected to scratch assay.  The cell layer and the wound area were 
immediately covered by collagen gel or crosslinked collagen gel and the closure of the 
wound underneath the collagen matrix was monitored.  In this model, hCFs would need to 
degrade native collagen or crosslinked collagen gel first before invasion.  As showed in Fig 
5.14, the leading front of the cells met at 18 hours post-scratching in the NC group while 
the cells in the TG2 group had only just begun migrating between 12 to 18 hours post-
scratch.  The average relative wound density (RWD) obtained from each group was 
presented over a 24-hour time frame in Fig. 5.15.  The wound healing process of hCFs 
started as early as 6 hours post-scratch.  But it was not until 12 hours post-scratch that 
hCFs in the crosslinked group started to migrate. 
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Figure 5.14 Wound closure process of hCFs cultured on collagen gel.  The pictures were captured from the real time-lapse movie at 0 hour, 6 hours, 12 hours and 18 hours.  Cells in NC 
group (upper panel) started migrating at 6 hours post wounding while cells in the TG2 group (lower panel) only started migrating after 12 hours post-scratching.  The dashed line 
highlighted the migrating front of the cell. 
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Figure 5.15 Wound closure process of hCFs cultured in collagen gel or crosslinked gel as shown in RWD over time 
diagram.  Results represent the mean values ±SD from a representative experiment with triplicate setting.  The 
experiment was repeated 2 times. 
2.7 Migration of hCFs determined by transwell assay 
In order to examine the migration of hCFs on crosslinked collagen gel, a modified transwell 
assay was performed.  hCFs which were attracted by the 10% FBS/DMEM in the lower 
chamber would first migrate across the collagen or crosslinked collagen gel, then squeeze 
through the membrane pore and finally reach the underside of the filter.  In Fig. 5.16, hCFs 
seeded on TG2 treated gel had higher mobility than cells cultured on NC according to the 
number of migrating cells after 48 hours.  This result is consistent with the previous finding 
on multiphoton images that TG2 modified collagen gel enhanced hCFs migration.  There 
was a concern that the difference in proliferation of hCFs on the NC and TG2 group during 
the 48 hours migration time frame might also influence this result.  Yet, cells were 
cultured in serum free medium which minimised the proliferation of HOBs.  Therefore, the 
cells observed at the lower side on the membrane were more likely to be migrating 
osteoblasts. 
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Figure 5.16 Analyse of transwell migration assay.  The mobility of hCFs was determined by the number of 
migrating cells after a 48-hour time frame.  The cells reached to the underside of the filter were fixed and 
stained with Diff-Quik® Stain Set.  Results represent the mean values ±SEM from 3 individual experiments 
(n=3).  The unpaired t test was used to analyse the data.  The p-value corresponding to p<0.05 when 
compared to the native collagen group (NC) is presented with a *  
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3. Discussion 
Several studies have demonstrated that TG2 treated matrix could increase cell adhesion of 
a variety of cell lines including osteoblasts, fibroblasts, hepatocytes, smooth muscle cells 
and endothelial cells (Verderio et al., 2001, Chau et al., 2005, Khew et al., 2008, 
Forsprecher et al., 2009, Spurlin et al., 2009, Ciardelli et al., 2010).  Currently, most studies 
recognise the importance of matrix alteration resulting from crosslinking in regulating cell 
behaviour through integrin receptors.  However, along with the recent study by 
Shanmugasundaram et al. (2012), the importance of exogenous TG2 in mediating cell 
behaviour was emphasised in this study.  Trapping of TG2 into collagen gel has been 
demonstrated in this study, although it was not entirely unexpected regarding crosslinking 
of TG2 to other substrates including β2-macroglobulin, fibronectin and type XI collagen 
was reported by others (Fesus et al., 1981, Barsigian et al., 1991b, Shanmugasundaram et 
al., 2012).  It has been also demonstrated that TGs was able to bind to collagen (Juprelle-
Soret et al., 1988, Upchurch et al., 1991) and the GTP-, GDP- and ATP-bound TG2 had no 
significant effect on its binding to ECM although there was a 2-3-fold enhancement in 
binding when TG2 was treated with calcium (Upchurch et al., 1991).  Therefore, the 
trapping of TG2 in the collagen matrix was consistent with current studies and it is feasible 
to suggest that the presence of TG2 within the matrix could be considered as a source of 
exogenous TG2. 
As demonstrated in previous chapter that exogenous TG2 could induce osteogenesis via 
binding of LRP5 receptors, there was a possibility that trapped TG2 in the matrix could 
bind to cell surface LRP5 and further contribute to the increased HOB mineralisation 
observed on crosslinked collagen gel.  Although the question of whether the high 
molecular weight TG2 complex still has ability to bind to LRP5 remains unknown.  Also, 
increased mobility of cells cultured on TG2-rich cell surface/ extracellular environment has 
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been demonstrated here and with monocytes (Akimov et al., 2000), breast cancer cells 
(Mangala et al., 2006) and keratinocytes (Edwards et al., 2006).  Several models were 
suggested to explain the possible role of TG2 in cell migration since it was found to 
interact with integrin β1 and β3 on cell membranes and in recycling endosomes (reviewed 
by Belkin, 2011).  Zemskov et al. (2007) proposed that binding of extracellular TG2 to LRP1 
could accelerate the endocytosis process which might also include cell membrane integrin 
internalisation and recycling.  Interestingly, in migrating cells, the localisation of integrin 
complexes to the leading edge was mediated through endocytic trafficking, suggesting a 
complex and dynamic control of cell surface adhesion molecules on the migrating cells.  
Therefore, it was possible that trapped TG2 in the TG2 gel could enhance hCF cell 
migration by hastening endocytosis of major integrins. 
Besides the auto-crosslinking of TG2 into the collagen matrix, a change in matrix surface 
topography was also observed in this study.  It was shown that the average collagen fibre 
size was increased in crosslinked collagen gel (2.7 ± 0.7 µm) compared to native collagen 
gel (0.9 ± 0.3 µm) and increased mineral deposition and ALP activity in the later stage of 
mineralisation were suggested when osteoblasts were cultured on crosslinked collagen 
gels.  The effect of surface topography on cell adhesion, morphology, proliferation and 
differentiation was demonstrated in many studies (reviewed by Martínez et al., 2009).  
Despite the fact that the effect of substrate topography on cell behaviours was varied 
according to differences in cell type, substrate material, feature geometry and parameters 
measured, several studies in agreement with the finding of this study are summarised as 
follows.  On silicon substrates with nanogrooves from 150nm to 1000nm groove pitches, 
the expression of bone differentiation genes, including alkaline phosphatase (ALP), 
osteocalcin (OCN), type I collagen and integrin α1 and β1, were higher when the groove 
width was wider (Lamers et al., 2010).  Also, increased nodule formation and ALP activity 
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were found when increasing the groove depth (ranging from 0 to 30µm) on titanium (Ti)- 
and hydroxylapatite (HA)-coated grooved substrata (Perizzolo et al., 2001).  Therefore, as 
illustrated in Fig. 5.17, greater diameter of crosslinked collagen fibres than non-crosslinked 
collagen fibres may result in deeper grooves between fibres and could be considered as 
one of the factors that affects osteogenesis. 
 
Figure 5.17 Illustration of groove width and depth.  (A) The synthetic grooved substrata (B) larger fibres and 
(C) smaller fibres.  Larger fibres result in wider groove width and deeper groove depth. 
On the other hand, the average collagen fibre diameter in human cornea is 3.2 ± 0.8 µm 
according to immunohistochemical analysis  (Mencucci et al., 2010).  Here, TG2 
crosslinked collagen fibres (2.7 ± 0.7 µm) provided a microenvironment which was very 
similar to the physiological environment of corneal stroma than native collagen gel in 
terms of diameter of collagen fibres.  TG2 crosslinked collagen, therefore, might enhance 
hCFs proliferation and migration by recreating a similar microenvironment to that of the 
corneal stromal layer. 
The mechanism of how TG2 alters the size of collagen fibres still requires investigation.  
However, higher magnification SEM images (100,000X) of collagen hydrogels which were 
fabricated under different temperatures revealed parallel-aligned fibrils within collagen 
fibres and the difference in size of collagen bundles was due to different number of fibrils 
per fibre rather than changes in fibril diameter (Raub et al., 2007).  Thus, it is reasonable to 
assume that instead of altering the formation of triple helix polypeptide chains, TG2 may 
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alter the fibril array by connecting more collagen fibrils to form larger collagen bundles.  
Binding of TG2 to collagen I could happen with or without its crosslinking activity even 
though the collagen binding site of TG2 has not yet been determined.  It was highly 
possible that crosslinking and/or binding of TG2 to collagen gel was associated with the 
alteration of biomaterial topography.  Regardless of these unsolved questions, important 
information was gained that TG2 might mediate the osteogenesis process by changing the 
size of extracellular collagen fibres.  This hypothesis could also suggest the role that TG2 
plays in physiological mineralisation.  Since the expression of extracellular/cell surface TG2 
and crosslinking activity were gradually increased during the mineralising process, these 
ECM/cell surface TG2 might alter the organisation of collagen fibres extracellularly and 
enhance cell mineralisation. 
Another important factor to evaluate was the cell compatibility of crosslinked collagen 
gels.  Although the Cell Proliferation Kit (Roche Diagnostics Ltd., West Sussex, UK) 
suggested a low XTT reduction rate of cells when cultured on collagen based matrix, here, 
a question was raised that whether the XTT assay was a reliable method to evaluate cell 
growth in this collagen gel system.  It was suggested that XTT assay was majorly based on 
the pyridine nucleotide redox status of cells (Gonzalez and Tarloff, 2001).  Therefore, this 
assay would be greatly influenced by the mitochondrial metabolic activity.  Alteration of 
mitochondrial metabolic activity was found with aging (Ji et al., 1990), chemical treatment 
(Hernández-Muñoz et al., 1994), cellular hydration state (Haussinger et al., 1994) and 
proliferating / quiescent stage of cells (DeBerardinis et al., 2008).  It was possible that the 
metabolic activity of cells grown on NC gel, TG2 gel and Lm/Fn coated plate were very 
different.  In this case, cells cultured on Fn coated plate could potentially increase 
metabolism to a higher rate than cells cultured on collagen based matrices.  Therefore, 
when using XTT value of cells cultured on Fn coated plate as a positive control, the 
Page | 201  
 
difference in cell basic metabolism rate on different surface shall be taken into 
consideration. 
The concern of XTT assay should not be directly linked to actual cell proliferation rate was 
further confirmed in this study.  While the XTT assay showed that there was decrease in 
XTT reduction during the 72-hour culture period, the multiphoton scanned pictures 
suggested that increasing cell number was found on native collagen and TG2 crosslinked 
gel.  For cells migrated to deeper layer of matrix, obtaining and releasing of XTT products 
were restricted by the physical barrier and relied on medium diffusion rate.  In other 
words, the metabolic activity of cells inside the collagen gel might be hidden by the matrix.  
The invasion of hCFs into collagen gel may explain the reason why the XTT value was low 
in the TG2 group. 
hCFs showed increased cell mobility in the TG2 collagen gel system as demonstrated by 
multiphoton scanning and transwell migration assay.  These findings show the potential of 
applying TG2 collagen gel to corneal wound areas, since it could encourage the 
repopulation of corneal fibroblasts into the matrix.  Infiltration of hCFs into collagen gel 
within the wounded area hopefully could accelerate the healing process and attract 
epithelial cells and endothelial cells migration and proliferation via chemoattration. 
The invasion model used in this study suggested that a delayed onset of cell invasion might 
be expected when applying crosslinked collagen gel to corneal wound areas (Fig. 5.18).  
This delayed onset of invasion could result from specific MMPs secretion being required to 
initialise the invasion of hCFs into crosslinked collagen gel.  The hCFs were cultured on 
type I collagen for 24 hours before being subjected to invasion assay.  It is reasonable to 
assume that it takes time for hCFs to express and secrete specific MMPs when they are 
first introduced onto crosslinked collagen gel as it is distinct from the original matrix they 
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were cultured on.  This observation might also suggest that crosslinked collagen gel has 
higher resistance to hCFs mediated degradation.  It was not completely surprising since 
higher resistance to enzymatic digestion was generally observed in crosslinked gel which 
has been demonstrated by Chau et al. (2005) previously.  Interestingly, even though the 
onset of cell invasion was delayed, the average invasion rate of hCFs on crosslinked 
collagen gel after start of invasion was comparable and even higher than hCFs on native 
collagen gel. 
 
Figure 5.18 (A) A putative models for application of TG2 crosslinked gel to corneal wound area.  Quiescent 
human corneal keratocytes (hCKs) are transformed into human corneal fibroblasts (hCFs) once the injury 
occurred.  Ideally, hCFs and human corneal epithelial cells (hCECs) are encouraged to migrate into or over 
the crosslinked collagen gel at the wounded area.  Therefore, the invasion model (B) used in this study tests 
the possible scenario of hCFs invasion in the in vitro model.  Cells are cultured and wound scratching is 
performed on the cell monolayer.  The wound closure happens underneath a layer of the crosslinked 
collagen gel. 
Overall, these results provided a promising point of view in using crosslinked collagen 
matrix for hard and soft tissue regeneration.  Currently there are two BMP bone graft 
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products approved for clinical use including INFUSE® bone graft which contains BMP-2 for 
spinal fusion and for treatment of open tibial shaft fractures and Stryker’s OP-1 which 
contains BMP-7 for treating long bone non-union fractures and lumbar spinal fusion.  
Collagen gel, in these cases, is used as a biodegradable carrier for BMPs instead of having a 
functional role in promoting osteoconduction, osteoinduction and adhesion or providing 
microarchitecture for the subsequent formation of new tissue.  Here, the TG2 treated 
collagen gel demonstrated competitive osteoinductivity at later stages of cell culture when 
compared to BMP-7 containing gel.  However, in order to achieve the same osetoinductive 
effect as BMP-7 containing gel in this study, the prime cost of TG2 crosslinked gel was 20 
times less when constructed in the laboratory.  In fact, the currently approved BMP-7 
product for bone fracture repair, OP-1 Implant, costs $5250 for one unit (3.3mg of BMP7 
addmixed with 1g of bovine bone collagen).  Here, TG2 crosslinked collagen gel 
demonstrated a comparable effect on improving osteoblast mineralisation to current 
treatments for bone fracture and the cost of crosslinked gel was much lower than using 
BMP containing product.  Nevertheless, combined with a previous study conducted by 
Chau et al. (2005), TG2 –treated collagen gel showed great potential to improve cell 
attachment and mineralisation via its crosslinking and non-crosslinking characteristics 
without compromising its resistance to enzymatic degradation.  Therefore, TG2 
crosslinked collagen is a promising biomaterial which meets the current requirements of 
bone grafts in the clinic.  Future work in applying TG2 crosslinked collagen gel to in vivo 
animal models may provide more insight into the mechanism of TG2-collagen induced 
mineralisation. 
This chapter also demonstrated the promising potential of TG2 crosslinked matrix for 
corneal wound healing.  It promotes corneal fibroblast proliferation and cell infiltration 
which could potentially improve the corneal wound healing process.  The major issue 
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remains to be conquered is the relatively poor proliferation of hCECs on crosslinked 
collagen gel.  According to XTT assays, corneal epithelial cells showed low proliferation 
even when cultured on TG2-collagen gel with Lm- or Fn- modified surfaces.  Developing a 
hCFs/hCECs co-culture system in the future may improve the poor epithelial cell 
proliferation on crosslinked collagen gel and advance the use of TG2 crosslinked gels in 
cornea repair and even the possibility of fabricating artificial substitutes. 
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Chapter VI 
General Discussion 
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TG2 has been implicated in bone development and mineralisation for years, yet the 
detailed mechanism still remains unclear due to the complexities of its multifunctional 
characteristics and compensation effects from other TG family members.  In this thesis, 
the relationship between expression of TG2 and osteoblast mineralisation was 
established, where the level of TG2 protein increased steadily during cell mineralisation.  A 
strong relationship between TG2 expression and mineralisation has been well 
demonstrated here and in other literatures (Nurminskaya and Kaartinen, 2006), yet, 
studying of the mechanism behind is still a great challenge. 
There are two main restrictions for the models used for studying biological functions of 
endogenous TG2 and mineralisation.  First, in this thesis, upregulation of FXIIIa was also 
observed in TG2 knockdown osteoblasts where mineralisation was not affected by low 
expression of TG2.  Therefore, even though the expression of TG2 may be coincident with 
bone development which suggested TG2 as one of the major regulators in physiological 
mineralisation, TG2 alone was not essential for bone development and could be 
compensated by other TG members.  It is also feasible that only a minimum level of TG2 
expression and/or crosslinking activity are required for mineral deposition.  The 
compensation effects from other TG members is in agreement with current TG2 
knockdown and knockout systems which explains the lack of gross skeletal abnormalities 
in TG2 knockout mice (De Laurenzi and Melino, 2001, Nanda et al., 2001) and TG2/FXIIIa 
double knockout mice(Williams et al., 2010).  The possible upregulated TG family 
members due to TG2 knockout were demonstrated to be TG1 (De Laurenzi and Melino, 
2001, Deasey et al., 2013), TG3 (Deasey et al., 2013) and FXIII (Tarantino et al., 2009). 
Secondly, the crosslinking inhibitors may act not only through their inhibitory effect on 
transamidating activity but also through conformation change and both effects should be 
considered when evaluating the results.  Culturing osteoblasts with synthetic TG2 
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crosslinking inhibitors, R283 (non-specific) and R294 (TG2-specific), did not block 
mineralisation of HOBs in this thesis.  Although it could be concluded that TG2 activity was 
not necessary for cell mineralisation, again, it was also feasible that only a minimum level 
of TG crosslinking activity was required for this process since there was still a low level of 
crosslinking activity present in the extracellular environment after treating with inhibitors.  
Interestingly, R294 treated groups showed an even higher mineralised area at the end 
point.  The Western blot results also suggested that inhibitor-treated cells showed more 
cleaved TG2 fragments and the fragments appeared coincidently with mineral deposition.  
Here, the increase in TG2 fragments was proposed to be related to the conformational 
change due to the binding of inhibitors which made TG2 more sensitive to enzymatic 
digestion.  Also, the enhancement of mineralisation and increase in TG2 fragments fitted 
the hypothesis that TG2 could contribute to mineralisation by acting as ATPase and this 
function is regulated by enzymatic digestion.  Therefore, these results demonstrated that 
TG2 might contribute to mineralisation through other biological functions and these 
functions were likely to be related to TG2 conformation.  Current study also supports this 
finding that restricting TG2 in certain conformations has been shown to affect different 
functions of TG2, for example, TG2 failed to induce differentiation of chondrocytes in its 
open conformation (Johnson and Terkeltaub, 2005). 
Another subject to be addressed was to distinguish the contribution of crosslinking activity 
from the 2 major TGs in osteoblasts, TG2 and FXIIIa, during mineralisation.  Judging from 
the results gained from ECM and/or cell surface transamidating activity, there was a shift 
from FXIIIa-dominant crosslinking activity to TG2-dominant crosslinking activity during 
mineralisation.  This was compliant with Al-Jallad et al. (2011) studies that an early 
increase in cell surface FXIIIa was observed in differentiation treated pre-osteoblasts.  
They also indicated that this increase in FXIIIa activity on the cell membrane was related to 
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collagen deposition.  However, a TG2 dominant crosslinking activity at later stages of 
differentiation was also observed in this thesis.  Therefore, a new postulation was 
proposed here that an early peak in FXIIIa activity on the differentiated cell surface could 
be important for collagen matrix deposition and, in the later stage of differentiation,TG2 
still played a major role in matrix stabilisation considering TG2 has a broader range of 
substrates than FXIIIa in ECM. 
The exogenous TG2 induced-calcification and downstream activation of β-catenin 
signalling were observed in the HOB model used here.  According to the results, TG2-
mediated activation of LRP5/β-catenin pathway occurred transiently at a very early stage 
of treatment.  Furthermore, according to the preliminary data, R283-inactivated TG2 
(semi-open form) and R294-inactivated TG2 (open form) might still reserve partial ability 
to enhance bone mineralisation.  And it seems that R283-inactivated TG2 could induce 
higher levels of mineralisation than R294-inactivated TG2.  Another important information 
gained from Co-IP assay was that TG100 antibody failed to recognise TG2/LRP5 complex 
on cell surface.  This could be due to the binding site for TG100 antibody on TG2 being 
masked in the TG2/LRP5 complex.  It is known that the epitope site of TG100 on TG2 
undergoes large conformational change when TG2 is in compact form.  All these suggested 
that certain conformation(s), most likely the closed conformation, of TG2 was required for 
the binding of TG2 to LRP5.  It, again, implies the important of TG2 conformation in 
mineralisation. 
Therefore, a putative model of regulatory signalling for osseous cell fates combined with 
findings in this thesis was proposed in Fig 6.1.  In this model, osteoprogenitor cells 
differentiated from mesenchymal origins express LRP5 receptors and immature 
osteoblasts usually undergo apoptosis.  The LRP5 was proposed to promote proliferation 
and/or survival of early osteoblast progenitors but not essential for osteoblast lineage 
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development from mesenchymal stem cells (reviewed by Westendorf et al., 2004).  
Exogenous TG2, either secreted from chondrocytes or from apoptosis of osteoblasts, could 
act through LRP5 receptor and further activate the Wnt/β-catenin pathway thus 
encouraging cell survival and differentiation.  Also, TG2 has been proposed to enhance cell 
adhesion and proliferation in the extracellular environment through both crosslinking 
dependent and independent pathways.  Later in mature osteoblasts, the Wnt signalling 
was down regulated by secreted Wnt inhibitors, such as sFRP and WIF, and the binding of 
Dkk to LRP5 would encourage the endocytosis of cell surface LRP5.  The extracellular TG2, 
during the terminal differentiation and mineralisation, could act as a matrix stabiliser 
through its crosslinking activity or act as a phosphate regulator through its ATPase activity.  
At the very end of the process, osteocytes lose the expression of LRP5 and undergo 
apoptosis.  The extracellular TG2, again, could promote cell adhesion and survival through 
different interactions with integrins and/or syndecans. 
Exogenous TG2 is also recognised as a stress or rescue protein in wound healing and may 
play a role in bone healing.  Cell necrosis always accompanies wounding, therefore, the 
releasing of TG2 from necrotic cells could promote cell survival and accelerate maturation 
of osteoblasts through binding to LRP5 receptor at the very early stage of bone 
regeneration. The extracellular TG2 induced β-catenin activation was involved in 
pathological calcification which has been demonstrated in vascular smooth muscle cells 
and warfarin induced valve calcification models (Faverman et al., 2008, Beazley et al., 
2012).  Overall, extracellular TG2 contributed to physiological and pathological calcification 
processes through both transamidating dependent and independent pathways and the 
function of TG2 may be regulated by endocytosis or enzymatic digestion at different 
stages of mineralisation. 
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Figure 6.1. Putative model for TG2-related regulation of osseous cell fates. 
Page | 211  
 
The advantages of applying TG2 for medical use were also demonstrated in this thesis.  
Crosslinking collagen gel with TG2 is an effective way to overcome the physical weakness 
of native collagen gel.  A previous study by Chau et al. (2005) has shown that TG2 
crosslinked collagen not only had improved physical characteristics, but also provided a 
more favourable environment for cell growth and differentiation.  The same study also 
suggested that the improved biological characteristics of crosslinked gels were the result 
of alteration of collagen matrix by TG2 transamidating activity.  In this thesis, TG2 
crosslinked gel elicited greater mineral deposition of HOBs than the positive control, BMP7 
contained collagen gel, used in the experiments.  This osteoinductive effect of crosslinked 
collagen gel was suggested to result from alteration of collagen fibre topography and/or 
trapped TG2 in the matrix.  This advanced biomatrix showed a great potential in bone 
repair and could be produced at a reasonable price when compared to current BMP 
products on the market.  However, BMP7 and TG2 did not have a synergic effect in 
osteoinduction.  A possible explanation was that BMP and TG2 mediated mineralisation 
had opposite effects in the process.  It was proposed in this thesis that trapped TG2 acted 
as a resource of exogenous TG2 and could further activate Wnt/β-catenin pathway 
through LRP5.  As reviewed in the literature, interaction between BMP and Wnt pathways 
is particularly complex in bone development and had opposite or cooperative effects 
depending on the developmental stages (Itasaki and Hoppler, 2010).  Therefore, 
combining BMP7 and TG2 was not an ideal method to improve the osteoinductive 
property of biomatrix. 
Results also demonstrated that TG2 crosslinked collagen was highly compatible for hCF 
growth and provided a greater environment for hCF repopulation.  This effect could be 
related to alteration of collagen fibres by TG2 which resulted in a similar size of collagen 
fibres to that observed in human corneal stroma.  This thesis also tested the possible 
Page | 212  
 
scenario in in vivo corneal wound closure.  It suggested that a delay in invasion onset time 
was expected due to a certain amount of time that was needed for cells to secrete the 
correct MMPs for invasion when first introduced to new matrix.  However, higher mobility 
of cells cultured in TG2 crosslinked group was observed in the transwell assay.  Future 
work will involve adequate modification of the matrix surface for HCECs proliferation and 
migration in order to advance the use of crosslinked collagen gel in corneal wound 
dressing. 
To summarise, the key contribution of this thesis was to refine current hypotheses of TG2 
in osteoblast mineralisation process.  The crosslinking activities of extracellular TG2 in cell 
mineralisation are likely to play a role in matrix maturation and stabilisation in the later 
stage of differentiation.  The extracellular TG2, even after proteolysis, can also contribute 
to Pi synthesis for mineral deposition via its ATPase activity.  The exogenous TG2, on the 
other hand, induces cell differentiation via binding of LRP5 receptor and activating 
downstream β-catenin signalling in HOB.  This effect is β-catenin signalling dependent and 
is likely to be an initial differentiation signal for osteoblasts in physiological bone 
development and the wound healing process.  In the future, it would be interesting to 
examine if TG2 activity and/or conformation are essential for the endogenous TG2-
mediated and exogenous TG2-induced mineralisation.  Using the wild type TG2, mutant 
C277S TG2 and mutant W271A TG2 could be a good model to study the effect of TG2 
conformation and activity during mineralisation. 
The use of TG2 modified matrix also demonstrated a great potential as an advanced 
biomatrix in bone repair.  Combining the finding in previous studies and the results here, 
TG2 crosslinked collagen gel is a mechanically strong biomatrix and its cell compatibility 
and pro-mineralisation effects are well established in in vitro systems.  It is worth studying 
the TG2 crosslinked collagen gel in animal bone fracture models and ultimately in clinical 
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trials.  Further added value of using TG2 crosslinked collagen gel as a corneal wound 
dressing was also demonstrated where the matrix shows great cell compatibility for hCFs 
to proliferate and migrate.  The next challenge to overcome in the future is to improve the 
cell compatibility of TG2 crosslinked gel for hCECs proliferation.  One possible way to 
address this goal is using hCFs/hCECs coculture system, addition of growth factor and 
modifying with type IV collagen. 
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